U.S. patent application number 13/211765 was filed with the patent office on 2011-12-08 for bicyclic amides as kinase inhibitors.
This patent application is currently assigned to NOVARTIS AG. Invention is credited to Joginder S. Bajwa, Guido Bold, Hans-Georg Capraro, Giorgio Caravatti, Andreas Floersheimer, Pascal Furet, Francois Gessier, Xinglong Jiang, Prasad Koteswara Kapa, Amanda Jane Littlewood-Evans, Paul W. Manley, Carole Pissot Soldermann, Christian Schnell, Andrea Vaupel.
Application Number | 20110301157 13/211765 |
Document ID | / |
Family ID | 35705284 |
Filed Date | 2011-12-08 |
United States Patent
Application |
20110301157 |
Kind Code |
A1 |
Bold; Guido ; et
al. |
December 8, 2011 |
BICYCLIC AMIDES AS KINASE INHIBITORS
Abstract
The invention relates to compounds of formula (I) and their use
in the treatment of the animal or human body, to pharmaceutical
compositions comprising a compound of formula I and to the use of a
compound of formula I for the preparation of pharmaceutical
compositions for use in the treatment of protein kinase dependent
diseases, especially of proliferative diseases, such as in
particular tumour diseases. ##STR00001##
Inventors: |
Bold; Guido;
(Gipf-Oberfrick, CH) ; Capraro; Hans-Georg;
(Rheinfelden, CH) ; Caravatti; Giorgio;
(Bottmingen, CH) ; Floersheimer; Andreas;
(Dornach, CH) ; Furet; Pascal; (Thann, FR)
; Manley; Paul W.; (Arlesheim, CH) ; Vaupel;
Andrea; (Riehen, CH) ; Pissot Soldermann; Carole;
(Rosenau, FR) ; Gessier; Francois; (Illfurth,
FR) ; Schnell; Christian; (Hesingue, FR) ;
Littlewood-Evans; Amanda Jane; (Oberwil, CH) ; Kapa;
Prasad Koteswara; (Parsippany, NJ) ; Bajwa; Joginder
S.; (Elmwood Park, NJ) ; Jiang; Xinglong;
(Hillsborough, NJ) |
Assignee: |
NOVARTIS AG
|
Family ID: |
35705284 |
Appl. No.: |
13/211765 |
Filed: |
August 17, 2011 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11575025 |
Feb 11, 2008 |
8026247 |
|
|
PCT/IB05/04030 |
Sep 14, 2005 |
|
|
|
13211765 |
|
|
|
|
Current U.S.
Class: |
514/230.5 ;
514/235.8; 514/252.18; 514/269; 544/105; 544/123; 544/295;
544/319 |
Current CPC
Class: |
C07D 239/47 20130101;
A61P 17/06 20180101; C07D 403/12 20130101; A61P 41/00 20180101;
A61P 37/00 20180101; A61P 37/02 20180101; A61P 1/16 20180101; A61P
35/00 20180101; A61P 13/12 20180101; A61P 3/10 20180101; A61P 27/02
20180101; A61P 25/00 20180101; A61P 25/28 20180101; C07D 413/12
20130101; A61P 9/08 20180101; A61P 29/00 20180101; A61P 9/00
20180101; A61P 37/06 20180101; A61P 35/02 20180101; A61P 11/06
20180101; A61P 9/10 20180101; A61P 15/00 20180101; A61P 43/00
20180101 |
Class at
Publication: |
514/230.5 ;
514/235.8; 514/252.18; 514/269; 544/105; 544/123; 544/295;
544/319 |
International
Class: |
A61K 31/538 20060101
A61K031/538; A61K 31/496 20060101 A61K031/496; A61K 31/505 20060101
A61K031/505; C07D 413/12 20060101 C07D413/12; C07D 413/14 20060101
C07D413/14; C07D 401/14 20060101 C07D401/14; C07D 239/34 20060101
C07D239/34; A61K 31/506 20060101 A61K031/506; C07D 401/12 20060101
C07D401/12; A61P 17/06 20060101 A61P017/06; A61P 29/00 20060101
A61P029/00; A61P 11/06 20060101 A61P011/06; A61P 9/00 20060101
A61P009/00; A61P 25/28 20060101 A61P025/28; A61P 35/02 20060101
A61P035/02; A61P 35/00 20060101 A61P035/00; C07D 403/12 20060101
C07D403/12; A61P 3/10 20060101 A61P003/10; A61P 37/00 20060101
A61P037/00; A61P 41/00 20060101 A61P041/00; A61K 31/5377 20060101
A61K031/5377 |
Foreign Application Data
Date |
Code |
Application Number |
Sep 15, 2004 |
GB |
0420520.9 |
Jun 8, 2005 |
GB |
0511687.6 |
Claims
1-13. (canceled)
14.
5-(2-Amino-pyrimidin-4-yloxy)-4-fluoro-2-methyl-2,3-dihydro-indole-1--
carboxylic acid (3-trifluoromethyl-phenyl)-amide,
5-(6-Chloro-pyrimidin-4-yloxy)-indole-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide,
5-(6-Amino-pyrimidin-4-yloxy)-indole-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide,
7-(6-Amino-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazine-4-carboxylic
acid (4-methyl-3-trifluoromethyl-phenyl)-amide,
7-(6-Amino-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazine-4-carboxylic
acid (4-fluoro-3-trifluoromethyl-phenyl)-amide,
7-(6-Amino-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazine-4-carboxylic
acid (3-trifluoromethyl-phenyl)-amide,
7-(6-Methylamino-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazine-4-carbo-
xylic acid (4-methyl-3-trifluoromethyl-phenyl)-amide,
7-(6-Methylamino-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazine-4-carbo-
xylic acid (3-trifluoromethyl-phenyl)-amide,
7-(2-Amino-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazine-4-carboxylic
acid (3-trifluoromethyl-phenyl)-amide, or
7-(2-Amino-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazine-4-carboxylic
acid (4-morpholin-4-ylmethyl-3-trifluoromethyl-phenyl)-amide, or a
tautomer thereof, or a salt thereof.
15. A compound of the following formula: ##STR00102## wherein
##STR00103## is a group selected from: ##STR00104## or a tautomer
thereof, or a salt thereof.
16. 6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(4-methyl-3-trifluoromethyl-phenyl)-amide or
6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(2-trifluoromethyl-pyridin-4-yl)-amide, or a tautomer thereof, or a
salt thereof.
17. A compound selected of the following formula: ##STR00105##
wherein ##STR00106## is selected from: ##STR00107## or a tautomer
thereof, or a salt thereof.
18. 6-(2-Acetylamino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic
acid (3-trifluoromethyl-phenyl)-amide,
6-(2-Methoxycarbonylamino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic
acid (3-trifluoromethyl-phenyl)-amide,
7-(2-Acetylamino-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazine-4-carbo-
xylic acid (4-methyl-3-trifluoromethyl-phenyl)-amide,
7-(2-Methoxycarbonylamino-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazin-
e-4-carboxylic acid (4-methyl-3-trifluoromethyl-phenyl)-amide,
7-(2-Amino-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazine-4-carboxylic
acid [4-(4-methyl-piperazin-1-yl
methyl)-3-trifluoromethyl-phenyl]-amide,
6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(4-morpholin-4-yl-3-trifluoromethyl-phenyl)-amide,
6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
cis/trans-(4-isopropyl-cyclohexyl)-amide,
6-(6-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(4-fluoro-3-trifluoromethyl-phenyl)-amide,
6-(6-Chloro-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic acid
(3-trifluoromethyl-phenyl)-amide,
6-(6-Amino-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic acid
(3-trifluoromethyl-phenyl)-amide,
6-(6-Methylamino-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic acid
(3-trifluoromethyl-phenyl)-amide,
6-(2-Amino-6-chloro-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic
acid (3-trifluoromethyl-phenyl)-amide,
6-(2-Amino-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic acid
(3-trifluoromethyl-phenyl)-amide,
6-(6-Chloro-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic acid
(4-fluoro-3-trifluoromethyl-phenyl)-amide,
6-(6-Amino-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic acid
(4-fluoro-3-trifluoromethyl-phenyl)-amide, or
6-(2-Amino-6-chloro-pyrimidin-4-yloxy)-naphthalene-1-carboxylic
acid (3-trifluoromethyl-4-chloro-phenyl)-amide, or a tautomer
thereof, or a salt thereof.
19.
6-(2-Amino-6-chloro-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic
acid (4-fluoro-3-trifluoromethyl-phenyl)-amide,
6-(2-Amino-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic acid
(4-fluoro-3-trifluoromethyl-phenyl)-amide,
6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-4-chloro-phenyl)-amide, ##STR00108##
6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
[4-(4-methyl-piperazin-1-yl-methyl)-3-trifluoromethyl-phenyl]-amide,
or 6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
[3,4-bis(trifluoromethyl)-phenyl]-amide, a compound of the
following formula: ##STR00109## wherein ##STR00110## is selected
from ##STR00111##
6-(6-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(3-cyclopropyl-4-fluoro-phenyl)-amide, a compound selected from the
following formula: ##STR00112## wherein ##STR00113## is selected
from ##STR00114##
6-(6-Methylamino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(4-morpholin-4-yl-3-trifluoromethyl-phenyl)-amide, a compound
selected from the formula: ##STR00115## wherein ##STR00116## is
selected from ##STR00117##
6-(6-Chloro-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide,
6-(6-Cyano-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide,
6-(6-Aminomethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide,
{6-[5-(3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyrimidin-4-
-ylmethyl}-carbamic acid methylester,
6-[5-(3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyrimidine-4-
-carboxylic acid ethyl ester,
6-[5-(3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyrimidine-4-
-carboxylic acid,
6-[5-(3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyrimidine-4-
-carboxylic acid dimethylamide,
6-[5-(3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyrimidine-4-
-carboxylic acid amide,
6-[5-(3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyrimidine-4-
-carboxylic acid methylamide,
6-[5-(3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyrimidine-4-
-carboxylic acid isopropylamide,
6-(6-Chloromethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide,
6-(6-Methylaminomethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic
acid (3-trifluoromethyl-phenyl)-amide,
6-(6-Dimethylaminomethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic
acid (3-trifluoromethyl-phenyl)-amide,
{6-[5-(4-Fluoro-3-trifluoromethyl-phenylcarbamoyl)-naphthalen-2-ylsulfany-
l]-pyrimidin-4-yl}-carbamic acid tert-butyl ester,
6-(6-Amino-pyrimidin-4-ylsulfanyl)-naphthalene-1-carboxylic acid
(4-fluoro-3-trifluoromethyl-phenyl)-amide,
6-(6-Amino-pyrimidin-4-ylsulfanyl)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide,
6-(6-Amino-pyrimidine-4-sulfinyl)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide,
6-(6-Amino-pyrimidine-4-sulfonyl)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide,
6-(6-Amino-pyrimidin-4-ylsulfanyl)-naphthalene-1-carboxylic acid
(3-trifluoromethoxy-phenyl)-amide,
6-(Pyridin-4-yl-methyl)-naphthalene-1-carboxylic acid
(4-fluoro-3-trifluoromethyl-phenyl)-amide,
6-(2-Methyl-pyridin-4-yloxy)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide,
4-[5-(3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyridine-2-c-
arboxylic acid butyl ester,
4-[5-(3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyridine-2-c-
arboxylic acid amide,
4-[5-(3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyridine-2-c-
arboxylic acid (2-dimethylamino-ethyl)-amide,
6-(2-Amino-pyridin-4-yloxy)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide,
{4-[5-(3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyridin-2-y-
l}-carbamic acid methyl ester,
6-[2-(2-Amino-pyrimidin-4-yl)-ethyl]-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide,
6-(6-Amino-pyrimidin-4-ylethynyl)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide,
6-(6-Amino-pyrimidin-4-yloxy)-1H-indole-3-carboxylic acid
(3-trifluoromethyl-phenyl)-amide,
6-(6-Amino-pyrimidin-4-yloxy)-1H-indole-3-carboxylic acid
(3-methoxy-phenyl)-amide,
6-(6-Amino-pyrimidin-4-yloxy)-1H-indole-3-carboxylic acid
(4-fluoro-3-trifluoromethyl-phenyl)-amide, a compound of the
following formula: ##STR00118## wherein R is selected from
##STR00119##
6-(6-Amino-pyrimidin-4-yloxy)-1-methyl-1H-indole-3-carboxylic acid
(3-trifluoro-methyl-phenyl)-amide, a compound of the following
formula ##STR00120## wherein R is selected from ##STR00121##
6-(6-Amino-pyrimidin-4-yloxy)-1-ethyl-1H-indole-3-carboxylic acid
(3-trifluoromethyl-phenyl)-amide,
6-(6-Amino-pyrimidin-4-yloxy)-1-ethyl-1H-indole-3-carboxylic acid
(4-fluoro-3-trifluoromethyl-phenyl)-amide,
6-(6-Amino-pyrimidin-4-yloxy)-1-iso-propyl-1H-indole-3-carboxylic
acid (3-trifluoromethyl-phenyl)-amide,
6-(6-Acetylaminopyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(4-piperazin-1-ylmethyl-3-trifluoromethylphenyl)amide,
6-(6-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(4-piperazin-1-ylmethyl-3-trifluoromethylphenyl)amide,
{6-[5-(4-piperazin-1-ylmethyl-3-trifluoromethylphenylcarbamoyl)naphthalen-
e-2-yloxy]pyrimidin-4-yl}carbamic acid methyl ester,
6-(6-Acetylamino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
[4-(4-methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-amide,
6-(6-Aminopyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
[4-(4-methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-amide,
(6-{5-[4-(4-Methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenylcarbamoy-
l]-naphthalen-2-yloxy}-pyrimidin-4-yl)-carbamic acid methyl ester,
6-(6-Acetylamino-pyrimidin-4-yloxy)naphthalene-1-carboxylic acid
[4-(4-isopropylpiperazin-1-ylmethyl)-3-trifluoromethylphenyl]amide,
6-(6-Aminopyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
[4-(4-isopropyl-piperazin-1-ylmethyl)-3-trifluoromethylphenyl]amide,
(6-{5-[4-(4-Isopropyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenylcarba-
moyl]-naphthalen-2-yloxy}-pyrimidin-4-yl)-carbamic acid methyl
ester,
7-(6-Acetylamino-pyrimidin-4-yloxy)-isoquinoline-4-carboxylic acid
[4-(4-methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-amide,
(6-{4-[4-(4-Methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenylcarbamoy-
l]-isoquinolin-7-yloxy}-pyrimidin-4-yl)-carbamic acid methyl ester,
7-(6-Amino-pyrimidin-4-yloxy)-isoquinoline-4-carboxylic acid
[4-(4-methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-amide,
7-(6-Amino-pyrimidin-4-yloxy)-isoquinoline-4-carboxylic acid
[5-tert-butyl-2-(4-isopropyl-phenyl)-2H-pyrazol-3-yl]-amide,
7-(6-Amino-pyrimidin-4-yloxy)-isoquinoline-4-carboxylic acid
[5-tert-butyl-2-(4-fluoro-phenyl)-2H-pyrazol-3-yl]-amide,
7-(6-Methylamino-pyrimidin-4-yloxy)-isoquinoline-4-carboxylic acid
(4-fluoro-3-trifluoromethyl-phenyl)-amide,
7-(6-Methylamino-pyrimidin-4-yloxy)-isoquinoline-4-carboxylic acid
(3-trifluoromethyl-phenyl)-amide,
6-(6-Methylamino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
[5-tert-butyl-2-(4-dimethylaminomethyl-phenyl)-2H-pyrazole-3-yl]-amide,
6-(6-Methylamino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
{5-tert-butyl-2-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-2H-pyrazol-3-y-
l}-amide, 6-(6-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic
acid
{5-tert-butyl-2-[4-(morpholin-4-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-amide,
6-(6-Methylamino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
{5-tert-butyl-2-[4-(morpholin-4-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-amide,
6-(6-Methylamino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
[5-tert-butyl-2-(3-methyl-phenyl)-2H-pyrazol-3-yl]-amide,
6-(6-Methylamino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
{5-tert-butyl-2-[3-(morpholin-4-ylmethyl)-phenyl]-2H-pyrazol-3-yl}-amide,
6-(6-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
[5-tert-butyl-2-(3-dimethylaminomethyl-phenyl)-2H-pyrazol-3-yl]-amide,
6-(6-Methylamino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
[5-tert-butyl-2-(3-dimethylaminomethyl-phenyl)-2H-pyrazol-3-yl]-amide,
6-(6-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
[5-tert-butyl-2-(3-dimethylcarbamoyl-phenyl)-2H-pyrazol-3-yl]-amide,
or 6-(6-Methylamino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic
acid
[5-tert-butyl-2-(3-dimethylcarbamoyl-phenyl)-2H-pyrazol-3-yl]-amide,
or a tautomer thereof, or a salt thereof.
20. 6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide, or a tautomer thereof, or a salt
thereof.
21. 6-(6-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide, or a tautomer thereof, or a salt
thereof.
22.
5-(2-Amino-6-chloro-pyrimidin-4-yloxy)-4-fluoro-2-methyl-2,3-dihydro--
indole-1-carboxylic acid (3-trifluoromethyl-phenyl)-amide, or a
tautomer thereof, or a salt thereof.
23. 6-(2-Amino-6-chloro-pyrimidin-4-yloxy)-naphthalene-1-carboxylic
acid (3-trifluoromethyl-phenyl)-amide, or a tautomer thereof, or a
salt thereof.
24. A pharmaceutical composition comprising a compound or salt
thereof according to claim 14, and a pharmaceutically acceptable
carrier.
25. A compound or salt thereof according to claim 14, for use in
the treatment of the animal or human body, especially in the
treatment of a protein kinase dependent disease.
26. A compound according to claim 25, wherein the protein kinase
dependent disease to be treated is a protein kinase dependent
disease, especially a proliferative disease, depending on any one
or more of the following protein kinases: EphB4, c-Abl, Bcr-Abl,
c-Kit, Raf, RET, PDGF-R and/or VEGF-R, especially VEGF-R.
27. Use of a compound according to claim 14 or a salt thereof, for
the preparation of a pharmaceutical composition for use in the
treatment of a protein kinase dependent disease.
28. The use according to claim 27 wherein the protein kinase
dependent disease is a protein kinase dependent disease, especially
a proliferative disease, depending on any one or more of the
following protein kinases: EphB4, c-Abl, Bcr-Abl, c-Kit, Raf, RET,
PDGF-R and/or VEGF-R, especially VEGF-R.
29. A compound as claimed in claim 25, wherein the protein kinase
dependent disease is selected from ocular neovascularisation,
diabetic retinopathy, age-related macular degeneration, psoriasis,
Von Hippel Lindau disease, hemangioblastoma, angioma, diabetic
nephropathy, malignant nephrosclerosis, thrombotic microangiopathy
syndrome, transplant rejection, glomerulonephritis,
mesangioproliferative glomerulonephritis, haemolytic-uraemic
syndrome, hypertensive nephrosclerosis, atheroma, arterial
restenosis, autoimmune disease, acute inflammation, hepatic
cirrhosis, diabetes, endometriosis, chronic asthma, arterial or
post-transplantational atherosclerosis, neurodegenerative
disorders, leukemias, breast cancer, adenocarcinoma, colorectal
cancer, lung cancer, renal cancer, liver cancer, pancreatic cancer,
ovarian cancer, cancer of the prostate, myeloma, multiple myeloma,
myelodysplastic syndrome, AML (acute myeloid leukemia), AMM
(agnogenic myeloid metaplasia), mesothelioma, glioma and/or
glioblastoma.
30. A compound as claimed in claim 26, wherein the protein kinase
dependent disease is selected from ocular neovascularisation,
diabetic retinopathy, age-related macular degeneration, psoriasis,
Von Hippel Lindau disease, hemangioblastoma, angioma, diabetic
nephropathy, malignant nephrosclerosis, thrombotic microangiopathy
syndrome, transplant rejection, glomerulonephritis,
mesangioproliferative glomerulonephritis, haemolytic-uraemic
syndrome, hypertensive nephrosclerosis, atheroma, arterial
restenosis, autoimmune disease, acute inflammation, hepatic
cirrhosis, diabetes, endometriosis, chronic asthma, arterial or
post-transplantational atherosclerosis, neurodegenerative
disorders, leukemias, breast cancer, adenocarcinoma, colorectal
cancer, lung cancer, renal cancer, liver cancer, pancreatic cancer,
ovarian cancer, cancer of the prostate, myeloma, multiple myeloma,
myelodysplastic syndrome, AML (acute myeloid leukemia), AMM
(agnogenic myeloid metaplasia), mesothelioma, glioma and/or
glioblastoma.
Description
[0001] The invention relates to compounds of formula I and their
use in the treatment of the animal or human body, to pharmaceutical
compositions comprising a compound of formula I and to the use of a
compound of formula I for the preparation of pharmaceutical
compositions for use in the treatment of protein kinase dependent
diseases, especially of proliferative diseases, such as in
particular tumour diseases.
[0002] Protein kinases (PKs) are enzymes which catalyze the
phosphorylation of specific serine, threonine or tyrosine residues
in cellular proteins. These post-translational modifications of
substrate proteins act as molecular switch regulating cell
proliferation, activation and/or differentiation. Aberrant or
excessive wild-type or mutated PK activity has been observed in
many disease states including benign and malignant proliferative
disorders. In many cases, it has been possible to treat diseases,
such as proliferative disorders, by making use of PK
inhibitors.
[0003] In view of the large number of protein kinases and the
multitude of proliferative and other PK-related diseases, there is
an ever-existing need to provide compounds that are useful as PK
inhibitors and thus in the treatment of these PK related
diseases.
[0004] It has now been found that the compounds of formula I show
inhibition of a number of protein kinases. The compounds of formula
I, described below in more detail, especially show inhibition of
one or more of the following protein kinases: EphB4, c-Abl,
Bcr-Abl, c-Kit, Raf kinases such as especially B-Raf, the
rearranged during transfection (RET) proto-oncogene,
Platelet-derived Growth Factor Receptors (PDGF-Rs) and most
especially the Vascular Endothelial Growth Factor Receptors
(VEGF-Rs) such as in particular VEGF-R2. The compounds of formula I
further also inhibit mutants of said kinases. In view of these
activities, the compounds of formula I can be used for the
treatment of diseases related to especially aberrant or excessive
activity of such types of kinases, especially those mentioned.
[0005] The invention especially relates to compounds of the formula
I
##STR00002##
wherein R.sub.1 is H; halo; cyano; --C.sub.0-C.sub.7--O--R.sub.3;
--C.sub.0-C.sub.7--NR.sub.4R.sub.5; or --C(.dbd.O)--R.sub.6;
R.sub.2 is substituted C.sub.3-C.sub.8-cycloalkyl; substituted
aryl; or substituted heterocyclyl; R.sub.3 is H or unsubstituted or
substituted lower alkyl; R.sub.4 and R.sub.5 are independently
selected from the group consisting of H; unsubstituted or
substituted lower alkyl; lower alkyl-carbonyl, wherein the lower
alkyl moiety is optionally substituted; and lower alkoxy-carbonyl,
wherein the lower alkyl moiety is optionally substituted; R.sub.6
is H; unsubstituted or substituted lower alkyl; lower alkoxy,
wherein the lower alkyl moiety is optionally substituted; or
unsubstituted, mono- or di-substituted amino; A, B and X are
independently selected from .dbd.C(R.sub.7)-- or N; E, G and T are
independently selected from .dbd.C(R.sub.8)-- or N; R.sub.7 and
R.sub.8 are independently selected from the group consisting of H,
halo and unsubstituted or substituted lower alkyl;
Y is --O--, --S--, --S(O)--, --S(O).sub.2--, --CH.sub.2--,
--CH.sub.2--CH.sub.2--, --CH.dbd.CH-- or --C.ident.O--;
[0006] Z is CH or N and Q is C.sub.1-C.sub.4-alkylene or
C.sub.2-C.sub.4-alkenylene, wherein C.sub.1-C.sub.4-alkylene or
C.sub.2-C.sub.4-alkenylene optionally may be substituted and
wherein one or more of the carbon atoms of said
C.sub.1-C.sub.4-alkylene or C.sub.2-C.sub.4-alkenylene chain
optionally may be replaced by a heteroatom independently selected
from nitrogen, oxygen and sulfur; and the bond between Q and Z
characterized by a dotted line is a single bond; with the proviso
that if Z is N, Q is not unsubstituted unbranched
C.sub.1-C.sub.4-alkylene; or Z is C and Q is as defined above
wherein the bond between Q and Z characterized by a dotted line is
a double bond; and W is either not present or
C.sub.1-C.sub.3-alkylene; or a tautomer thereof, or a salt
thereof.
[0007] The present invention also relates to a method of treating a
kinase dependent and/or proliferative disease comprising
administering a compound of the formula I to a warm-blooded animal,
especially a human, and the use of a compound of the formula I,
especially for treating a kinase dependent disease or disorder. The
present invention also relates to pharmaceutical preparations
comprising a compound of the formula I, especially for the
treatment of a kinase dependent disease or disorder, a process for
the manufacture of a compound of the formula I, and novel starting
materials and intermediates for their manufacture. The present
invention also relates to the use of a compound of formula I in the
manufacture of a pharmaceutical preparation for the treatment of a
kinase dependent disease.
[0008] The general terms used hereinbefore and hereinafter
preferably have, within this disclosure, the following meanings,
unless otherwise indicated:
[0009] The term "lower" defines a moiety with up to and including
maximally 7, especially up to and including maximally 4, carbon
atoms, said moiety being branched or straight-chained. Lower alkyl,
for example, is n-pentyl, n-hexyl or n-heptyl or preferably
C.sub.1-C.sub.4-alkyl, especially as methyl, ethyl, n-propyl,
sec-propyl, n-butyl, isobutyl, sec-butyl, tert-butyl.
[0010] The term "C.sub.0-C.sub.7--" is as defined above for "lower"
with the difference that in case of "C.sub.0--" no carbon atom is
present.
[0011] Substituted lower alkyl or a substituted lower alkyl moiety
is a lower alkyl radical/moiety substituted by one or more,
preferably one, substituent, selected independently from e.g.
amino, N-lower alkylamino, N,N-di-lower alkylamino, N-lower
alkanoylamino, N,N-di-lower alkanoylamino, hydroxy, lower alkoxy,
lower alkanoyl, lower alkanoyloxy, cyano, nitro, carboxy, lower
alkoxycarbonyl, carbamoyl, N-lower alkyl-carbamoyl, N,N-di-lower
alkyl-carbamoyl, amidino, guanidino, ureido, mercapto, lower
alkylthio, halo, or unsubstituted or substituted heterocyclyl.
[0012] C.sub.1-C.sub.4-alkylene and C.sub.2-C.sub.4-alkenylene may
be branched or unbranched and are in particular
C.sub.2-C.sub.3-alkylene and C.sub.2-C.sub.3-alkenylene,
respectively. In optionally substituted C.sub.1-C.sub.4-alkylene or
C.sub.2-C.sub.4-alkenylene, the substituents are e.g. selected from
amino, N-lower alkylamino, N,N-di-lower alkylamino, N-lower
alkanoylamino, N,N-di-lower alkanoylamino, hydroxy, lower alkoxy,
lower alkanoyl, lower alkanoyloxy, cyano, nitro, carboxy, lower
alkoxycarbonyl, carbamoyl, N-lower alkyl-carbamoyl, N,N-di-lower
alkyl-carbamoyl, amidino, guanidino, ureido, mercapto, lower
alkylthio and halo, or lower alkyl substituted by one or more,
preferably one, of said substituents.
[0013] Mono- or di-substituted amino is amino substituted by one or
two radicals selected independently of one another from e.g.
substituted and especially unsubstituted lower alkyl.
[0014] Substituted C.sub.3-C.sub.8-cycloalkyl is especially
cyclopropyl or cyclohexyl and is preferably substituted as
described for substituted aryl.
[0015] Substituted aryl is preferably an aromatic radical with 4 to
8 carbon atoms, especially phenyl, wherein said radical is
substituted by one or more, preferably by one or two, radicals such
as e.g. unsubstituted or substituted lower alkyl, amino, N-lower
alkylamino, N,N-di-lower alkylamino, N-lower alkanoylamino,
N,N-di-lower alkanoylamino, hydroxy, lower alkoxy, lower alkanoyl,
lower alkanoyloxy, cyano, nitro, carboxy, lower alkoxycarbonyl,
carbamoyl, N-lower alkyl-carbamoyl, N,N-di-lower alkyl-carbamoyl,
amidino, guanidino, ureido, mercapto, lower alkylthio, halo, or
unsubstituted or substituted heterocyclyl.
[0016] Unsubstituted or substituted heterocyclyl is preferably a
saturated, partially saturated or unsaturated mono- or bicyclic
radical having from 4 to 8 ring members and from 1 to 3 heteroatoms
which are preferably selected from nitrogen, oxygen and sulfur,
said radical being unsubstituted or substituted preferably as
described for substituted aryl.
Halo(geno) is preferably iodo, bromo, chloro or fluoro, especially
fluoro, chloro or bromo. R.sub.1 is preferably amino; halo, such as
especially chloro; cyano; lower alkyl-amino, such as especially
methylamino; amino-lower alkyl, such as especially amino-methyl;
mono- or di-lower alkyl-amino-lower alkyl, such as especially
methylamino-methyl or dimethylamino-methyl; lower alkoxy-carbonyl,
such as especially methoxy-carbonyl, ethoxy-carbonyl or
butoxy-carbonyl; mono- or di-lower alkyl-amino-carbonyl, such as
especially methylamino-carbonyl, dimethylamino-carbonyl or
isopropylamino-carbonyl;
(2)-dimethylamino-ethyl-(1)-amino-carbonyl; lower
alkyl-carbonyl-amino such as especially methylcarbonyl-amino; lower
alkoxy-carbonyl-amino, such as especially methoxycarbonyl-amino or
butoxycarbonyl-amino; carboxyl; hydroxy-methyl; chloro-methyl or
methoxy-carbonyl-amino-methyl. R.sub.1 is most preferably amino; or
methylcarbonyl-amino. R.sub.2 is preferably a cyclohexyl, phenyl or
pyridyl, especially a phenyl, radical wherein said radical is
substituted by one or more, especially 1 or 2, substituents
independently selected from the group consisting of lower alkyl;
cyclopropyl; methoxy; halo; halo-lower alkyl, such as especially
trifluoromethyl or difluoroethyl; trifluoromethoxy; morpholinyl,
such as especially morpholin-4-yl; morpholinyl-lower alkyl, such as
especially morpholin-4-ylmethyl; piperazinyl-lower alkyl and lower
alkyl-piperazinyl-lower alkyl, such as especially
4-methylpiperazin-1-ylmethyl. R.sub.2 is most preferably phenyl,
substituted by one or two radicals independently selected from the
group consisting of fluoro, trifluoromethyl and
4-methylpiperazin-1-ylmethyl. Preferably X is .dbd.C(R.sub.7)-- and
one of A and B is N while the other is .dbd.C(R.sub.7)--; most
preferably X and A are both .dbd.CH-- and B is N. Preferably E, G
and T are .dbd.C(R.sub.7)--; most preferably E, G and T are all
.dbd.CH--. R.sub.7 and R.sub.8 are preferably H or halo; most
preferably R.sub.7 and R.sub.8 are H. Y is preferably --O--. Z is
preferably N or C, most preferably C. Q is preferably
C.sub.2-C.sub.4-alkenylene, or C.sub.1-C.sub.4-alkylene wherein one
or more, especially one, of the carbon atoms of
C.sub.1-C.sub.4-alkylene is replaced by a heteroatom independently
selected from nitrogen, oxygen and sulfur, especially from oxygen.
Q is especially selected from --O--CH.sub.2--[Z],
--O--CH.sub.2--CH.sub.2--[Z], --CH.dbd.CH-- and
--CH.dbd.CH--CH.dbd., wherein "--[Z]" indicates where the bivalent
radical is bound to Z in formula I if there are two possibilities;
most preferably Q is --CH.dbd.CH--CH.dbd.. W is preferably not
present.
[0017] Where the plural form is used for compounds, salts,
pharmaceutical compositions, diseases and the like, this is
intended to mean also a single compound, salt, or the like.
[0018] In view of the close relationship between the compounds of
formula I in free form and in the form of their salts, including
those salts that can be used as intermediates, for example in the
purification or identification of the compounds of formula I,
tautomers or tautomeric mixtures and their salts, any reference
hereinbefore and hereinafter to these compounds is to be understood
as referring also to the corresponding tautomers of these
compounds, tautomeric mixtures of these compounds, N-oxides of
these compounds, or salts of any of these, as appropriate and
expedient and if not mentioned otherwise. Tautomers can, e.g., be
present in cases where amino or hydroxy are bound to carbon atoms
that are bound to adjacent atoms by double bonds (e.g. keto-enol or
imine-enamine tautomerism).
[0019] Where "a compound . . . , a tautomer thereof; or a salt
thereof" or the like is mentioned, this means "a compound . . . , a
tautomer thereof, or a salt of the compound or the tautomer".
[0020] Asymmetric carbon atoms of a compound of formula I that are
optionally present may exist in the (R), (S) or (R,S)
configuration, preferably in the (R) or (S) configuration.
Substituents at a double bond or a ring may be present in cis-
(=Z-) or trans (=E-) form. The compounds may thus be present as
mixtures of isomers or preferably as pure isomers.
[0021] Salts are preferably the pharmaceutically acceptable salts
of the compounds of formula I.
[0022] Salt-forming groups are groups or radicals having basic or
acidic properties. Compounds having at least one basic group or at
least one basic radical, for example amino, a secondary amino group
not forming a peptide bond or a pyridyl radical, may form acid
addition salts, for example with inorganic acids, such as
hydrochloric acid, sulfuric acid or a phosphoric acid, or with
suitable organic carboxylic or sulfonic acids, for example
aliphatic mono- or di-carboxylic acids, such as trifluoroacetic
acid, acetic acid, propionic acid, glycolic acid, succinic acid,
maleic acid, fumaric acid, hydroxymaleic acid, malic acid, tartaric
acid, citric acid or oxalic acid, or amino acids such as arginine
or lysine, aromatic carboxylic acids, such as benzoic acid,
2-phenoxy-benzoic acid, 2-acetoxy-benzoic acid, salicylic acid,
4-aminosalicylic acid, aromatic-aliphatic carboxylic acids, such as
mandelic acid or cinnamic acid, heteroaromatic carboxylic acids,
such as nicotinic acid or isonicotinic acid, aliphatic sulfonic
acids, such as methane-, ethane- or 2-hydroxyethanesulfonic acid,
or aromatic sulfonic acids, for example benzene-, p-toluene- or
naphthalene-2-sulfonic acid. When several basic groups are present
mono- or poly-acid addition salts may be formed.
[0023] Compounds having acidic groups, a carboxy group or a
phenolic hydroxy group, may form metal or ammonium salts, such as
alkali metal or alkaline earth metal salts, for example sodium,
potassium, magnesium or calcium salts, or ammonium salts with
ammonia or suitable organic amines, such as tertiary monoamines,
for example triethylamine or tri-(2-hydroxyethyl)-amine, or
heterocyclic bases, for example N-ethyl-piperidine or
N,N'-dimethylpiperazine. Mixtures of salts are possible.
[0024] Compounds having both acidic and basic groups can form
internal salts.
[0025] For the purposes of isolation or purification, as well as in
the case of compounds that are used further as intermediates, it is
also possible to use pharmaceutically unacceptable salts, e.g. the
picrates. Only pharmaceutically acceptable, non-toxic salts may be
used for therapeutic purposes, however, and those salts are
therefore preferred.
[0026] The terms "treatment" or "therapy" refer to the prophylactic
or preferably therapeutic (including but not limited to palliative,
curing, symptom-alleviating, symptom-reducing, kinase-regulating
and/or kinase-inhibiting) treatment of said diseases, especially of
the diseases mentioned below.
[0027] Where subsequently or above the term "use" is mentioned (as
verb or noun) (relating to the use of a compound of the formula I
or a pharmaceutically acceptable salt thereof), this includes any
one or more of the following embodiments of the invention,
respectively: the use in the treatment of a protein kinase
dependent disease, the use for the manufacture of pharmaceutical
compositions for use in the treatment of a protein kinase dependent
disease, methods of use of one or more compounds of the formula I
in the treatment of a protein kinase dependent disease, the use of
pharmaceutical preparations comprising one or more compounds of the
formula I for the treatment of a protein kinase dependent disease,
and one or more compounds of the formula I for use in the treatment
of a protein kinase dependent disease, as appropriate and expedient
and if not stated otherwise. In particular, diseases to be treated
and are thus preferred for "use" of a compound of formula I are
selected from protein kinase dependent ("dependent" meaning also
"supported", not only "solely dependent") diseases mentioned
herein, especially proliferative diseases mentioned herein, more
especially any one or more of these or other diseases that depend
on one or more of c-Abl, Bcr-Abl, c-Kit, Raf kinases such as
especially B-Raf, the rearranged during transfection (RET)
proto-oncogene, Platelet-derived Growth Factor Receptors (PDGF-Rs)
and most especially the Vascular Endothelial Growth Factor
Receptors (VEGF-Rs) such as in particular VEGF-R2, or a mutant of
any one or more of these, and a compound of the formula I can
therefore be used in the treatment of a kinase dependent disease,
especially a disease depending on one or more of the kinases
mentioned above and below, where (especially in the case of
aberrantly highly-expressed, constitutively activated and/or
mutated kinases) said kinase-dependent disease is dependent on the
activity of one or more of the said kinases or the pathways they
are involved.
[0028] The compounds of formula I have valuable pharmacological
properties and are useful in the treatment of protein kinase
dependent diseases, for example as drugs to treat proliferative
diseases.
[0029] The efficacy of the compounds of formula I as inhibitors of
c-Abl protein tyrosine kinase activity can be demonstrated as
follows:
[0030] An in vitro enzyme assay is performed in 96-well plates as a
filter binding assay as described by Geissler et al., in Cancer
Res. 1992; 52:4492-4498, with the following modifications. The
His-tagged kinase domain of c-Abl is cloned and expressed in the
baculovirus/Sf9 system as described by Bhat at al. in J. Biol.
Chem. 1997; 272:16170-16175. A protein of 37 kD (c-Abl kinase) is
purified by a two-step procedure over a Cobalt metal chelate column
followed by an anion exchange column with a yield of 1-2 mg/L of
Sf9 cells (Bhat et al., reference cited). The purity of the c-Abl
kinase is >90% as judged by SDS-PAGE after Coomassie blue
staining. The assay contains (total volume of 30 .mu.L): c-Abl
kinase (50 ng), 20 mM Tris.HCl, pH 7.5, 10 mM MgCl.sub.2, 10 .mu.M
Na.sub.3VO.sub.4, 1 mM DTT and 0.06 .mu.Ci/assay
[.gamma..sup.33P]-ATP (5 .mu.M ATP) using 30 .mu.g/ml
poly-Ala,Glu,Lys,Tyr-6:2:5:1 (Poly-AEKY, Sigma P1152) in the
presence of 1% DMSO. Reactions are terminated by adding 10 .mu.L of
250 mM EDTA and 30 .mu.L of the reaction mixture is transferred
onto Immobilon-PVDF membrane (Millipore, Bedford, Mass., USA)
previously soaked for 5 min with methanol, rinsed with water, then
soaked for 5 min with 0.5% H.sub.3PO.sub.4 and mounted on vacuum
manifold with disconnected vacuum source. After spotting all
samples, vacuum is connected and each well rinsed with 200 .mu.L
0.5% H.sub.3PO.sub.4. Membranes are removed and washed on a shaker
with 0.5% H.sub.3PO.sub.4 (4 times) and once with ethanol.
Membranes are counted after drying at ambient temperature, mounting
in Packard TopCount 96-well frame, and addition of 10 .mu.L/well of
Microscint.TM. (Packard). Using this test system, the compounds of
formula I show IC.sub.50 values of inhibition in the range of 0.001
to 100 .mu.M, usually between 0.05 and 5 .mu.M.
[0031] Bcr-Abl inhibition can be determined by a capture ELISA as
follows: The murine myeloid progenitor cell line 32Dcl3 transfected
with the p210 Bcr-Abl expression vector pGDp210Bcr/Abl
(32D-bcr/abl) is obtained from J Griffin (Bazzoni et al., J. Clin
Invest. 98, 521-8 (1996); Zhao et al., Blood 90, 4687-9 (1997)).
The cells express the fusion bcr-abl protein with a constitutively
active abl kinase and proliferate growth factor-independent. The
cells are expanded in RPMI 1640 (AMIMED; cat #1-41F01), 10% fetal
calf serum, 2 mM glutamine (Gibco) ("complete medium"), and a
working stock is prepared by freezing aliquots of 2.times.10.sup.6
cells per vial in freezing medium (95% fetal calf serum, 5%
dimethylsulfoxide (SIGMA, D-2650). After thawing, the cells are
used during maximally 10-12 passages for the experiments. The
antibody anti-abl SH3 domain cat. # 06-466 from Upstate
Biotechnology is used for the ELISA. For detection of bcr-abl
phosphorylation, the anti-phosphotyrosine antibody Ab PY20,
labelled with alkaline phosphatase (PY10(AP)) from ZYMED (cat. #
03-7722) is used. As comparison and reference compound,
(N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3--
pyridyl)-2-pyrimidine-amine, in the form of the methane sulfonate
(monomesylate) salt (STI571) (marketed as Gleevec.RTM. or
Glivec.RTM., Novartis), is used. A stock solution of 10 mM is
prepared in DMSO and stored at -20.degree. C. For the cellular
assays, the stock solution is diluted in complete medium in two
steps (1:100 and 1:10) to yield a starting concentration of 10
.mu.M followed by preparation of serial three-fold dilutions in
complete medium. No solubility problems are encountered using this
procedure. The test compounds of formula I are treated analogously.
For the assay, 200,000 32D-bcr/abl cells in 50 .mu.l are seeded per
well in 96 well round bottom tissue culture plates. 50 .mu.l per
well of serial threefold dilutions of the test compound are added
to the cells in triplicates. The final concentration of the test
compound range e.g. from 5 .mu.M down to 0.01 .mu.M. Untreated
cells are used as control. The compound is incubated together with
the cells for 90 min at 37.degree. C., 5% CO.sub.2, followed by
centrifugation of the tissue culture plates at 1300 rpm (Beckman
GPR centrifuge) and removal of the supernatants by careful
aspiration taking care not to remove any of the pelleted cells. The
cell pellets are lysed by addition of 150 .mu.l lysis buffer (50 mM
Tris/HCl, pH 7.4, 150 mM sodium chloride, 5 mM EDTA, 1 mM EGTA, 1%
NP-40 (non-ionic detergent, Roche Diagnostics GmbH, Mannheim,
Germany), 2 mM sodium ortho-vanadate, 1 mM phenylmethyl
sulfonylfluoride, 50 .mu.g/ml aprotinin and 80 .mu.g/ml leupeptin)
and either used immediately for the ELISA or stored frozen at
-20.degree. C. until usage. The anti-abl SH3 domain antibody is
coated at 200 ng in 50 .mu.l PBS per well to black ELISA plates
(Packard HTRF-96 black plates; 6005207) overnight at 4.degree. C.
After washing 3.times. with 200 .mu.l/well PBS containing 0.05%
Tween 20 (PBST) and 0.5% TopBlock (Juro, Cat. # TB 232010),
residual protein binding sites are blocked with 200 .mu.l/well
PBST, 3% TopBlock for 4 h at room temperature, followed by
incubation with 50 .mu.l lysates of untreated or test
compound-treated cells (20 .mu.g total protein per well) for 3-4 h
at 4.degree. C. After 3.times. washing, 50 .mu.l/well PY20(AP)
(Zymed) diluted to 0.5 .mu.g/ml in blocking buffer is added and
incubated overnight (4.degree. C.). For all incubation steps, the
plates are covered with plate sealers (Costar, cat. # 3095).
Finally, the plates are washed another three times with washing
buffer and once with deionized water before addition of 90 .mu./ml
of the AP substrate CPDStar RTU with Emerald II. The plates now
sealed with Packard Top Seal.TM.-A plate sealers (cat. # 6005185)
are incubated for 45 min at room temperature in the dark and
luminescence is quantified by measuring counts per second (CPS)
with a Packard Top Count Microplate Scintillation Counter (Top
Count). For the final optimized version of the ELISA, 50 .mu.l of
the lysates of the cells grown, treated and lysed in 96 well tissue
culture plates, are transferred directyl from these plates to the
ELISA plates that are precoated with 50 ng/well of the rabbit
poylclonal ant-abl-SH3 domain AB 06-466 from Upstate. The
concentration of the anti-phosphotyrosine AB PY20 (AP) can be
reduced to 0.2 .mu.g/ml. Washing, blocking and incubation with the
luminescent substrate are as above. The quantification is achieved
as follows: The difference between the ELISA readout (CPS) obtained
for with the lysates of the untreated 32D-bcr/abl cells and the
readout for the assay background (all components, but without cell
lysate) is calculated and taken as 100% reflecting the
constitutively phosphorylated bcr-abl protein present in these
cells. The activity of the compound in the bcr-abl kinase activity
is expressed as percent reduction of the bcr-abl phosphorylation.
The values for the IC.sub.50 are determined from the dose response
curves by graphical inter- or extrapolation. The compounds of
formula I here show IC.sub.50 values in the range from 20 nM to 20
.mu.M.
[0032] The efficacy of the compounds of formula I as inhibitors of
c-Kit and PDGF-R tyrosine kinase activity can be demonstrated as
follows:
[0033] BaF3-Tel-PDGFRbeta and BaF3-KitD816V are BaF3 murine
proB-cell lymphoma cell derivatives [the BaF3 cell line is
available from the German Collection of Microorganisms and Cell
Cultures (DSMZ), Braunschweig, Germany] that have been rendered
IL-3-independent by stable transduction with Tel-fusion-activated
PDGF/.beta.-R wild-type (Golub T. R. et al., Cell 77(2): 307-316,
1994) or D816V-mutation-activated c-kit, respectively. Cells are
cultured in RPMI-1640 (Animed # 1-14F01-I) supplemented with 2%
L-glutamine (Animed # 5-10K50-H) and 10% fetal calf serum (FCS,
Animed # 2-01F16-I). Wild-type, untransfected BaF3 cells are
maintained in above medium plus 10 U/ml IL-3 (mouse Interleukin-3,
Roche # 1380745).
[0034] Cells are diluted in fresh medium to a final density of
3.times.10.sup.5 cells per ml and 50 .mu.l aliquots seeded into
96-well plates (1.5.times.10.sup.4 cells per well). 50 .mu.l
2.times. compound solutions are added. As internal control, the
kinase inhibitor PKC412 is routinely used. Control cells treated
with DMSO (0.1% final concentration) serve as growth reference (set
as 100% growth). In addition, a plate blank value is routinely
determined in a well containing only 100 .mu.l of medium and no
cells. IC.sub.50 determinations are performed based on eight 3-fold
serial dilutions of the test compound, starting at 10 .mu.M.
Following incubation of the cells for 48 h at 37.degree. C. and 5%
CO.sub.2, the effect of inhibitors on cell viability is assessed by
the resazurin sodium salt dye reduction assay (commercially known
as AlamarBlue assay) basically as previously described (O'Brien J.
et al., Eur. J. Biochem. 267: 5421-5426, 2000). 10 .mu.l of
AlamarBlue is added per well and the plates incubated for 6 h at
37.degree. C. and 5% CO.sub.2. Thereafter, fluorescence is measured
using a Gemini 96-well plate reader (Molecular Devices) with the
following settings: Excitation 544 nm and Emission 590 nm.
[0035] Acquired raw data are exported to Excel-file format. For
data analysis, the plate blank value is subtracted from all data
points. The anti-proliferative effect of a compound by the
AlamarBlue read-out was then calculated as percentage of the value
of the control cells set as 100%. IC.sub.50 values are determined
using XLfit software program. The compounds of formula I show an
IC.sub.50 for c-Kit and PDGF/.beta.-R in the range of 0.0003 to 20
.mu.M, especially between 0.001 and 0.1 .mu.M.
[0036] Active Raf kinases, such as active B-Raf protein, of human
sequence are purified from insect cells using the baculoviral
expression system. Raf inhibition is tested in 96-well microplates
coated with I.kappa.B-.alpha. and blocked with Superblock. The
phosphorylation of I.kappa.B-.alpha. at Serine 36 is detected using
a phospho-I.kappa.B-.alpha. specific antibody (Cell Signaling
#9246), an anti-mouse IgG alkaline phosphatase conjugated secondary
antibody (Pierce # 31320), and an alkaline phosphatase substrate,
ATTOPHOS (Promega, #S101).
[0037] RET kinase inhibition is determined as follows:
Cloning and expression: The baculovirus donor vector pFB-GSTX3 is
used to generate a recombinant baculovirus that expresses the amino
acid region 658-1072 (Swiss prot No. Q9BTB0) of the cytoplasmic
kinase domain of human RET-Men2A which corresponds to the wild-type
kinase domain of RET (wtRET) and RET-Men2B, which differs from the
wtRET by the activating mutation in the activation loop M918T. The
coding sequence for the cytoplasmic domain of wtRET is amplified by
PCR from a cDNA library using specific primers. RET-Men2B is
generated through site-directed mutagenesis resulting in the M918T
mutation. The amplified DNA fragments and the pFB-GSTX3 vector are
made compatible for ligation by digestion with SalI and KpnI.
Ligation of these DNA fragments results in the baculovirus donor
plasmids pFB-GX3-RET-Men2A and pFB-GX3-RET-Men2B, respectively.
Production of virus: The baculovirus donor plasmids containing the
kinase domains are transfected into the DH10Bac cell line (GIBCO)
and the transfected cells are plated on selective agar plates.
Colonies without insertion of the fusion sequence into the viral
genome (carried by the bacteria) are blue. Single, white colonies
are picked and viral DNA (bacmid) is isolated from the bacteria by
standard plasmid purification procedures. Sf9 cells or Sf21 cells
(American Type Culture Collection) are then transfected in 25
cm.sup.2 flasks with the viral DNA using Cellfectin reagent.
Protein expression in Sf9 cells: Virus-containing media is
collected from the transfected cell culture and used for infection
to increase its titer. Virus-containing media obtained after two
rounds of infection is used for large-scale protein expression. For
large-scale protein expression 100 cm.sup.2 round tissue culture
plates are seeded with 5.times.10.sup.7 cells/plate and infected
with 1 ml of virus-containing media (approximately 5 MOIs). After 3
days, the cells are scraped off the plate and centrifuged at 500
rpm for 5 minutes. Cell pellets from 10-20, 100 cm.sup.2 plates are
re-suspended in 50 ml of ice-cold lysis buffer (25 mM Tris-HCl, pH
7.5, 2 mM EDTA, 1% NP-40, 1 mM DTT, 1 mM PMSF). The cells are
stirred on ice for 15 minutes and then centrifuged at 5,000 rpms
for 20 minutes. Purification of GST-tagged proteins: The
centrifuged cell lysate is loaded onto a 2 ml glutathione-sepharose
column (Pharmacia) and washed 3.times. with 10 ml of 25 mM
Tris-HCl, pH 7.5, 2 mM EDTA, 1 mM DTT, 200 mM NaCl. The GST-tagged
proteins are then eluted by 10 applications (1 ml each) of 25 mM
Tris-HCl, pH 7.5, 10 mM reduced-glutathione, 100 mM NaCl, 1 mM DTT,
10% glycerol and stored at -70.degree. C. Measure of enzyme
activity: Tyrosine protein kinase assays with either purified
GST-wtRET or GST-RET-Men2B protein are carried out in a final
volume of 30 .mu.L containing 15 ng of either GST-wtRET or
GST-RET-Men2B protein, 20 mM Tris-HCl, pH 7.5, 1 mM MnCl.sub.2, 10
mM MgCl.sub.2, 1 mM DTT, 3 .mu.g/ml poly(Glu,Tyr) 4:1, 1% DMSO, 2.0
.mu.M ATP (.gamma.-[.sup.33P]-ATP 0.1 .mu.Ci). The activity is
assayed in the presence or absence of inhibitors, by measuring the
incorporation of .sup.33P from [.gamma..sup.33P] ATP into
poly(Glu,Tyr) 4:1. The assay is carried out in 96-well plates at
ambient temperature for 15 minutes under conditions described above
and terminated by the addition of 20 .mu.L of 125 mM EDTA.
Subsequently, 40 .mu.L of the reaction mixture are transferred onto
Immobilon-PVDF membrane (Millipore) previously soaked for 5 minutes
with methanol, rinsed with water, then soaked for 5 minutes with
0.5% H.sub.3PO.sub.4 and mounted on vacuum manifold with
disconnected vacuum source. After spotting all samples, vacuum is
connected and each well rinsed with 200 .mu.L 0.5% H.sub.3PO.sub.4.
Membranes are removed and washed 4.times. on a shaker with 1.0%
H.sub.3PO.sub.4, once with ethanol. Membranes are counted after
drying at ambient temperature, mounting in Packard TopCount 96-well
frame, and addition of 10 .mu.L/well of Microscint.TM. (Packard).
IC.sub.50 values are calculated by linear regression analysis of
the percentage inhibition of each compound in duplicate, at 4
concentrations (usually 0.01, 0.1, 1 and 10 .mu.M). One unit of
protein kinase activity is defined as 1 nmole of .sup.33P
transferred from [.gamma..sup.33P] ATP to the substrate
protein/minute/mg of protein at 37.degree. C. The compounds of
formula I here show IC.sub.50 values in the range between 0.005 and
20 .mu.M, especially between 0.01 and 1 .mu.M.
[0038] VEGF-R1 inhibition can be shown as follows: the test is
conducted using Flt-1 VEGF-receptor tyrosine kinase. The detailed
procedure is as follows: 30 .mu.l kinase solution (kinase domain of
Flt-1, Shibuya et al., Oncogene 5, 519-24 [1990], according to the
specific activity, in order to achieve an activity of 4000-6000
counts per minute [cpm] in the sample without inhibitor) in 20 mM
Tris.HCl pH 7.5, 3 mM manganese dichloride (MnCl.sub.2), 3 mM
magnesium chloride (MgCl.sub.2) and 3 .mu.g/ml poly(Glu,Tyr) 4:1
(Sigma, Buchs, Switzerland), 8 .mu.M [.sup.33P]-ATP (0.2
.mu.Ci/batch), 1% dimethyl sulfoxide, and 0 to 50 .mu.M of the
compound to be tested are incubated together for 10 minutes at room
temperature. The reaction is then ended by the addition of 10 .mu.l
0.25 Methylenediaminetetraacetate (EDTA) pH 7. Using a multichannel
dispenser (LAB SYSTEMS, USA), an aliquot of 20 .mu.l is applied to
a PVDF (=polyvinyl difluoride) Immobilon P membrane (Millipore,
USA), which is incorporated into a Millipore microtitre filter
manifold, and connected to a vacuum. Following complete elimination
of the liquid, the membrane is washed 4 times successively in a
bath containing 0.5% phosphoric acid (H.sub.3PO.sub.4), incubated
for 10 minutes each time while shaking, then mounted in a Hewlett
Packard TopCount Manifold and the radioactivity measured after the
addition of 10 .mu.l Microscint.RTM. (.beta.-scintillation counter
liquid; Packard USA). IC.sub.50-values are determined by linear
regression analysis of the percentages for the inhibition of each
compound in three concentrations (as a rule 0.01, 0.1, and 1
.mu.M). The IC.sub.50 values that can be found with the compounds
of formula I are in the range of 0.01 to 100 .mu.M, especially in
the range from 0.01 to 20 .mu.M.
[0039] Analogously to the above test, the efficacy of the compounds
according to the invention as inhibitors of VEGF-R2 tyrosine kinase
activity can be tested using the VEGF receptor tyrosine kinase KDR.
In this test, instead of the Flt-1 kinase domain, the KDR kinase
domain (Parast et al., Biochemistry 37 (47), 16788-801 (1998)) is
used. The only difference in carrying out this test from the above
test lies in the concentration of poly(Glu,Tyr) 4:1 (8 .mu.g/ml),
MnCl.sub.2 (1 mM) and MgCl.sub.2 (10 mM). Compounds of formula I in
this instance have IC.sub.50 values in the range of 0.0003 .mu.M to
20 .mu.M, especially in the range of 10 nM to 500 nM.
[0040] The inhibition of VEGF-induced receptor autophosphorylation
can be confirmed with an in vitro experiments in cells such as
transfected CHO cells, which permanently express human VEGF-R2
(KDR), are seeded in complete culture medium (with 10% fetal calf
serum=FCS) in 6-well cell-culture plates and incubated at
37.degree. C. under 5% CO.sub.2 until they show about 80%
confluency. The compounds to be tested are then diluted in culture
medium (without FCS, with 0.1% bovine serum albumin) and added to
the cells. (Controls comprise medium without test compounds). After
two hours of incubation at 37.degree. C., recombinant VEGF is
added; the final VEGF concentration is 20 ng/ml. After a further
five minutes incubation at 37.degree. C., the cells are washed
twice with ice-cold PBS (phosphate-buffered saline) and immediately
lysed in 100 .mu.l lysis buffer per well. The lysates are then
centrifuged to remove the cell nuclei, and the protein
concentrations of the supernatants are determined using a
commercial protein assay (BIORAD). The lysates can then either be
immediately used or, if necessary, stored at -20.degree. C.
[0041] A sandwich ELISA is carried out to measure the VEGF-R2
phosphorylation: a monoclonal antibody to VEGF-R2 (for example Mab
1495.12.14; prepared by H. Towbin, Novartis or comparable
monoclonal antibody) is immobilized on black ELISA plates
(OptiPlate.TM. HTRF-96 from Packard). The plates are then washed
and the remaining free protein-binding sites are saturated with 3%
TopBlock.RTM. (Juro, Cat. # TB232010) in phosphate buffered saline
with Tween 20.RTM. (polyoxyethylen(20)sorbitane monolaurate,
ICl/Uniquema) (PBST). The cell lysates (20 .mu.g protein per well)
are then incubated in these plates overnight at 4.degree. C.
together with an antiphosphotyrosine antibody coupled with alkaline
phosphatase (PY20:AP from Zymed). The (plates are washed again and
the) binding of the antiphosphotyrosine antibody to the captured
phosphorylated receptor is then demonstrated using a luminescent AP
substrate (CDP-Star, ready to use, with Emerald II; Applied
Biosystems). The luminescence is measured in a Packard Top Count
Microplate Scintillation Counter. The difference between the signal
of the positive control (stimulated with VEGF) and that of the
negative control (not stimulated with VEGF) corresponds to
VEGF-induced VEGF-R2 phosphorylation (=100%). The activity of the
tested substances is calculated as percent inhibition of
VEGF-induced VEGF-R2 phosphorylation, wherein the concentration of
substance that induces half the maximum inhibition is defined as
the IC.sub.50 (inhibitory dose for 50% inhibition). The compounds
of formula I here show an IC.sub.50 in the range of 0.0003 to 20
.mu.M, especially between 0.001 and 0.1 .mu.M.
[0042] Based on the property of the compounds of formula I as
potent VEGF receptor inhibitors, the compounds of formula I are
especially suitable for the treatment of diseases associated with
deregulated angiogenesis, especially diseases caused by ocular
neovascularisation, especially retinopathies such as diabetic
retinopathy or age-related macula degeneration, psoriasis, Von
Hippel Lindau disease, hemangioblastoma, angioma, mesangial cell
proliferative disorders such as chronic or acute renal diseases,
e.g. diabetic nephropathy, malignant nephrosclerosis, thrombotic
microangiopathy syndromes or transplant rejection, or especially
inflammatory renal disease, such as glomerulonephritis, especially
mesangioproliferative glomerulonephritis, haemolytic-uraemic
syndrome, diabetic nephropathy, hypertensive nephrosclerosis,
atheroma, arterial restenosis, autoimmune diseases, acute
inflammation, fibrotic disorders (e.g. hepatic cirrhosis),
diabetes, endometriosis, chronic asthma, arterial or
post-transplantational atherosclerosis, neurodegenerative
disorders, and especially neoplastic diseases (especially solid
tumours but also leukemias), such as especially breast cancer,
adenocarcinoma, colorectal cancer, lung cancer (especially
non-small-cell lung cancer), renal cancer, liver cancer, pancreatic
cancer, ovarian cancer or cancer of the prostate as well as
myeloma, especially multiple myeloma, myelodysplastic syndrome, AML
(acute myeloid leukemia), AMM (agnogenic myeloid metaplasia),
mesothelioma, glioma and glioblastoma. A compound of formula I is
especially suited also to preventing the metastatic spread of
tumours and the growth of micrometastases.
[0043] With the groups of preferred compounds of formula I
mentioned hereinafter, definitions of substituents from the general
definitions mentioned hereinbefore may reasonably be used, for
example, to replace more general definitions with more specific
definitions or especially with definitions characterized as being
preferred.
[0044] In another aspect the present invention relates to compounds
of the formula I wherein
R.sub.1 is H; halo; --C.sub.0-C.sub.7--O--R.sub.3;
--C.sub.0-C.sub.7--NR.sub.4R.sub.5; or --C(.dbd.O)--R.sub.6;
R.sub.2 is substituted C.sub.3-C.sub.8-cycloalkyl; substituted
aryl; or substituted heterocyclyl; R.sub.3 is H or unsubstituted or
substituted lower alkyl; R.sub.4 and R.sub.5 are independently
selected from the group consisting of H; unsubstituted or
substituted lower alkyl; lower alkyl-carbonyl, wherein the lower
alkyl moiety is optionally substituted; and lower alkoxy-carbonyl,
wherein the lower alkyl moiety is optionally substituted; R.sub.6
is H; unsubstituted or substituted lower alkyl; lower alkoxy,
wherein the lower alkyl moiety is optionally substituted; or
unsubstituted, mono- or di-substituted amino; A, B and X are
independently selected from .dbd.C(R.sub.7)-- or N; E, G and T are
independently selected from .dbd.C(R.sub.8)-- or N; R.sub.7 and
R.sub.8 are independently selected from the group consisting of H,
halo and unsubstituted or substituted lower alkyl;
Y is --O--, --S--, --S(O)--, --S(O).sub.2--, --CH.sub.2-- or
--CH.sub.2--CH.sub.2--;
[0045] Z is CH or N and Q is C.sub.1-C.sub.4-alkylene or
C.sub.2-C.sub.4-alkenylene, wherein C.sub.1-C.sub.4-alkylene or
C.sub.2-C.sub.4-alkenylene optionally may be substituted and
wherein one or more of the carbon atoms of said
C.sub.1-C.sub.4-alkylene or C.sub.2-C.sub.4-alkenylene chain
optionally may be replaced by a heteroatom independently selected
from nitrogen, oxygen and sulfur; and the bond between Q and Z
characterized by a dotted line is a single bond; with the proviso
that if Z is N, Q is not unsubstituted unbranched
C.sub.1-C.sub.4-alkylene; or Z is C and Q is as defined above
wherein the bond between Q and Z characterized by a dotted line is
a double bond; and W is either not present or
C.sub.1-C.sub.3-alkylene; or a tautomer thereof, or a salt
thereof.
[0046] Preference is given to a compound of formula I, wherein
R.sub.1 is halo; --C.sub.0-C.sub.7--NR.sub.4R.sub.5; or
--C(.dbd.O)--R.sub.6; R.sub.2 is substituted
C.sub.3-C.sub.8-cycloalkyl; substituted aryl; or substituted
heterocyclyl; R.sub.4 and R.sub.5 are independently selected from
the group consisting of H; lower alkyl; lower alkyl-carbonyl; and
lower alkoxy-carbonyl; R.sub.6 is lower alkyl, lower alkoxy, lower
alkyl-amino, di-lower alkyl-amino-lower alkyl-amino or di-lower
alkyl-amino; A, B and X are independently selected from
.dbd.C(R.sub.7)-- or N;
E, G and T are .dbd.C(R.sub.8)--;
[0047] R.sub.7 and R.sub.8 are independently selected from H and
halo; Y is --O--, --S-- or --CH.sub.2--, especially --O--; Z is N
and Q is C.sub.1-C.sub.4-alkylene or C.sub.2-C.sub.4-alkenylene,
wherein one or more, especially one, of the carbon atoms of said
C.sub.1-C.sub.4-alkylene or C.sub.2-C.sub.4-alkenylene chain
optionally may be replaced by a heteroatom independently selected
from nitrogen, oxygen and sulfur, especially from oxygen, the
Nitrogen optionally substituted by lower alkyl; and the bond
between Q and Z characterized by a dotted line in formula I is a
single bond; with the proviso that Q is not unsubstituted
unbranched C.sub.1-C.sub.4-alkylene; or Z is C and Q is as defined
above wherein the bond between Q and Z characterized by a dotted
line in formula I is a double bond; and W is
C.sub.1-C.sub.3-alkylene or especially not present; or a tautomer
thereof, or a salt thereof.
[0048] Special preference is given to a compound of formula I,
wherein
Z is N and Q is C.sub.2-C.sub.4-alkenylene, or
C.sub.1-C.sub.4-alkylene wherein one or more, especially one, of
the carbon atoms of C.sub.1-C.sub.4-alkylene is replaced by a
heteroatom independently selected from nitrogen, oxygen and sulfur,
especially from oxygen; and the bond between Q and Z characterized
by a dotted line in formula I is a single bond; or Z is C and Q is
as defined above wherein the bond between Q and Z characterized by
a dotted line in formula I is a double bond; and wherein the other
substituents and symbols have the meanings as described herein,
especially the meanings described as being preferred; or a tautomer
thereof, or a salt thereof.
[0049] Especially preferred is further a compound of formula I,
wherein
R.sub.1 is halo; --C.sub.0-C.sub.7--NR.sub.4R.sub.5; or
--C(.dbd.O)--R.sub.6; R.sub.2 is a cyclohexyl, phenyl, pyridyl,
2H-indazolyl, 1,3-dihydro-2-benzofuranyl or pyrazole radical
wherein said radical is substituted by one or more substituents
independently selected from the group consisting of lower alkyl;
C.sub.3-C.sub.8-cycloalkyl, optionally substituted by morpholinyl;
lower alkoxy; halo; halo-lower alkyl; halo-lower alkoxy; SF.sub.5;
morpholinyl; morpholinyl-lower alkyl; piperazinyl-lower alkyl;
lower alkyl-piperazinyl-lower alkyl and phenyl, wherein said phenyl
is optionally substituted by lower alkyl, halo, di-lower
alkyl-amino-lower alkyl, lower alkyl-piperazinyl-lower alkyl or
morpholinyl-lower alkyl; R.sub.4 and R.sub.5 are independently
selected from the group consisting of H; lower alkyl; lower
alkyl-carbonyl; and lower alkoxy-carbonyl; R.sub.6 is lower alkoxy,
lower alkyl-amino or di-lower alkyl-amino; X is .dbd.C(R.sub.7)--
and one of A and B is N while the other is .dbd.C(R.sub.7)--;
E, G and T are .dbd.C(R.sub.8)--;
[0050] R.sub.7 and R.sub.8 are independently selected from the
group consisting of H and halo;
Y is --O--;
[0051] Z is N and Q is C.sub.2-C.sub.3-alkylene or
C.sub.2-C.sub.3-alkenylene, wherein one of the carbon atoms of said
C.sub.2-C.sub.3-alkylene chain optionally may be replaced by
oxygen; and the bond between Q and Z characterized by a dotted line
in formula I is a single bond; with the proviso that Q is not
unsubstituted unbranched C.sub.2-C.sub.3-alkylene; or
Z is C and Q is --CH.dbd.CH--CH.dbd.; and
[0052] W is not present; or a tautomer thereof, or a salt
thereof.
[0053] Especially preferred is further a compound of formula I,
wherein
R.sub.1 is chloro; cyano; methylamino; amino-methyl;
methylamino-methyl; dimethylamino-methyl; methoxy-carbonyl,
ethoxy-carbonyl; butoxy-carbonyl; methylamino-carbonyl,
dimethylamino-carbonyl; isopropylamino-carbonyl;
(2)-dimethylamino-ethyl-(1)-amino-carbonyl; methylcarbonyl-amino;
methoxycarbonyl-amino; butoxycarbonyl-amino; carboxyl;
hydroxymethyl; chloro-methyl or methoxy-carbonyl-amino-methyl;
R.sub.2 is a cyclohexyl, phenyl, pyridyl, 2H-indazolyl,
1,3-dihydro-2-benzofuranyl or pyrazole radical wherein said radical
is substituted by one or more substituents independently selected
from the group consisting of methyl: ethyl; propyl; butyl;
cyclopropyl; morpholin-4-ylcyclohexyl; methoxy; fluoro; chloro;
bromo; trifluoromethyl; difluoroethyl; trifluoromethoxy; SF.sub.5;
morpholinyl; morpholin-4-ylmethyl; piperazinyl-methyl;
4-methylpiperazin-1-ylmethyl; 4-ethylpiperazin-1-ylmethyl;
4-propylpiperazin-1-ylmethyl and phenyl, wherein said phenyl is
optionally substituted by methyl, fluoro, dimethylamino-methyl,
morpholin-4-ylmethyl, 4-methylpiperazin-1-ylmethyl or
dimethylaminocarbonyl;
##STR00003##
R.sub.9 is H, methyl, ethyl or propyl; one of A and B is N while
the other is .dbd.CH--;
Y is --O--; --S--; --CH.sub.2--CH.sub.2--; --CH.dbd.CH-- or
--C.ident.C--;
[0054] W is CH.sub.2 or not present; or a tautomer thereof, or a
salt thereof.
[0055] Even more especially preferred is a compound of formula I,
wherein
Z is C and Q is --CH.dbd.CH--CH.dbd.;
[0056] and wherein the other substituents and symbols have the
meanings as described herein, especially the meanings described as
being preferred; or a tautomer thereof, or a salt thereof.
[0057] Even more especially preferred is further a compound of
formula I, wherein
##STR00004##
and wherein the other substituents and symbols have the meanings as
described herein, especially the meanings described as being
preferred; or a tautomer thereof, or a salt thereof.
[0058] Even more especially preferred is further a compound of
formula I, wherein
R.sub.2 is phenyl which is substituted by one or more substituents
independently selected from the group consisting of fluoro;
trifluoromethyl and 4-methylpiperazin-1-ylmethyl; and wherein the
other substituents and symbols have the meanings as described
herein, especially the meanings described as being preferred; or a
tautomer thereof, or a salt thereof.
[0059] Most preferred is a compound of the formula I, or a tautomer
thereof or a (preferably pharmaceutically acceptable) salt thereof,
as exemplified hereinbelow under `Examples`, or its use as defined
herein.
[0060] Preference is furthermore given to a compound of formula I,
wherein
R.sub.1 is H; halo; --C.sub.0-C.sub.7--O--R.sub.3;
--C.sub.0-C.sub.7--NR.sub.4R.sub.5; or --C(.dbd.O)--R.sub.6;
R.sub.2 is substituted C.sub.3-C.sub.3-cycloalkyl; substituted
aryl; or substituted heterocyclyl; R.sub.3 is H or unsubstituted or
substituted lower alkyl; R.sub.4 and R.sub.5 are independently
selected from the group consisting of H; unsubstituted or
substituted lower alkyl; lower alkyl-carbonyl, wherein the lower
alkyl moiety is optionally substituted; and lower alkoxy-carbonyl,
wherein the lower alkyl moiety is optionally substituted; R.sub.6
is H; unsubstituted or substituted lower alkyl; lower alkoxy,
wherein the lower alkyl moiety is optionally substituted; or
unsubstituted, mono- or di-substituted amino; A, B and X are
independently selected from .dbd.C(R.sub.7)-- or N; E, G and T are
independently selected from .dbd.C(R.sub.8)-- or N; R.sub.7 and
R.sub.8 are independently selected from the group consisting of H,
halo and unsubstituted or substituted lower alkyl;
Y is --O--, --S-- or --CH.sub.2--;
[0061] Z is CH or N and Q is C.sub.1-C.sub.4-alkylene or
C.sub.2-C.sub.4-alkenylene, wherein C.sub.1-C.sub.4-alkylene or
C.sub.2-C.sub.4-alkenylene optionally may be substituted and
wherein one or more of the carbon atoms of said
C.sub.1-C.sub.4-alkylene or C.sub.2-C.sub.4-alkenylene chain
optionally may be replaced by a heteroatom independently selected
from nitrogen, oxygen and sulfur; and the bond between Q and Z
characterized by a dotted line is a single bond; with the proviso
that if Z is N, Q is not unsubstituted unbranched
C.sub.1-C.sub.4-alkylene; or Z is C and Q is as defined above
wherein the bond between Q and Z characterized by a dotted line is
a double bond; and W is either not present or
C.sub.1-C.sub.3-alkylene; or a tautomer thereof, or a salt
thereof.
[0062] Special preference is furthermore given to a compound of
formula I, wherein
R.sub.1 is halo; --C.sub.0-C.sub.7--NR.sub.4R.sub.5; or
--C(.dbd.O)--R.sub.6; R.sub.2 is a cyclohexyl, phenyl or pyridyl
radical wherein said radical is substituted by one or more
substituents independently selected from the group consisting of
lower alkyl; halo; halo-lower alkyl; morpholinyl; morpholinyl-lower
alkyl; and lower alkyl-piperazinyl-lower alkyl; R.sub.4 and R.sub.5
are independently selected from the group consisting of H; lower
alkyl; lower alkyl-carbonyl; and lower alkoxy-carbonyl; R.sub.6 is
lower alkoxy, lower alkyl-amino or di-lower alkyl-amino; X is
.dbd.C(R.sub.7)-- and one of A and B is N while the other is
.dbd.C(R.sub.7)--;
E, G and T are .dbd.C(R.sub.8)--;
[0063] R.sub.7 and R.sub.8 are independently selected from the
group consisting of H and halo;
Y is --O--;
[0064] Z is N and Q is C.sub.2-C.sub.3-alkylene or
C.sub.2-C.sub.3-alkenylene, wherein one of the carbon atoms of said
C.sub.2-C.sub.3-alkylene chain optionally may be replaced by
oxygen; and the bond between Q and Z characterized by a dotted line
in formula I is a single bond; with the proviso that Q is not
unsubstituted unbranched C.sub.2-C.sub.3-alkylene; or
Z is C and Q is --CH.dbd.CH--CH.dbd.; and
[0065] W is not present; or a tautomer thereof, or a salt
thereof.
[0066] Compounds of formula I are prepared analogously to methods
that, for other compounds, are in principle known in the art, and
are especially prepared according to the methods described
hereinbelow under `Examples`.
[0067] The starting materials used in the preparation of the
compounds of formula I are known, capable of being prepared
according to known processes, or commercially obtainable. In
particular, the anilines to be used as starting material in the
preparation of the compounds of formula I can be prepared as
described in WO 03/099771 or analogously thereto, are commercially
available or can be prepared according to known processes.
[0068] The invention relates also to pharmaceutical compositions
comprising a compound of formula I, to their use in the therapeutic
(in a broader aspect of the invention also prophylactic) treatment
or a method of treatment of a kinase dependent disease, especially
the preferred diseases mentioned above, to the compounds for said
use and to pharmaceutical preparations and their manufacture,
especially for said uses.
[0069] The present invention also relates to pro-drugs of a
compound of formula I that convert in vivo to the compound of
formula I as such. Any reference to a compound of formula I is
therefore to be understood as referring also to the corresponding
pro-drugs of the compound of formula I, as appropriate and
expedient.
[0070] The pharmacologically acceptable compounds of the present
invention may be present in or employed, for example, for the
preparation of pharmaceutical compositions that comprise an
effective amount of a compound of the formula I, or a
pharmaceutically acceptable salt thereof, as active ingredient
together or in admixture with one or more inorganic or organic,
solid or liquid, pharmaceutically acceptable carriers (carrier
materials).
[0071] The invention relates also to a pharmaceutical composition
that is suitable for administration to a warm-blooded animal,
especially a human (or to cells or cell lines derived from a
warm-blooded animal, especially a human, e.g. lymphocytes), for the
treatment of (this, in a broader aspect of the invention, also
includes the prevention of (=prophylaxis against)) a disease that
responds to inhibition of protein kinase activity, comprising an
amount of a compound of formula I or a pharmaceutically acceptable
salt thereof, preferably which is effective for said inhibition,
together with at least one pharmaceutically acceptable carrier.
[0072] The pharmaceutical compositions according to the invention
are those for enteral, such as nasal, rectal or oral, or
parenteral, such as intramuscular or intravenous, or topical, such
as a gel, paste, ointment, cream or foam, administration to
warm-blooded animals (especially a human), that comprise an
effective dose of the pharmacologically active ingredient, alone or
together with a significant amount of a pharmaceutically acceptable
carrier. The dose of the active ingredient depends on the species
of warm-blooded animal, the body weight, the age and the individual
condition, individual pharmacokinetic data, the disease to be
treated and the mode of administration.
[0073] The invention relates also to a method of treatment for a
disease that responds to inhibition of a protein kinase and/or a
proliferative disease, which comprises administering a (against the
mentioned diseases) prophylactically or especially therapeutically
effective amount of a compound of formula I according to the
invention, or a tautomer thereof or a pharmaceutically acceptable
salt thereof, especially to a warm-blooded animal, for example a
human, that, on account of one of the mentioned diseases, requires
such treatment.
[0074] The dose of a compound of the formula I or a
pharmaceutically acceptable salt thereof to be administered to
warm-blooded animals, for example humans of approximately 70 kg
body weight, preferably is from approximately 3 mg to approximately
10 g, more preferably from approximately 10 mg to approximately 1.5
g, most preferably from about 100 mg to about 1000 mg/person/day,
divided preferably into 1-3 single doses which may, for example, be
of the same size. Usually, children receive half of the adult
dose.
[0075] The pharmaceutical compositions comprise from approximately
1% to approximately 95%, preferably from approximately 20% to
approximately 90%, active ingredient. Pharmaceutical compositions
according to the invention may be, for example, in unit dose form,
such as in the form of ampoules, vials, suppositories, dragees,
tablets or capsules.
[0076] The pharmaceutical compositions of the present invention are
prepared in a manner known per se, for example by means of
conventional dissolving, lyophilizing, mixing, granulating or
confectioning processes.
[0077] A compound of the formula I may also be used to advantage in
combination with other antiproliferative agents. Such
antiproliferative agents include, but are not limited to aromatase
inhibitors; antiestrogens; topoisomerase I inhibitors;
topoisomerase II inhibitors; microtubule active agents; alkylating
agents; histone deacetylase inhibitors; compounds which induce cell
differentiation processes; cyclooxygenase inhibitors; MMP
inhibitors; mTOR inhibitors; antineoplastic antimetabolites; platin
compounds; compounds targeting/decreasing a protein or lipid kinase
activity and further anti-angiogenic compounds; compounds which
target, decrease or inhibit the activity of a protein or lipid
phosphatase; gonadorelin agonists; anti-androgens; methionine
aminopeptidase inhibitors; bisphosphonates; biological response
modifiers; antiproliferative antibodies; heparanase inhibitors;
inhibitors of Ras oncogenic isoforms; telomerase inhibitors;
proteasome inhibitors; agents used in the treatment of hematologic
malignancies; compounds which target, decrease or inhibit the
activity of Flt-3; Hsp90 inhibitors; temozolomide (TEMODAL.RTM.);
and leucovorin.
[0078] The term "aromatase inhibitor" as used herein relates to a
compound which inhibits the estrogen production, i.e. the
conversion of the substrates androstenedione and testosterone to
estrone and estradiol, respectively. The term includes, but is not
limited to steroids, especially atamestane, exemestane and
formestane and, in particular, non-steroids, especially
aminoglutethimide, roglethimide, pyridoglutethimide, trilostane,
testolactone, ketokonazole, vorozole, fadrozole, anastrozole and
letrozole. Exemestane can be administered, e.g., in the form as it
is marketed, e.g. under the trademark AROMASIN. Formestane can be
administered, e.g., in the form as it is marketed, e.g. under the
trademark LENTARON. Fadrozole can be administered, e.g., in the
form as it is marketed, e.g. under the trademark AFEMA. Anastrozole
can be administered, e.g., in the form as it is marketed, e.g.
under the trademark ARIMIDEX. Letrozole can be administered, e.g.,
in the form as it is marketed, e.g. under the trademark FEMARA or
FEMAR. Aminoglutethimide can be administered, e.g., in the form as
it is marketed, e.g. under the trademark ORIMETEN. A combination of
the invention comprising a chemotherapeutic agent which is an
aromatase inhibitor is particularly useful for the treatment of
hormone receptor positive tumors, e.g. breast tumors.
[0079] The term "antiestrogen" as used herein relates to a compound
which antagonizes the effect of estrogens at the estrogen receptor
level. The term includes, but is not limited to tamoxifen,
fulvestrant, raloxifene and raloxifene hydrochloride. Tamoxifen can
be administered, e.g., in the form as it is marketed, e.g. under
the trademark NOLVADEX. Raloxifene hydrochloride can be
administered, e.g., in the form as it is marketed, e.g. under the
trademark EVISTA. Fulvestrant can be formulated as disclosed in
U.S. Pat. No. 4,659,516 or it can be administered, e.g., in the
form as it is marketed, e.g. under the trademark FASLODEX. A
combination of the invention comprising a chemotherapeutic agent
which is an antiestrogen is particularly useful for the treatment
of estrogen receptor positive tumors, e.g. breast tumors.
[0080] The term "anti-androgen" as used herein relates to any
substance which is capable of inhibiting the biological effects of
androgenic hormones and includes, but is not limited to,
bicalutamide (CASODEX), which can be formulated, e.g. as disclosed
in U.S. Pat. No. 4,636,505.
[0081] The term "gonadorelin agonist" as used herein includes, but
is not limited to abarelix, goserelin and goserelin acetate.
Goserelin is disclosed in U.S. Pat. No. 4,100,274 and can be
administered, e.g., in the form as it is marketed, e.g. under the
trademark ZOLADEX. Abarelix can be formulated, e.g. as disclosed in
U.S. Pat. No. 5,843,901.
[0082] The term "topoisomerase I inhibitor" as used herein
includes, but is not limited to topotecan, gimatecan, irinotecan,
camptothecian and its analogues, 9-nitrocamptothecin and the
macromolecular camptothecin conjugate PNU-166148 (compound A1 in
WO99/17804). Irinotecan can be administered, e.g. in the form as it
is marketed, e.g. under the trademark CAMPTOSAR. Topotecan can be
administered, e.g., in the form as it is marketed, e.g. under the
trademark HYCAMTIN.
[0083] The term "topoisomerase II inhibitor" as used herein
includes, but is not limited to the anthracyclines such as
doxorubicin (including liposomal formulation, e.g. CAELYX),
daunorubicin, epirubicin, idarubicin and nemorubicin, the
anthraquinones mitoxantrone and losoxantrone, and the
podophillotoxines etoposide and teniposide. Etoposide can be
administered, e.g. in the form as it is marketed, e.g. under the
trademark ETOPOPHOS. Teniposide can be administered, e.g. in the
form as it is marketed, e.g. under the trademark VM 26-BRISTOL.
Doxorubicin can be administered, e.g. in the form as it is
marketed, e.g. under the trademark ADRIBLASTIN or ADRIAMYCIN.
Epirubicin can be administered, e.g. in the form as it is marketed,
e.g. under the trademark FARMORUBICIN. Idarubicin can be
administered, e.g. in the form as it is marketed, e.g. under the
trademark ZAVEDOS. Mitoxantrone can be administered, e.g. in the
form as it is marketed, e.g. under the trademark NOVANTRON.
[0084] The term "microtubule active agent" relates to microtubule
stabilizing, microtubule destabilizing agents and microtublin
polymerization inhibitors including, but not limited to taxanes,
e.g. paclitaxel and docetaxel, vinca alkaloids, e.g., vinblastine,
especially vinblastine sulfate, vincristine especially vincristine
sulfate, and vinorelbine, discodermolides, cochicine and
epothilones and derivatives thereof, e.g. epothilone B or D or
derivatives thereof. Paclitaxel may be administered e.g. in the
form as it is marketed, e.g. TAXOL. Docetaxel can be administered,
e.g., in the form as it is marketed, e.g. under the trademark
TAXOTERE. Vinblastine sulfate can be administered, e.g., in the
form as it is marketed, e.g. under the trademark VINBLASTIN R.P.
Vincristine sulfate can be administered, e.g., in the form as it is
marketed, e.g. under the trade-mark FARMISTIN. Discodermolide can
be obtained, e.g., as disclosed in U.S. Pat. No. 5,010,099. Also
included are Epothilone derivatives which are disclosed in WO
98/10121, U.S. Pat. No. 6,194,181, WO 98/25929, WO 98/08849, WO
99/43653, WO 98/22461 and WO 00/31247. Especially preferred are
Epothilone A and/or B.
[0085] The term "alkylating agent" as used herein includes, but is
not limited to, cyclophosphamide, ifosfamide, melphalan or
nitrosourea (BCNU or Gliadel). Cyclophosphamide can be
administered, e.g., in the form as it is marketed, e.g. under the
trademark CYCLOSTIN. Ifosfamide can be administered, e.g., in the
form as it is marketed, e.g. under the trademark HOLOXAN.
[0086] The term "histone deacetylase inhibitors" or "HDAC
inhibitors" relates to compounds which inhibit the histone
deacetylase and which possess antiproliferative activity. This
includes compounds disclosed in WO 02/22577, especially
N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]-amino]methyl]ph-
enyl]-2E-2-propenamide,
N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]--
2E-2-propenamide and pharmaceutically acceptable salts thereof. It
further especially includes Suberoylanilide hydroxamic acid
(SAHA).
[0087] The term "antineoplastic antimetabolite" includes, but is
not limited to, 5-fluorouracil (5-FU); capecitabine; gemcitabine;
DNA de-methylating agents, such as 5-azacytidine and decitabine;
methotrexate; edatrexate; and folic acid antagonists such as
pemetrexed. Capecitabine can be administered, e.g., in the form as
it is marketed, e.g. under the trademark XELODA. Gemcitabine can be
administered, e.g., in the form as it is marketed, e.g. under the
trademark GEMZAR. Also included is the monoclonal antibody
trastuzumab which can be administered, e.g., in the form as it is
marketed, e.g. under the trademark HERCEPTIN.
[0088] The term "platin compound" as used herein includes, but is
not limited to, carboplatin, cis-platin, cisplatinum and
oxaliplatin. Carboplatin can be administered, e.g., in the form as
it is marketed, e.g. under the trademark CARBOPLAT. Oxaliplatin can
be administered, e.g., in the form as it is marketed, e.g. under
the trademark ELOXATIN.
[0089] The term "compounds targeting/decreasing a protein or lipid
kinase activity and further anti-angiogenic compounds" as used
herein includes, but is not limited to: protein tyrosine kinase
and/or serine and/or threonine kinase inhibitors or lipid kinase
inhibitors, e.g.:
a) compounds targeting, decreasing or inhibiting the activity of
the fibroblast growth factor-receptors (FGF-Rs); b) compounds
targeting, decreasing or inhibiting the activity of the
insulin-like growth factor I receptor (IGF-IR), especially
compounds which inhibit the IGF-IR, such as those compounds
disclosed in WO 02/092599; c) compounds targeting, decreasing or
inhibiting the activity of the Trk receptor tyrosine kinase family;
d) compounds targeting, decreasing or inhibiting the activity of
the Axl receptor tyrosine kinase family; e) compounds targeting,
decreasing or inhibiting the activity of the c-Met receptor; f)
compounds targeting, decreasing or inhibiting the activity of
members of the protein kinase C (PKC) and Raf family of
serine/threonine kinases, members of the MEK, SRC, JAK, FAK, PDK
and Ras/MAPK family members, or PI(3) kinase family, or of the
PI(3)-kinase-related kinase family, and/or members of the
cyclin-dependent kinase family (CDK) and are especially those
staurosporine derivatives disclosed in U.S. Pat. No. 5,093,330,
e.g. midostaurin; examples of further compounds include e.g.
UCN-01, safingol, BAY 43-9006, Bryostatin 1, Perifosine;
Ilmofosine; RO 318220 and RO 320432; GO 6976; Isis 3521;
LY333531/LY379196; isochinoline compounds such as those disclosed
in WO 00/09495; FTIs; PD184352 or QAN697 (a P13K inhibitor); g)
compounds targeting, decreasing or inhibiting the activity of a
protein-tyrosine kinase, such as imatinib mesylate (GLIVEC/GLEEVEC)
or tyrphostin. A tyrphostin is preferably a low molecular weight
(Mr<1500) compound, or a pharmaceutically acceptable salt
thereof, especially a compound selected from the
benzylidenemalonitrile class or the S-arylbenzenemalonirile or
bisubstrate quinoline class of compounds, more especially any
compound selected from the group consisting of Tyrphostin
A23/RG-50810; AG 99; Tyrphostin AG 213; Tyrphostin AG 1748;
Tyrphostin AG 490; Tyrphostin B44; Tyrphostin B44 (+) enantiomer;
Tyrphostin AG 555; AG 494; Tyrphostin AG 556, AG957 and adaphostin
(4-{[(2,5-dihydroxyphenyl)methyl]amino}-benzoic acid adamantyl
ester; NSC 680410, adaphostin); and h) compounds targeting,
decreasing or inhibiting the activity of the epidermal growth
factor family of receptor tyrosine kinases (EGF-R, ErbB2, ErbB3,
ErbB4 as homo- or heterodimers), such as compounds which target,
decrease or inhibit the activity of the epidermal growth factor
receptor family are especially compounds, proteins or antibodies
which inhibit members of the EGF receptor tyrosine kinase family,
e.g. EGF receptor, ErbB2, ErbB3 and ErbB4 or bind to EGF or EGF
related ligands, and are in particular those compounds, proteins or
monoclonal antibodies generically and specifically disclosed in WO
97/02266, e.g. the compound of ex. 39, or in EP 0 564 409, WO
99/03854, EP 0520722, EP 0 566 226, EP 0 787 722, EP 0 837 063,
U.S. Pat. No. 5,747,498, WO 98/10767, WO 97/30034, WO 97/49688, WO
97/38983 and, especially, WO 96/30347 (e.g. compound known as CP
358774), WO 96/33980 (e.g. compound ZD 1839) and WO 95/03283 (e.g.
compound ZM105180); e.g. trastuzurnab (HERCEPTIN), cetuximab,
Iressa, erlotinib (Tarceva.TM.), CI-1033, EKB-569, GW-2016, E1.1,
E2.4, E2.5, E6.2, E6.4, E2.11, E6.3 or E7.6.3, and
7H-pyrrolo-[2,3-d]pyrimidine derivatives which are disclosed in WO
03/013541.
[0090] Further anti-angiogenic compounds include compounds having
another mechanism for their activity, e.g. unrelated to protein or
lipid kinase inhibition e.g. thalidomide (THALOMID) and
TNP-470.
[0091] Compounds which target, decrease or inhibit the activity of
a protein or lipid phosphatase are e.g. inhibitors of phosphatase
1, phosphatase 2A, PTEN or CDC25, e.g. okadaic acid or a derivative
thereof.
[0092] Compounds which induce cell differentiation processes are
e.g. retinoic acid, .alpha.- .gamma.- or .delta.-tocopherol or
.alpha.- .gamma.- or .delta.-tocotrienol.
[0093] The term "cyclooxygenase inhibitor" as used herein includes,
but is not limited to, e.g. Cox-2 inhibitors, 5-alkyl substituted
2-arylaminophenylacetic acid and derivatives, such as celecoxib
(CELEBREX), rofecoxib (VIOXX), etoricoxib, valdecoxib or a
5-alkyl-2-arylaminophenylacetic acid, e.g.
5-methyl-2-(2'-chloro-6'-fluoroanilino)phenyl acetic acid,
lumiracoxib.
[0094] The term "mTOR inhibitors" relates to compounds which
inhibit the mammalian target of rapamycin (mTOR) and which possess
antiproliferative activity such as sirolimus (Rapamune.RTM.),
everolimus (Certican.TM.), CCI-779 and ABT578.
[0095] The term "bisphosphonates" as used herein includes, but is
not limited to, etridonic, clodronic, tiludronic, pamidronic,
alendronic, ibandronic, risedronic and zoledronic acid. "Etridonic
acid" can be administered, e.g., in the form as it is marketed,
e.g. under the trademark DIDRONEL. "Clodronic acid" can be
administered, e.g., in the form as it is marketed, e.g. under the
trademark BONEFOS. "Tiludronic acid" can be administered, e.g., in
the form as it is marketed, e.g. under the trademark SKELID.
"Pamidronic acid" can be administered, e.g. in the form as it is
marketed, e.g. under the trademark AREDIA.TM.. "Alendronic acid"
can be administered, e.g., in the form as it is marketed, e.g.
under the trademark FOSAMAX. "Ibandronic acid" can be administered,
e.g., in the form as it is marketed, e.g. under the trademark
BONDRANAT. "Risedronic acid" can be administered, e.g., in the form
as it is marketed, e.g. under the trademark ACTONEL. "Zoledronic
acid" can be administered, e.g. in the form as it is marketed, e.g.
under the trademark ZOMETA.
[0096] The term "heparanase inhibitor" as used herein refers to
compounds which target, decrease or inhibit heparin sulphate
degradation. The term includes, but is not limited to, PI-88.
[0097] The term "biological response modifier" as used herein
refers to a lymphokine or interferons, e.g. interferon .gamma..
[0098] The term "inhibitor of Ras oncogenic isoforms", e.g. H-Ras,
K-Ras, or N-Ras, as used herein refers to compounds which target,
decrease or inhibit the oncogenic activity of Ras e.g. a "farnesyl
transferase inhibitor", e.g. L-744832, DK8G557 or R115777
(Zarnestra).
[0099] The term "telomerase inhibitor" as used herein refers to
compounds which target, decrease or inhibit the activity of
telomerase. Compounds which target, decrease or inhibit the
activity of telomerase are especially compounds which inhibit the
telomerase receptor, e.g. telomestatin.
[0100] The term "methionine aminopeptidase inhibitor" as used
herein refers to compounds which target, decrease or inhibit the
activity of methionine aminopeptidase. Compounds which target,
decrease or inhibit the activity of methionine aminopeptidase are
e.g. bengamide or a derivative thereof.
[0101] The term "proteasome inhibitor" as used herein refers to
compounds which target, decrease or inhibit the activity of the
proteasome. Compounds which target, decrease or inhibit the
activity of the proteasome include e.g. PS-341 and MLN 341.
[0102] The term "matrix metalloproteinase inhibitor" or ("MMP
inhibitor") as used herein includes, but is not limited to collagen
peptidomimetic and nonpeptidomimetic inhibitors, tetracycline
derivatives, e.g. hydroxamate peptidomimetic inhibitor batimastat
and its orally bioavailable analogue marimastat (BB-2516),
prinomastat (AG3340), metastat (NSC 683551) BMS-279251, BAY
12-9566, TAA211, MMI270B or AAJ996.
[0103] The term "agents used in the treatment of hematologic
malignancies" as used herein includes, but is not limited to
FMS-like tyrosine kinase inhibitors e.g. compounds targeting,
decreasing or inhibiting the activity of Flt-3; interferon,
1-b-D-arabinofuransylcytosine (ara-c) and bisulfan; and ALK
inhibitors e.g. compounds which target, decrease or inhibit
anaplastic lymphoma kinase.
[0104] The term "compounds which target, decrease or inhibit the
activity of Flt-3" are especially compounds, proteins or antibodies
which inhibit Flt-3, e.g. PKC412, midostaurin, a staurosporine
derivative, SU11248 and MLN518.
[0105] The term "HSP90 inhibitors" as used herein includes, but is
not limited to, compounds targeting, decreasing or inhibiting the
intrinsic ATPase activity of HSP90; degrading, targeting,
decreasing or inhibiting the HSP90 client proteins via the
ubiquitin proteasome pathway. Compounds targeting, decreasing or
inhibiting the intrinsic ATPase activity of HSP90 are especially
compounds, proteins or antibodies which inhibit the ATPase activity
of HSP90 e.g., 17-allylamino, 17-demethoxygeldanamycin (17AAG), a
geldanamycin derivative; other geldanamycin related compounds;
radicicol and HDAC inhibitors.
[0106] The term "antiproliferative antibodies" as used herein
includes, but is not limited to trastuzumab (Herceptin.TM.),
Trastuzumab-DM1, bevacizumab (Avastin.TM.), rituximab
(Rituxan.RTM.), PRO64553 (anti-CD40) and 2C4 Antibody. By
antibodies is meant e.g. intact monoclonal antibodies, polyclonal
antibodies, multispecific antibodies formed from at least 2 intact
antibodies, and antibodies fragments so long as they exhibit the
desired biological activity.
[0107] For the treatment of acute myeloid leukemia (AML), compounds
of formula I can be used in combination with standard leukemia
therapies, especially in combination with therapies used for the
treatment of AML. In particular, compounds of formula I can be
administered in combination with e.g. farnesyl transferase
inhibitors and/or other drugs useful for the treatment of AML, such
as Daunorubicin, Adriamycin, Ara-C, VP-16, Teniposide,
Mitoxantrone, Idarubicin, Carboplatinum and PKC412.
[0108] The structure of the active agents identified by code nos.,
generic or trade names may be taken from the actual edition of the
standard compendium "The Merck Index" or from databases, e.g.
Patents International (e.g. IMS World Publications).
[0109] The above-mentioned compounds, which can be used in
combination with a compound of the formula I, can be prepared and
administered as described in the art such as in the documents cited
above.
[0110] A compound of the formula I may also be used to advantage in
combination with known therapeutic processes, e.g., the
administration of hormones or especially radiation.
[0111] A compound of formula I may in particular be used as a
radiosensitizer, especially for the treatment of tumors which
exhibit poor sensitivity to radiotherapy.
[0112] By "combination", there is meant either a fixed combination
in one dosage unit form, or a kit of parts for the combined
administration where a compound of the formula I and a combination
partner may be administered independently at the same time or
separately within time intervals that especially allow that the
combination partners show a cooperative, e.g. synergistic, effect,
or any combination thereof.
EXAMPLES
[0113] The following Examples serve to illustrate the invention
without limiting the scope thereof.
[0114] Temperatures are measured in degrees Celsius. Unless
otherwise indicated, the reactions take place at room temperature
under N.sub.2-atmosphere.
[0115] The R.sub.f values which indicate the ratio of the distance
moved by each substance to the distance moved by the eluent front
are determined on silica gel thin-layer plates (Merck, Darmstadt,
Germany) by thin-layer chromatography using the respective named
solvent systems.
ABBREVIATIONS
[0116] Anal. elemental analysis (for indicated atoms, difference
between calculated and measured value.gtoreq.0.4%) [0117] aq.
aqueous [0118] brine saturated solution of NaCl in water [0119]
conc. concentrated [0120] DEPC diethyl-cyanophosphonate [0121] DIPE
diisopropyl-ether [0122] DMAP dimethylaminopyridine [0123] DMEU
1,3-dimethyl-2-imidazolidinone [0124] DMF dimethyl formamide [0125]
DMSO dimethyl sulfoxide [0126] ether diethylether [0127] Et.sub.3N
triethylamine [0128] EtOAc ethyl acetate [0129] EtOH ethanol [0130]
eq. equivalent [0131] Ex. Example [0132] h hour(s) [0133] HATU
O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium-hexafluorophospha-
te [0134] HPLC high pressure liquid chromatography [0135] HV high
vacuum [0136] l litre(s) [0137] Me methyl [0138] MeOH methanol
[0139] min minute(s) [0140] m.p. melting point [0141] MPLC medium
pressure liquid chromatography [0142] Combi Flash system: normal
phase SiO.sub.2 [0143] Gilson system: reversed phase Nucleosil C18
(H.sub.2O/CH.sub.3CN+TFA), generally product obtained as free base
after neutralization with NaHCO.sub.3 [0144] MS mass spectrum
[0145] NMM N-methyl-morpholine [0146] NMP N-methyl-pyrrolidone
[0147] prep-HPLC preparative high pressure liquid chromatography;
Waters system; column: reversed phase Atlantis.TM. (100.times.19
mm), dC18 OBD (H.sub.2O/CH.sub.3CN+0.1% TFA), 5 .mu.M, generally
product obtained as a TFA salt after lyophilization.
propylphosphonic anhydride [0148] N-propylphosphonic acid
anhydride, cyclic trimer [68957-94-8]; 50% in DMF [0149] R.sub.f
ratio of fronts (TLC) [0150] rt room temperature [0151] sat.
saturated [0152] THF tetrahydrofuran (distilled from
Na/benzophenone) [0153] TFA trifluoroacetic acid [0154] TLC thin
layer chromatography [0155] t.sub.Ret retention time (HPLC) [0156]
triphosgene bis(trichloromethyl) carbonate [0157] sat.
saturated
HPLC Conditions:
[0158] .sup.At.sub.Ret.sup.-: retention time [min] for System A:
Linear gradient 20-100% CH.sub.3CN (0.1% TFA) and H.sub.2O (0.1%
TFA) in 13 min+5 min 100% CH.sub.3CN (0.1% TFA); detection at 215
nm, flow rate 1 ml/min at 25 or 30.degree. C. Column: Nucleosil
120-3 C18 (125.times.3.0 mm). .sup.Bt.sub.Ret.sup.-: retention time
[min] for System B: Linear gradient 5-40% CH.sub.3CN (0.1% TFA) and
H.sub.2O (0.1% TFA) in 9 min+7 min 40% CH.sub.3CN (0.1% TFA);
detection at 215 nm, flow rate 1 ml/min at 25 or 30.degree. C.
Column: Nucleosil 120-3 C18 (125.times.3.0 mm).
.sup.Ct.sub.Ret.sup.-: retention time [min] for System C: Linear
gradient 15-100% CH.sub.3CN (0.1% TFA) and H.sub.2O (0.1% TFA) in
2.25 min+1.25 min 100% CH.sub.3CN (0.1% TFA); detection at 215 nm,
flow rate 2 ml/min at 25 or 30.degree. C. Column: CC (50.times.4.6
mm) Uptisphere UP3ODB-5QS. .sup.Dt.sub.Ret.sup.-: retention time
[min] for System D: Linear gradient 20-100% CH.sub.3CN (0.1% TFA)
and H.sub.2O (0.1% TFA) in 5 min+1 min 100% CH.sub.3CN (0.1% TFA);
detection at 215 nm, flow rate 1 ml/min at 25 or 30.degree. C.
Column: CC (250.times.4.6 mm) Nucleosil 100-5 C18.
.sup.Et.sub.Ret.sup.-: retention time [min] for System E: Linear
gradient 20-100% CH.sub.3CN (0.1% TFA) and H.sub.2O (0.1% TFA) in
14 min+5 min 100% CH.sub.3CN (0.1% TFA); detection at 215 nm, flow
rate 1 ml/min at 25 or 30.degree. C. Column: CC 70/4 (70.times.4.0
mm) Nucleosil 100-3 C18. .sup.Ft.sub.Ret.sup.-: retention time
[min] for System F: Linear gradient 5-100% CH.sub.3CN and H.sub.2O
(0.1% TFA) in 4 min+0.5 min 100% CH.sub.3CN; PDA MaxPlot detection
(210.0 nm to 400.0 nm), flow rate 3 ml/min at 35.degree. C. Column:
Sunfire.TM. (4.6.times.20 mm) C18, 3.5 .mu.m.
.sup.Gt.sub.Ret.sup.-: retention time [min] for System G: Linear
gradient 5-100% CH.sub.3CN (0.07% formic acid) and H.sub.2O (0.1%
formic acid) in 4 min+0.5 min 100% CH.sub.3CN (0.07% formic acid);
PDA MaxPlot detection (210.0 nm to 400.0 nm), flow rate 1.8 ml/min
at 40.degree. C. Column: X-Terra.TM. (4.6.times.50 mm) MSC18, 5
.mu.m.
[0159] Anilines used as educts: Most respective anilines are either
commercially available or described in WO 03/099771 or WO 05/051366
or can be prepared analogously to the therein exemplified
derivatives.
##STR00005##
Example 1
rac-5-(2-Amino-6-chloro-pyrimidin-4-yloxy)-4-fluoro-2-methyl-2,3-dihydro-i-
ndole-1-carboxylic acid (3-trifluoromethyl-phenyl)-amide
[0160] 0.68 mMol
rac-5-(2-Amino-6-chloro-pyrimidin-4-yloxy)-4-fluoro-2-methyl-2,3-dihydro--
indole (Step 1.2) are dissolved in 5 ml THF. Then 106 .mu.l (0.77
mMol) 3-trifluoromethyl-phenylisocyanat are added and the solution
is stirred for 1 h at rt. Concentration and chromatography (Combi
Flash; EtOAc/hexane 1:9.fwdarw.1:1) gives the title compound: MS:
[M+1].sup.+=482/484; HPLC: .sup.At.sub.Ret=16.4; Anal.: C, H, N,
Cl, F.
[0161] The starting material is prepared as follows:
Step 1.1:
5-(2-Amino-6-chloro-pyrimidin-4-yloxy)-4-fluoro-2-methyl-1H-indo-
le
[0162] 1.00 g (6.05 mMol) 2-amino-4,6-dichloro-pyrimidine and 993
mg (6.05 mMol) 4-fluoro-5-hydroxy-2-methylindole [preparation see:
WO 00/47212 Ex. 237] are suspended in 25 ml acetone. Then 12 ml 1 N
NaOH in water are added and the mixture is stirred at an oilbath
temperature of 70.degree. C. for 5 h. Then additional 210 mg
2-amino-4,6-dichloro-pyrimidine are added portionwise and stirring
continued for another 4.5 h. The reaction mixture is partially
concentrated and the crystallized title compound filtered off and
washed with water: m.p.: 255-258.degree. C.; MS:
[M+1].sup.+=293/295; HPLC: .sup.At.sub.Ret=13.7.
Step 1.2:
rac-5-(2-Amino-6-chloro-pyrimidin-4-yloxy)-4-fluoro-2-methyl-2,3-
-dihydro-1H-indole
[0163] A solution of 200 mg (0.68 mMol) of
5-(2-amino-6-chloro-pyrimidin-4-yloxy)-4-fluoro-2-methyl-1H-indole
in 4 ml acetic acid is cooled to 10-15.degree. C. Then 214 mg (3.4
mMol) NaBH.sub.3CN are added. After 3 h stirring at rt, 8 g of ice
are added, then the mixture is made basic by addition of 1 N NaOH
and extracted three times with EtOAc. The organic layers are washed
with water and brine, dried (Na.sub.2SO.sub.4) and concentrated at
it in vacuo: HPLC: .sup.At.sub.Ret=9.9.
Example 2
rac-5-(2-Amino-pyrimidin-4-yloxy)-4-fluoro-2-methyl-2,3-dihydro-indole-1-c-
arboxylic acid (3-trifluoromethyl-phenyl)-amide
[0164] A solution of 230 mg (0.48 mMol)
rac-5-(2-amino-6-chloro-pyrimidin-4-yloxy)-4-fluoro-2-methyl-2,3-dihydro--
indole-1-carboxylic acid (3-trifluoromethyl-phenyl)-amide and 75
.mu.l (0.54 mMol) Et.sub.3N in 12 ml THF is hydrogenated in the
presence of 63 mg Pd/C (10%; Engelhard 4505). The catalyst is
filtered off, the filtrate concentrated and the residue dissolved
in EtOAc and H.sub.2O. The aqueous layer is extracted twice with
EtOAc. The organic layers are washed with water and brine, dried
(Na.sub.2SO.sub.4) and concentrated. Crystallization from
EtOAc/DIPE gives the title compound: MS: [M+1].sup.+=448; HPLC:
.sup.At.sub.Ret=12.7.
Example 3
5-(6-Chloro-pyrimidin-4-yloxy)-indole-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0165] A solution of 492 mg (2.00 mMol) of
5-(6-chloro-pyrimidin-4-yloxy)-1H-indole (WO 03/099771; Stage
163.1), 344 mg (2.12 mMol) of 1,1'-carbonyl-diimidazol and 6 mg
DMAP in 7 ml CH.sub.3CN is stirred at 80.degree. C. for 8 h. After
cooling to rt, 356 .mu.l (2.86 mMol) 3-trifluoromethyl-aniline are
added to the suspension, which then is stirred again for 9 h at
80.degree. C. The reaction mixture is filtered and the filtrate
diluted with EtOAc and H.sub.2O. The aqueous layer is extracted
twice with EtOAc. The organic layers are washed with water and
brine, dried (Na.sub.2SO.sub.4) and concentrated. Reversed phase
MPLC (Gilson system) gives the title compound: MS:
[M+1].sup.+=433/435; TLC (EtOAc/CH.sub.2Cl.sub.2 3:97):
R.sub.f=0.15; HPLC: .sup.At.sub.Ret=16.8.
Example 4
5-(6-Amino-pyrimidin-4-yloxy)-indole-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0166] To a solution of 150 mg (0.35 mMol)
5-(6-chloro-pyrimidin-4-yloxy)-indole-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide in 2 ml DMF, 45 mg (0.69 mMol)
NaN.sub.3 are added at rt. After 2 h at 65.degree. C., the solution
containing 5-(6-azido-pyrimidin-4-yloxy)-indole-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide is cooled to rt. Then 12 mg Pd/C
(10%; Engelhard 4505) are added and the mixture is hydrogenated for
1 h. The catalyst is filtered off and the filtrate concentrated in
vacuo. Reversed phase MPLC (Gilson system) gives the title
compound: MS: [M+1].sup.+=414; HPLC: .sup.At.sub.Ret=12.6.
Example 5
7-(6-Amino-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazine-4-carboxylic
acid (4-methyl-3-trifluoromethyl-phenyl)-amide
[0167] 104 mg (0.35 mMol) triphosgene are dissolved in 13 ml ice
cooled CH.sub.2Cl.sub.2. Then a solution of 183 mg (1.05 mMol)
5-amino-2-methylbenzotrifluoride and 209 .mu.l (1.5 mMol) Et.sub.3N
in 6 ml CH.sub.2Cl.sub.2 is added during 8 min. After 3 minutes,
the mixture is warmed up to rt by a water bath and then a solution
of 244 mg (1.00 mMol)
6-(3,4-dihydro-2H-benzo[1,4]oxazin-7-yloxy)-pyrimidin-4-ylamine
(Step 5.6) and 139 .mu.l (1.0 mMol) Et.sub.3N in 6 ml
CH.sub.2Cl.sub.2 is added during 10 min. After 2.5 h at rt, the
mixture is diluted with sat. Na.sub.2CO.sub.3/H.sub.2O 1:1 and
EtOAc, the aqueous phase separated off and extracted twice with
EtOAc. The organic layers are washed with water and brine, dried
(Na.sub.2SO.sub.4) and concentrated partially. Addition of ether
and hexane gives the crystalline title compound: MS:
[M+1].sup.+=446; TLC (EtOAc): R.sub.f=0.30; HPLC:
.sup.At.sub.Ret=12.3.
[0168] The starting material is prepared as follows:
Step 5.1: 2-(2,4-Dimethoxy-phenylamino)-ethanol
[0169] 30.6 g (0.20 Mol) 2,4-dimethoxy-aniline are dissolved in 200
ml EtOAc. Then 14.8 ml (95%; 0.20 Mol) of 2-bromethanol and 33.6 g
(0.40 Mol) NaHCO.sub.3 are added and the suspension is heated to
77.degree. C. for 20 h. The mixture is cooled to it and filtered.
Concentration of the filtrate and column chromatography (SiO.sub.2;
hexane/EtOAc 3:1.fwdarw.2:1.fwdarw.1:1) gives the title compound as
an oil: MS: [M+1].sup.+=198; TLC (EtOAc): R.sub.f=0.50; HPLC:
.sup.Bt.sub.Ret=9.2.
Step 5.2: (2-Bromo-ethyl)-(2,4-dihydroxy-phenyl)-carbamic acid
benzyl ester
[0170] 22 g (0.11 Mol) 2-(2,4-dimethoxy-phenylamino)-ethanol and
125 ml HBr (62% in H.sub.2O) are heated to 140.degree. C. for 15 h.
The resulting dark solution is concentrated in vacuo. The residue
is diluted with 60 ml water and 120 ml EtOAc and cooled in an ice
bath. Then 30 ml (95%; 0.20 Mol) benzyl chloroformate are added.
Under vigorous stirring, 90 ml Na.sub.2CO.sub.3 2 M are added
dropwise during 20 min. After 90 min stirring at rt, the reaction
mixture is filtered, the aqueous phase of the filtrate separated
off and extracted twice with 30 ml EtOAc. The organic layers are
washed with 30 ml brine, dried (Na.sub.2SO.sub.4) and concentrated.
Column chromatography (SiO.sub.2; hexane/EtOAc
4:1.fwdarw.7:3.fwdarw.3:2) gives the title compound as an oil: MS:
[M+1].sup.+=366/368; TLC (EtOAc/hexane 1:1): R.sub.f=0.34; HPLC:
.sup.At.sub.Ret=12.6.
Step 5.3: 7-Hydroxy-2,3-dihydro-benzo[1,4]oxazine-4-carboxylic acid
benzyl ester
[0171] To a solution of 32 g (87.4 mMol)
(2-bromo-ethyl)-(2,4-dihydroxy-phenyl)-carbamic acid benzyl ester
in 100 ml DMF, 16 g (116 mMol) K.sub.2CO.sub.3 are added. After 1 h
stirring at rt, the reaction mixture is filtered and the filtrate
concentrated in vacuo. The resulting brown oil is diluted with 120
ml EtOAc and 50 ml citric acid (5% in H.sub.2O). The aqueous phase
is separated off and extracted twice with EtOAc. The organic layers
are washed with water and brine, dried (Na.sub.2SO.sub.4) and
concentrated, giving the oily title compound: MS: [M+1].sup.+=286;
TLC (EtOAc/hexane 1:1): R.sub.f=0.61; HPLC:
.sup.At.sub.Ret=13.0.
Step 5.4:
7-(6-Chloro-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazine-4-c-
arboxylic acid benzyl ester
[0172] To a solution of 9.73 g (95%; 32.5 mMol)
7-hydroxy-2,3-dihydro-benzo[1,4]oxazine-4-carboxylic acid benzyl
ester in 96 ml of acetone, 4.84 g (32.5 mMol)
4,6-dichloropyrimidine are added. Then a solution of 1.3 g (32.5
mMol) NaOH in 48 ml of water is added and the mixture stirred for 2
h at rt. Addition of some seeding crystals leads to the
crystallization of the title compound, which is filtered off and
washed with acetone/H.sub.2O 1:1: m.p.: 110.degree. C.; MS:
[M+1].sup.+=398/400; HPLC: .sup.At.sub.Ret=16.4. More product can
be isolated from the filtrate by extraction (EtOAc; NaHCO.sub.3,
water and brine) and column chromatography (SiO.sub.2; hexane/EtOAc
9:1.fwdarw.4:1.fwdarw.3:1).
Step 5.5:
7-6-Azido-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazine-4-car-
boxylic acid benzyl ester
[0173] To a solution of 8.0 g (20.1 mMol)
7-(6-chloro-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazine-4-carboxylic
acid benzyl ester in 35 ml DMF, 2.61 g (40.2 mMol) NaN.sub.3 are
added. After heating at 70.degree. C. for 90 min, the resulting
mixture is diluted with EtOAc and water, the aqueous phase
separated off and extracted twice with EtOAc. The organic layers
are washed with water and brine, dried (Na.sub.2SO.sub.4) and
concentrated, giving the title compound: MS: [M+1].sup.+=405; HPLC:
.sup.At.sub.Ret=16.6.
Step 5.6:
6-(3,4-Dihydro-2H-benzo[1,4]oxazin-7-yloxy)-pyrimidin-4-ylamine
[0174] A solution of 20.1 mMol
7-(6-azido-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazine-4-carboxylic
acid benzyl ester in 500 ml THF is hydrogenated in the presence of
3.5 g Pd/C (10%; Engelhard 4505). The catalyst is filtered off, the
filtrate concentrated and crystallized from DIPE, giving the title
compound: m.p.: 140-141.degree. C.; MS: [M+1].sup.+=245; TLC
(EtOAc): R.sub.f=0.11.
Example 6
7-(6-Amino-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazine-4-carboxylic
acid (4-fluoro-3-trifluoromethyl-phenyl)-amide
[0175] Prepared analogously to Ex. 5: MS: [M+1].sup.+=450; TLC
(EtOAc): R.sub.f=0.23; HPLC: .sup.At.sub.Ret=11.9.
Example 7
7-(6-Amino-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazine-4-carboxylic
acid (3-trifluoromethyl-phenyl)-amide
[0176] A solution of 120 .mu.l (0.87 mMol)
3-trifluoromethyl-phenyl-isocyanate in 9 ml ether is added dropwise
to 0.20 g (0.82 mMol)
6-(3,4-dihydro-2H-benzo[1,4]oxazin-7-yloxy)-pyrimidin-4-ylamine in
4.5 ml THF. After 45 min at rt, 10 ml hexane are added. Then the
crystallized title compound is filtered off and washed with hexane:
MS: [M+1].sup.+=432; TLC (EtOAc): R.sub.f=0.32; HPLC:
.sup.At.sub.Ret=11.9; Anal.: C, H, N, F.
Example 8
7-(6-Methylamino-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazine-4-carbox-
ylic acid (4-methyl-3-trifluoromethyl-phenyl)-amide
[0177] 73 mg (0.25 mMol) triphosgene are dissolved in 9 ml ice
cooled CH.sub.2Cl.sub.2. Then a solution of 134 mg (97%; 0.74 mMol)
5-amino-2-methylbenzotrifluoride and 146 .mu.l (1.05 mMol)
Et.sub.3N in 4 ml CH.sub.2Cl.sub.2 is added during 5 min. After 3
minutes, the mixture is warmed up to it by a water bath and then a
solution of 180 mg (0.70 mMol)
[6-(3,4-dihydro-2H-benzo[1,4]oxazin-7-yloxy)-pyrimidin-4-yl]-methyl-
-amine (Step 8.2) and 98 .mu.l (0.70 mMol) Et.sub.3N in 4 ml
CH.sub.2Cl.sub.2 is added during 5 min. After 2.5 h at rt, the
mixture is diluted with sat. Na.sub.2CO.sub.3/H.sub.2O 1:1 and
EtOAc, the aqueous phase separated off and extracted twice with
EtOAc. The organic layers are washed with water and brine, dried
(Na.sub.2SO.sub.4) and concentrated. Crystallization from THF and
hexane gives the title compound: m.p.: 180-182.degree. C.; MS:
[M+1].sup.+=460; TLC (EtOAc): R.sub.f=0.38; HPLC:
.sup.Bt.sub.Ret=12.7.
[0178] The starting material is prepared as follows:
Step 8.1:
7-(6-Methylamino-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazin-
e-4-carboxylic acid benzyl ester
[0179] To a suspension of 1.39 g (3.49 mMol)
7-(6-chloro-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazine-4-carboxylic
acid benzyl ester (Step 5.4) in 8 ml THF, 8.7 ml (2 M in THF; 17.5
mMol) methylamine are added. After stirring in a sealed vessel for
16 h at rt, the resulting mixture is dissolved with EtOAc and MeOH.
Then 6 g of SiO.sub.2 are added and the mixture is concentrated in
vacuo. The resulting powder is put on top of a SiO.sub.2 column
(EtOAc/hexane 1:3) and the title compound eluted with EtOAc/hexane
1:3.fwdarw.1:1.fwdarw.2:1: MS: [M+1].sup.+=393; TLC (EtOAc/hexane
1:1): R.sub.f=0.08; HPLC: .sup.At.sub.Ret=12.1.
Step 8.2:
[6-(3,4-Dihydro-2H-benzo[1,4]oxazin-7-yloxy)-Pyrimidin-4-yl]-met-
hyl-amine
[0180] A solution of 0.79 g (2.0 mMol)
7-(6-methylamino-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazine-4-carbo-
xylic acid benzyl ester in 50 ml THF is hydrogenated in the
presence of 0.35 g Pd/C (10%; Engelhard 4505). The catalyst is
filtered off, the filtrate concentrated partially and the title
compound crystallized by addition of hexane: m.p.: 153.degree. C.;
MS: [M+1].sup.+=259; TLC (EtOAc): R.sub.f=0.16; HPLC:
.sup.Bt.sub.Ret=10.6.
Example 9
7-(6-Methylamino-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazine-4-carbox-
ylic acid (3-trifluoromethyl-phenyl)-amide
[0181] Prepared analogously to Ex. 7: m.p.: 180.degree. C.; MS:
[M+1].sup.+=446; TLC (EtOAc): R.sub.f 0.47; HPLC:
.sup.At.sub.Ret=12.3; Anal.: C, H, N, F.
Example 10
7-(2-Amino-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazine-4-carboxylic
acid (3-trifluoromethyl-phenyl)-amide
[0182] A solution of 0.183 g (0.75 mMol)
4-(3,4-dihydro-2H-benzo[1,4]oxazin-7-yloxy)-pyrimidin-2-ylamine
(Step 10.2) in 3 ml of acetonitrile is treated at rt with 0.114 ml
(0.825 mMol) 1-isocyanato-3-trifluoromethyl-benzene and stirred for
2 h at rt. The solvent is evaporated and the residue
chromatographed on a 40 g silica gel column on a Combi-Flash
Companion.TM. (Isco Inc.) apparatus using EtOAc as solvent. The
title compound is obtained as a colorless foam: MS:
[M+1].sup.+=432; TLC (EtOAc): R.sub.f=0.31; HPLC:
.sup.Ct.sub.Ret=1.88 min.
[0183] The starting material is prepared as follows:
Step 10.1:
7-(2-amino-6-chloro-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]ox-
azine-4-carboxylic acid benzyl ester
[0184] To a solution of 5.8 g (0.0203 Mol) crude
7-hydroxy-2,3-dihydro-benzo[1,4]oxazine-4-carboxylic acid benzyl
ester (Step 5.3) in 30 ml of DMF are added 2.0 g anhydrous
potassium carbonate and 3.3 g (0.0201 Mol)
2-amino-4,6-dichloropyrimidine and the resulting mixture is heated
to 80.degree. C. for 16 h. After cooling to rt the mixture is
filtered and the DMF evaporated to leave a dark brown oil. This
material is purified by flash-chromatography on a 240 g silica gel
column using CH.sub.2Cl.sub.2/MeOH 100:0.5.fwdarw.100:2.5 as
eluent. Pure fractions are evaporated to leave a yellow oil. On
addition of 15 ml of EtOAc the product crystallizes. It is filtered
off, washed with EtOAc/hexane 1:1 and dried. The title compound is
obtained as colorless crystals: m.p.: 161-163.degree. C.; MS:
[M+1].sup.+=412.9; TLC (CH.sub.2Cl.sub.2/MeOH/NH.sub.3.sup.aq
350:50:1): R.sub.f=0.76; HPLC: .sup.Ct.sub.Ret=2.57 min.
Step 10.2:
4-(3,4-dihydro-2H-benzo[1,4]oxazin-7-yloxy)-pyrimidin-2-ylamine
[0185] 2.0 g (4.8 mMol)
7-(2-amino-6-chloro-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazine-4-ca-
rboxylic acid benzyl ester are dissolved in 100 ml of a 1:1 mixture
of THF and methanol and hydrogenated at rt in the presence of 0.5 g
Pd/C (10%; Engelhard 4505). The catalyst is filtered off, the
filtrate concentrated and partitioned between 40 ml conc. sodium
bicarbonate and 50 ml of EtOAc. The organic layer is washed with
brine, dried with sodium sulfate and evaporated. The crude title
compound is obtained as an amorphous material: MS: [M+1].sup.+=245;
TLC(CH.sub.2Cl.sub.2/MeOH/NH.sub.3.sup.aq 350:50:1): R.sub.f=0.47;
HPLC: .sup.Ct.sub.Ret=0.86 min.
Example 11
7-(2-Amino-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazine-4-carboxylic
acid (4-morpholin-4-ylmethyl-3-trifluoromethyl-phenyl)-amide
[0186] A solution of 0.86 ml (7.13 mMol) trichloromethyl
chloroformate in 4 ml of dry THF is treated at 40.degree. C. with a
solution of 0.51 g (2.09 mMol)
4-(3,4-dihydro-2H-benzo[1,4]oxazin-7-yloxy)-pyrimidin-2-ylamine.
The mixture is stirred under reflux for 2 h, cooled to rt and
evaporated to leave a tan foam. This is added to a solution of
4-morpholin-4-ylmethyl-3-trifluoromethyl-phenylamine (0.362 g, 1.4
mMol) in 4 ml of ethanol. The mixture is heated to 80.degree. C.
and stirred at that temperature for 3 h. After cooling to it the
solvent is evaporated and the residue partitioned between
CH.sub.2Cl.sub.2 and sat. sodium bicarbonate solution. The organic
phase is dried with sodium sulfate and evaporated. The residue is
purified on a 40 g silica gel column on a Combi-Flash Companion.TM.
(Isco Inc.) apparatus using EtOAc for 10 min, then a gradient of 1
to 30% acetone in EtOAc. The title compound is obtained as a
slightly reddish foam: MS: [M+1].sup.+=531; TLC (EtOAc):
R.sub.f=0.10; HPLC: .sup.Ct.sub.Ret=1.32 min.
Example 12
[0187] The following compounds can be obtained analogously to Ex.
10 or 11.
TABLE-US-00001 ##STR00006## ##STR00007## ##STR00008## TLC R.sub.f
HPLC t.sub.Ret [min] m.p. [.degree. C.] MS [M + 1].sup.+ a)
##STR00009## 0.23.sup.1) 12.7.sup.A) 500 b) ##STR00010##
0.35.sup.2) 2.03.sup.C) 127-130 465.8 c) ##STR00011## 2.13.sup.C)
146-149 499.9 d) ##STR00012## 1.92.sup.C) 119-124 449.9 e)
##STR00013## 2.01.sup.C) 191-195 465.9 f) ##STR00014## 1.97.sup.C)
133-136 445.9 .sup.1)TLC(EtOAc/hexane 2:1); .sup.2)TLC(EtOAc)
Example 13
6-(2-Amino-6-chloro-pyrimidin-4-yloxy)-naphthalene-1-carboxylic
acid (3-trifluoromethyl-phenyl)-amide
[0188] To an ice cooled solution of 3.5 g (11 mMol)
6-(2-amino-6-chloro-pyrimidin-4-yloxy)-naphthalene-1-carboxylic
acid in 60 ml DMF, 1.8 ml (16 mMol) NMM and 3.1 ml (20 mMol) DEPC
are added, followed by 1.5 ml (12 mMol) of
3-amino-benzotrifluoride. After 2 h stirring at 0.degree. C. and 16
h at rt, the solution is concentrated in vacuo. The residue is
re-dissolved in water and EtOAc, the aqueous phase separated off
and extracted twice with EtOAc. The organic layers are washed twice
with water and brine, dried (Na.sub.2SO.sub.4) and after addition
of SiO.sub.2 concentrated. The resulting powder is put on top of a
SiO.sub.2 column (EtOAc/hexane 1:9) and eluted with EtOAc/hexane
1:9.fwdarw.1:1. Partial concentration of the product containing
fractions leads to crystallization. Filtration and washing with
hexane gives the title compound: m.p.: 234-236.degree. C.; MS:
[M+1].sup.+=459; TLC (EtOAc/hexane 1:2): R.sub.f=0.24; HPLC:
.sup.At.sub.Ret=16.2.
[0189] The starting material is prepared as follows:
Step 13.1:
6-(2-Amino-6-chloro-pyrimidin-4-yloxy)-naphthalene-1-carboxylic
acid
[0190] A suspension of 6.56 g (40 mMol)
2-amino-4,6-dichloropyrimidine and 7.52 g (40 mMol)
6-hydroxy-1-naphthoic acid in 160 ml acetone and 80 ml 1 N
NaOH.sup.aq. is heated to 62.degree. C. for 36 h. The mixture is
cooled to rt, partially concentrated in vacuo and the residue
poured into 1.6 l ice water. Under vigorous stirring, 20 ml 2 N HCl
are added dropwise (pH 4). After stirring the suspension for 30
min, the title compound is filtered off and washed with water: MS:
[M+1].sup.+=316/318; HPLC: .sup.At.sub.Ret=12.8.
Example 14
6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0191] A solution of 660 mg (1.44 mMol)
6-(2-amino-6-chloro-pyrimidin-4-yloxy)-naphthalene-1-carboxylic
acid (3-trifluoromethyl-phenyl)-amide in 70 ml THF and 0.22 ml
(1.58 mMol) Et.sub.3N is hydrogenated in the presence of 0.4 g Pd/C
(10%; Engelhard 4505). The catalyst is filtered off, the filtrate
concentrated and the residue diluted with EtOAc and H.sub.2O. The
aqueous layer is extracted twice with EtOAc. The organic layers are
washed with water and brine, dried (Na.sub.2SO.sub.4) and
concentrated. Chromatography (Combi Flash; hexane/EtOAc
1:1.fwdarw.EtOAc) gives the title compound: m.p.: 218.degree. C.;
MS: [M+1].sup.+=425; TLC (EtOAc/hexane 1:1): R.sub.f=0.07.
Example 15
6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(4-methyl-3-trifluoromethyl-phenyl)-amide
[0192] To an ice cooled solution of 140 mg (0.50 mMol)
6-(2-amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid in 3 ml
DMF, 78 .mu.l (97%; 0.53 mMol) 4-methyl-3-trifluoromethyl-aniline,
74 .mu.l (0.67 mMol) NMM and 124 .mu.l (0.83 mMol) DEPC are added.
After overnight stirring, the mixture is poured into water and
EtOAc, the aqueous phase separated off and extracted twice with
EtOAc. The organic layers are washed with water and brine, dried
(Na.sub.2SO.sub.4) and concentrated. Chromatography (Combi Flash;
hexane/EtOAc 4:1.fwdarw.1:9) and crystallization from hexane gives
the title compound: MS: [M+1].sup.+=439; TLC (EtOAc): R.sub.f=0.49;
HPLC: .sup.At.sub.Ret=12.7.
[0193] The starting material is prepared as follows:
Step 15.1: 6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic
acid
[0194] A solution of 230 mg (0.73 mMol)
6-(2-amino-6-chloro-pyrimidin-4-yloxy)-naphthalene-1-carboxylic
acid (Step 13.1) in 41 ml THF and 1 ml Et.sub.3N is hydrogenated in
the presence of 0.17 g Pd/C (10%; Engelhard 4505). The catalyst is
filtered off and the filtrate concentrated. The residue is
dissolved in EtOAc and H.sub.2O and the aqueous layer extracted
twice with EtOAc. Acidification of the aqueous phase with 2 N HCl
(.fwdarw.pH 3-4) leads to the crystallization of the title
compound, which is filtered off and washed with water: MS:
[M+1].sup.+=282; HPLC: .sup.Bt.sub.Ret=13.6.
Example 16
6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(2-trifluoromethyl-pyridin-4-yl)-amide
[0195] 0.24 mMol
6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid, 43 mg
(0.26 mMol) 4-amino-2-(trifluoromethyl)pyridine [J. Med. Chem. 36
(1993), 733-746], 20 mg (0.16 mMol) DMAP and 0.8 ml (5.7 mMol)
Et.sub.3N are dissolved in 4 ml DMF. Then 0.6 ml (1 mMol)
propylphosphonic anhydride are added and the mixture is stirred for
3 days at rt. The mixture is poured into water and EtOAc, the
aqueous phase separated off and extracted twice with EtOAc. The
organic layers are washed with water and brine, dried
(Na.sub.2SO.sub.4) and concentrated. Reversed phase chromatography
gives the title compound: MS: [M+1].sup.+=426; HPLC:
.sup.At.sub.Ret=11.9.
Example 17
[0196] The following compounds can be obtained analogously to Ex.
15.
TABLE-US-00002 ##STR00015## ##STR00016## ##STR00017## TLC.sub.Rf
HPLC .sup.At.sub.Ret [min] m.p. [.degree. C.] MS [M + 1].sup.+
Anal. a) ##STR00018## 0.19.sup.1) 12.4 425 b) ##STR00019##
0.30.sup.1) 13.1 228-229 413 C, H, N c) ##STR00020## 0.21.sup.1)
12.6 205-206 443 C, H, N d) ##STR00021## 0.29.sup.1) 13.5 463/465
e) ##STR00022## 12.3 493 .sup.1)TLC(EtOAc/hexane 2:1)
Example 18
6-(2-Acetylamino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0197] A solution of 170 mg (0.40 mMol)
6-(2-amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide (Ex. 14) in 3 ml pyridine is
diluted with 2 ml CH.sub.2Cl.sub.2. Then 0.20 ml of an
acetylchloride solution (2.2 M in CH.sub.2Cl.sub.2; 0.44 mMol) are
added dropwise, followed by another 0.10 ml after 40 min. After
totally 75 min, the reaction mixture is diluted with EtOAc and
H.sub.2O. The aqueous layer is separated off and extracted twice
with EtOAc. The organic layers are washed with water and brine,
dried (Na.sub.2SO.sub.4) and concentrated. Chromatography (Combi
Flash; hexane/EtOAc 1:1.fwdarw.EtOAc), partial concentration and
crystallization by addition of DIPE gives the title compound: m.p.:
216-217.degree. C.; MS: [M+1].sup.+=467; TLC (EtOAc): R.sub.f=0.36;
HPLC: .sup.At.sub.Ret=13.1; Anal.: C, H, N, F.
Example 19
6-(2-Methoxycarbonylamino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic
acid (3-trifluoromethyl-phenyl)-amide
[0198] A solution of 200 mg (0.47 mMol)
6-(2-amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide (Ex. 14) in 5 ml pyridine is
diluted with 3 ml CH.sub.2Cl.sub.2. Then 7.1 ml of a methyl
chloroformate solution (2.8 M in CH.sub.2Cl.sub.2; 20 mMol) are
added portionwise during 7 h. The reaction mixture is diluted with
EtOAc and H.sub.2O. The aqueous layer is separated off and
extracted twice with EtOAc. The organic layers are washed with
water and brine, dried (Na.sub.2SO.sub.4) and concentrated.
Stirring in DIPE gives the title compound: m.p.: 199-200.degree.
C.; MS: [M+1].sup.+=483; HPLC: .sup.At.sub.Ret=13.6; Anal.: C, H,
N, F.
Example 20
7-(2-Acetylamino-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazine-4-carbox-
ylic acid (4-methyl-3-trifluoromethyl-phenyl)-amide
[0199] Prepared at 0.degree. C. as described in Ex. 18 from 161 mg
(0.36 mMol)
7-(2-amino-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazine-4-carbo-
xylic acid (4-methyl-3-trifluoromethyl-phenyl)-amide (Ex. 12f): MS:
[M+1].sup.+=488; TLC (EtOAc): R.sub.f=0.47; HPLC:
.sup.At.sub.Ret=12.9; Anal.: C, H, N, F.
Example 21
7-(2-Methoxycarbonylamino-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazine-
-4-carboxylic acid (4-methyl-3-trifluoromethyl-phenyl)-amide
[0200] Prepared as described in Ex. 19 from 150 mg (0.34 mMol)
7-(2-amino-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazine-4-carboxylic
acid (4-methyl-3-trifluoromethyl-phenyl)-amide (Ex. 12f): MS:
[M+1].sup.+=504; TLC (EtOAc): R.sub.f=0.52; HPLC:
.sup.At.sub.Ret=13.3; Anal.: C, H, N, F.
Example 22
7-(2-Amino-pyrimidin-4-yloxy)-2,3-dihydro-benzo[1,4]oxazine-4-carboxylic
acid [4-(4-methyl-piperazin-1-yl
methyl)-3-trifluoromethyl-phenyl]-amide
[0201] A solution of 0.174 g (0.71 mMol)
4-(3,4-dihydro-2H-benzo[1,4]oxazin-7-yloxy)-pyrimidin-2-ylamine
(Step 10.2) and 0.291 g (0.68 mMol)
[4-(4-methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-carbamic
acid phenyl ester hydrochloride in 0.75 ml of DMSO is warmed to
60.degree. C. After the addition of 0.133 ml (0.77 mMol) of
N,N-diisopropyl-ethylamine the mixture is stirred at 60.degree. C.
for 1.5 h. A solution of 0.055 g potassium hydroxide in 0.1 ml of
water is added at 50.degree. C. and the mixture stirred rapidly for
about 10 min. After cooling to rt the mixture is partitioned
between EtOAc and water and the organic layer washed with brine. 2
g of silica gel are added and the solvent evaporated. The resulting
powder is applied to a 40 g silica gel column on a Combi-Flash
Companion.TM. (Isco Inc.) apparatus and eluted with EtOAc (A) and
MeOH/NH.sub.3.sup.aq 10:3 (B) with a gradient of 0% B.fwdarw.10% B
in 30 min then 10% B for 20 min. The title compound is obtained as
a yellowish foam: MS: [M+1].sup.+=543.9; TLC
(CH.sub.2Cl.sub.2/MeOH/NH.sub.3.sup.aq 350:50:1): R.sub.f=0.36;
HPLC: .sup.Ct.sub.Ret=1.30 min.
[0202] The starting material is prepared as follows:
Step 22.1:
[4-(4-Methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-ca-
rbamic acid phenyl ester hydrochloride
[0203] As described in Synth. Commun. 30 (2000), 1937 the title
compound can be prepared by dropwise addition of a solution of
[4-(4-methyl-piperazin-1-ylmethyl)-3-trifluoromethyl]-aniline (1.0
eq.) in THF to a solution of phenyl chloroformate (1.1 eq.) in THF
at -25.degree. C. and warming the mixture up to rt.
Example 23
6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(4-morpholin-4-yl-3-trifluoromethyl-phenyl)-amide
[0204] To a solution of 184 mg (0.65 mMol)
6-(2-amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (Step
15.1) in 5 ml NMP, 214 .mu.l (1.95 mMol) NMM and 247 mg (0.65 mMol)
HATU are added. After 15 min stirring, 242 mg (0.98 mMol)
4-morpholin-4-yl-3-trifluoromethyl-aniline are added, followed by
some DMAP. After 16 h, the mixture is poured into water and EtOAc,
the aqueous phase separated off and extracted twice with EtOAc. The
organic layers are washed with sat. Na.sub.2CO.sub.3/H.sub.2O 1:1,
water and brine, dried (Na.sub.2SO.sub.4) and concentrated.
Chromatography (Combi Flash; hexane/EtOAc 4:1.fwdarw.1:9) and
crystallization from EtOAc/hexane gives the title compound: MS:
[M+1].sup.+=510; TLC (EtOAc/hexane 2:1): R.sub.f=0.17; HPLC:
.sup.At.sub.Ret=12.5.
Example 24
6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
cis/trans-(4-isopropyl-cyclohexyl)-amide
[0205] To an ice cooled solution of 180 mg (0.47 mMol)
6-(2-amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (Step
15.1) in 5 ml DMF, 69 .mu.l (0.63 mMol) NMM and 118 .mu.l (0.79
mMol) DEPC are added, followed by 133 mg (0.94 mMol)
cis/trans-(4-isopropyl-cyclohexyl)-amine [Arzneim. Forsch. 19
(1969), 140]. After 16 h stirring, the mixture is poured into water
and EtOAc, the aqueous phase separated off and extracted twice with
EtOAc. The organic layers are washed with water and brine, dried
(Na.sub.2SO.sub.4) and concentrated. Chromatography (Combi Flash;
CH.sub.2Cl.sub.2/EtOAc 9:1.fwdarw.3:2) gives the title compound as
a cis/trans mixture: MS: [M+1].sup.+=405;
TLC(CH.sub.2Cl.sub.2/EtOAc 1:1): R.sub.f=0.18; HPLC:
.sup.At.sub.Ret=13.6.
Example 25
6-(6-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(4-fluoro-3-trifluoromethyl-phenyl)-amide
[0206] To an ice cooled solution of 120 mg (0.43 mMol)
6-(6-amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (Step
25.3) in 3 ml DMF, 63 .mu.l (0.57 mMol) NMM and 107 .mu.l (0.72
mMol) DEPC are added, followed by 111 .mu.l (0.86 mMol)
4-fluoro-3-trifluoromethyl-aniline. The solution is stirred for 1 h
at 0.degree. C. and 5 h at rt. Then it is poured into water and
EtOAc, the aqueous phase separated off and extracted twice with
EtOAc. The organic layers are washed with water and brine, dried
(Na.sub.2SO.sub.4) and concentrated. Chromatography (Combi Flash;
hexane/EtOAc 4:1.fwdarw.1:9) and crystallization from hexane gives
the title compound: m.p.: 224-225.degree. C.; MS: [M+1].sup.+=443;
TLC (EtOAc): R.sub.f=0.38; HPLC: .sup.At.sub.Ret=12.5.
[0207] The starting material is prepared as follows:
Step 25.1: 6-(6-Chloro-pyrimidin-4-yloxy)-naphthalene-1-carboxylic
acid
[0208] 23.6 g (125 mMol) 6-hydroxy-1-naphthoic acid are dissolved
in a solution of 10.7 g (265 mMol) NaOH in 125 ml water. Then 19.8
g (133 mMol) 4,6-dichloro-pyrimidine dissolved in 125 ml acetone
are added dropwise during 30 min. The suspension is stirred for 20
h at it and then partially concentrated in vacuo. The resulting
residue is diluted with 600 ml EtOAc and 300 ml water and acidified
to pH 3 with 4 NHCl The aqueous layer is separated off and
extracted 3 times with EtOAc. The organic phases are washed 3 times
with water and brine, dried (Na.sub.2SO.sub.4), treated with
charcoal and partially concentrated. The resulting suspension is
diluted with 400 ml ether, the crystals filtered off and washed
with hexane, yielding the title compound: m.p.: 194-195.degree. C.;
MS: [M+1].sup.+=301.
Step 25.2: 6-(6-Azido-pyrimidin-4-yloxy)-naphthalene-1-carboxylic
acid
[0209] To 1.00 g (3.3 mMol)
6-(6-chloro-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid in 11
ml DMF, 0.43 g (6.6 mMol) NaN.sub.3 are added. After stirring for
2.5 h at 60.degree. C., the reaction mixture is concentrated in
vacuo (40.degree. C.). The residue is dissolved in water and EtOAc,
the aqueous phase separated off and extracted twice with EtOAc. The
organic layers are washed with brine, dried (Na.sub.2SO.sub.4) and
concentrated, giving the title compound: MS: [M+1].sup.+=308; HPLC:
.sup.At.sub.Ret=13.4. More product can be precipitated from the
combined aqueous phases by acidifying them with citric acid to
pH.apprxeq.12.
Step 25.3: 6-(6-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic
acid
[0210] 0.49 g (1.6 mMol)
6-(6-azido-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid in 25
ml THF are hydrogenated in the presence of 0.2 g Pd/C (10%;
Engelhard 4505). The partially crystallized product can be isolated
by dissolving it in a mixture of MeOH/EtOAc/THF at 40.degree. C.,
filtration, extensively washing with MeOH/CH.sub.2Cl.sub.2, and
concentration of the filtrate: m.p.: 288-290.degree. C.; MS:
[M+1].sup.+282; HPLC: .sup.At.sub.Ret=8.6.
Alternative Method for Synthesis of
6-(6-amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
[0211] 1.00 g (3.3 mMol)
6-(6-Chloro-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid and
0.43 g (6.6 mMol) NaN.sub.3 are stirred for 2 h at 65.degree. C. in
11 ml DMF. The suspension is cooled to rt, 200 mg Pd/C (10%;
Engelhard 4505) are added and the mixture is hydrogenated for 16 h.
The catalyst is filtered off and the filtrate concentrated in
vacuo. The residue is re-dissolved in 5 ml DMF and poured into 150
ml water and 3 ml 10% citric acid. Filtration and washing with
water gives the title compound.
Example 26
6-(6-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0212] To a solution of 11.0 g (39.1 mMol)
6-(6-amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid, 5.9 ml
(47 mMol) 3-trifluoromethyl-aniline, 54 ml (390 mMol) Et.sub.3N and
2.4 g (19.6 mMol) DMAP in 200 ml DMF, 46 ml (78 mMol)
propylphosphonic anhydride are added dropwise. After 2 h, the
mixture is concentrated in vacuo and the residue diluted with water
and EtOAc. The aqueous phase is separated off and extracted twice
with EtOAc. The organic layers are washed with water and brine,
dried (Na.sub.2SO.sub.4) and concentrated. Column chromatography
(SiO.sub.2; CH.sub.2Cl.sub.2/EtOAc 2:1.fwdarw.1:1.fwdarw.1:3) and
crystallization from EtOAc gives the title compound: m.p.:
243-244.degree. C.; MS: [M+1].sup.+=425; HPLC:
.sup.At.sub.Ret=12.6; Anal.: C, H, N, F.
Example 27
6-(6-Chloro-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0213] To a solution of 300 mg (0.92 mMol)
6-hydroxy-benzooxazole-3-carboxylic acid
(3-trifluoromethyl-phenyl)-amide (Step 27.3) and 138 mg (0.92 mMol)
4,6-dichiorpyrimidine in 9 ml acetone, 0.92 ml NaOH.sup.aq. 1 N are
added. Then the mixture is stirred for 120 min at 50.degree. C. and
concentrated in vacuo. The residue is dissolved in EtOAc and water,
the aqueous phase separated off and extracted twice with EtOAc. The
organic layers are washed with water and brine, dried
(Na.sub.2SO.sub.4) and concentrated. Chromatography (Combi Flash;
hexane/EtOAc 85:15.fwdarw.4:1) gives the title compound: MS:
[M+1].sup.+=437; TLC (hexane/EtOAc 1:1): R.sub.f=0.42; HPLC:
.sup.At.sub.Ret=15.9.
[0214] The starting material is prepared as follows:
Step 27.1:
1-(4-Benzyloxy-2-hydroxy-phenyl)-3-(3-trifluoromethyl-phenyl)-u-
rea
[0215] To a solution of 4.44 g (20.6 mMol)
2-amino-5-benzyloxy-phenol [preparation see: WO 03/045925; page
146] in 90 ml THF, a solution of 3.01 ml (21.9 mMol)
3-trifluoromethyl-phenylisocyanate in 90 ml THF is added dropwise.
After 15 h at rt, the reaction mixture is concentrated partially in
vacuo, the residue is re-dissolved in water and EtOAc, the aqueous
phase separated off and extracted twice with EtOAc. The organic
layers are washed with water and brine, dried (Na.sub.2SO.sub.4)
and concentrated. The crude product is dissolved in 50 ml boiling
EtOAc. Addition of 40 ml hexane and cooling to it gives the
crystalline title compound: m.p.: 184-185.degree. C.; MS:
[M+1].sup.+=403; HPLC: .sup.At.sub.Ret=15.3.
Step 27.2: 6-Benzyloxy-benzooxazole-3-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0216] To a solution of 6.80 g (16.9 mMol) of
1-(4-benzyloxy-2-hydroxy-phenyl)-3-(3-trifluoromethyl-phenyl)-urea
in 100 ml DMF, 11.9 ml (0.17 Mol) dibromo-methane are added,
followed by small portions of 19.3 g (59 mMol) of Cs.sub.2CO.sub.3.
After 10 h at rt, the reaction mixture is concentrated in vacuo and
the residue dissolved in EtOAc and a 10% citric acid solution. The
separated aqueous phase is extracted twice with EtOAc. The organic
layers are washed with water and brine, dried (Na.sub.2SO.sub.4)
and concentrated. The dark brown oil is dissolved in
CH.sub.2Cl.sub.2/MeOH, then 28 g of SiO.sub.2 are added and the
mixture is evaporated. The resulting powder is put on top of a
chromatography column (SiO.sub.2; hexane/EtOAc 3:1) and the title
compound eluted with hexane/EtOAc 3:1 as an oil: MS:
[M+1].sup.+=415; TLC (hexane/EtOAc 1:1): R.sub.f=0.59; HPLC:
.sup.At.sub.Ret=17.2.
Step 27.3: 6-Hydroxy-benzooxazole-3-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0217] As a solution in 60 ml THF, 1.67 g (4.0 mMol)
6-benzyloxy-benzooxazole-3-carboxylic acid
(3-trifluoromethyl-phenyl)-amide are hydrogenated in the presence
of 0.9 g Pd/C (10%; Engelhard 5125). The catalyst is filtered off,
washed with THF and the filtrate diluted with hexane. Partial
concentration leads to the crystalline title compound, which is
filtered off and washed with hexane: m.p.: 173-174.degree. C.; MS:
[M+1].sup.+=325; HPLC: .sup.At.sub.Ret=13.3.
Example 28
6-(6-Amino-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0218] 150 mg (0.34 mMol)
6-(6-Chloro-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic acid
(3-trifluoromethyl-phenyl)-amide and 45 mg (0.69 mMol) NaN.sub.3 in
2 ml DMF are stirred for 5 h at 60.degree. C. giving
6-(6-azido-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic acid
(3-trifluoromethyl-phenyl)-amide (MS: [M+1].sup.+=444). After
cooling to rt, 35 mg Pd/C (10%; Engelhard 4505) are added and the
mixture is hydrogenated for 30 min. The catalyst is filtered off,
washed with DMF and the filtrate concentrated in vacuo.
Chromatography (Combi Flash; hexane/EtOAc 1:1.fwdarw.EtOAc) gives
the title compound: MS: [M+1].sup.+=418; TLC (EtOAc: R.sub.f=0.25;
HPLC: .sup.At.sub.Ret=12.0.
Example 29
6-(6-Methylamino-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0219] In a sealed tube, 0.43 mMol of
6-(6-chloro-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic acid
(3-trifluoromethyl-phenyl)-amide in 2 ml THF and 2 ml methylamine
(2 N in THF) are stirred for 16 h at rt. Concentration,
chromatography (Combi Flash; CH.sub.2Cl.sub.2/MeOH
99:1.fwdarw.95:5) and crystallization from hexane gives the title
compound: MS: [M+1].sup.+=432; TLC(CH.sub.2Cl.sub.2/MeOH 9:1:
R.sub.f=0.34; HPLC: .sup.At.sub.Ret=12.5.
Example 30
6-(2-Amino-6-chloro-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic
acid (3-trifluoromethyl-phenyl)-amide
[0220] To an ice cooled solution of 300 mg (0.92 mMol)
6-hydroxy-benzooxazole-3-carboxylic acid
(3-trifluoromethyl-phenyl)-amide (Step 27.3) and 151 mg (0.92 mMol)
2-amino-4,6-dichlorpyrimidine in 8 ml DMF, 600 mg (1.84 mMol)
Cs.sub.2CO.sub.3 are added. Then the mixture is stirred for 4 h at
rt and 1.5 h at 40.degree. C. and finally concentrated in vacuo.
The residue is dissolved in EtOAc and water/brine 1:1. The
separated aqueous phase is extracted twice with EtOAc. The organic
layers are washed with water/brine 1:1 and brine, dried
(Na.sub.2SO.sub.4) and concentrated. Chromatography (Combi Flash;
CH.sub.2Cl.sub.2/MeOH 99:1.fwdarw.95:5) gives the title compound:
MS: [M+1].sup.+=452/454; TLC(CH.sub.2Cl.sub.2/MeOH 9:1):
R.sub.f=0.51; HPLC: .sup.At.sub.Ret=15.3.
Example 31
6-(2-Amino-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0221] Hydrogenation of 38 mg
6-(2-amino-6-chloro-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic
acid (3-trifluoromethyl-phenyl)-amide as described in Ex. 14 gives
the title compound: MS: [M+1].sup.+=418; HPLC:
.sup.At.sub.Ret=12.5.
Example 31A
6-(6-Chloro-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic acid
(4-fluoro-3-trifluoromethyl-phenyl)-amide
[0222] To a solution of 650 mg (1.90 mMol)
6-hydroxy-benzooxazole-3-carboxylic acid
(4-fluoro-3-trifluoromethyl-phenyl)-amide in 15 ml acetone, 2.5 ml
1 N NaOH.sup.aq. are dropped in followed by a solution of 325 mg
(2.18 mMol) 4,6-dichlorpyrimidine in 5 ml acetone. After 75 min the
reaction mixture is concentrated in vacuo and the residue dissolved
in EtOAc, water and brine. The aqueous phase is separated off and
extracted twice with EtOAc. The organic layers are washed with 2
portions of water/brine 1:1 and brine, dried (Na.sub.2SO.sub.4) and
concentrated. Chromatography (Combi Flash; CH.sub.2Cl.sub.2/EtOAc
97:3.fwdarw.9:1) gives the title compound: MS: [M+1].sup.+=455/457;
TLC(CH.sub.2Cl.sub.2/EtOAc 9:1): R.sub.f=0.26; HPLC:
.sup.At.sub.Ret=16.3.
[0223] The starting material is prepared as follows:
Step 31A.1:
1-(4-Benzyloxy-2-hydroxy-phenyl)-3-(4-fluoro-3-trifluoromethyl-phenyl)-ur-
ea
[0224] To a solution of 3.01 g (14 mMol) 2-amino-5-benzyloxy-phenol
[preparation see: WO 03/045925; page 146] in 60 ml THF, a solution
of 2.11 ml (14.8 mMol) 4-fluoro-3-trifluoromethyl-phenylisocyanate
in 50 ml THF is added dropwise. After 1.5 h at rt, the reaction
mixture is concentrated partially in vacuo, the residue is
re-dissolved in water and EtOAc. The organic layers are separated
off and washed with water and brine, dried (Na.sub.2SO.sub.4) and
concentrated to a volume of .apprxeq.80 ml. Addition of 50 ml
hexane gives the crystalline title compound: m.p.: 188-191.degree.
C.; MS: [M+1].sup.+=421; TLC (hexane/EtOAc 1:1): R.sub.f=0.31.
Step 31A.2: 6-Benzyloxy-benzooxazole-3-carboxylic acid
(4-fluoro-3-trifluoromethyl-phenyl)-amide
[0225] 12.5 g (38.3 mMol) Cs.sub.2CO.sub.3 are added to a solution
of 4.6 g (10.9 mMol)
1-(4-benzyloxy-2-hydroxy-phenyl)-3-(4-fluoro-3-trifluoromethyl-phenyl)-ur-
ea in 100 ml DMF, followed by 7.6 ml (109 mMol) CH.sub.2Br.sub.2.
This dark green mixture is stirred for 13 h at it and 70 min at
50.degree. C. Then it is concentrated in vacuo and the residue
re-dissolved in EtOAc and a 10% citric acid solution. The separated
aqueous phase is extracted twice with EtOAc. The organic layers are
washed with 2 portions of water and brine, dried (Na.sub.2SO.sub.4)
and after addition of SiO.sub.2 concentrated. The resulting powder
is put on top of a chromatography column (SiO.sub.2) and the title
compound eluted with hexane/EtOAc 4:1: m.p.: 144-146.degree. C.;
MS: [M-1]=431; TLC (hexane/EtOAc 1:1): R.sub.f=0.57.
Step 31A.3: 6-Hydroxy-benzooxazole-3-carboxylic acid
(4-fluoro-3-trifluoromethyl-phenyl)-amide
[0226] Hydrogenation of 1.69 g (3.91 mMol)
6-benzyloxy-benzooxazole-3-carboxylic acid
(4-fluoro-3-trifluoromethyl-phenyl)-amide in 60 ml THF in the
presence of 0.85 g Pd/C (10%; Engelhard 5125), filtration, partial
concentration of the filtrate, dilution with .apprxeq.15 ml hexane
and cooling to 0.degree. C. gives the crystalline title compound:
m.p.: 171-172.degree. C.; MS: [M-1]=341; HPLC:
.sup.At.sub.Ret=13.7.
Example 31B
6-(6-Amino-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic acid
(4-fluoro-3-trifluoromethyl-phenyl)-amide
[0227] 50 mg (0.11 mMol)
6-(6-Chloro-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic acid
(4-fluoro-3-trifluoromethyl-phenyl)-amide and 14.3 mg (0.22 mMol)
NaN.sub.3 in 1.5 ml DMF are stirred for 5 h at 60.degree. C. giving
6-(6-azido-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic acid
(4-fluoro3-trifluoromethyl-phenyl)-amide (MS: [M-1]=460). After
cooling to rt, 13 mg Pd/C (10%; Engelhard 4505) are added and the
mixture is hydrogenated over night. The catalyst is filtered off,
washed with DMF and the filtrate concentrated in vacuo.
Chromatography (Combi Flash; CH.sub.2Cl.sub.2/EtOAc
3:2.fwdarw.EtOAc) gives the title compound: MS: [M+1].sup.+=436;
TLC (EtOAc: R.sub.f=0.22; HPLC: .sup.At.sub.Ret=12.5.
Example 32
6-(2-Amino-6-chloro-pyrimidin-4-yloxy)-naphthalene-1-carboxylic
acid (3-trifluoromethyl-4-chloro-phenyl)-amide
[0228] To an ice cooled solution of 161 mg (0.51 mMol)
6-(2-amino-6-chloro-pyrimidin-4-yloxy)-naphthalene-1-carboxylic
acid (Step 13.1) in 5 ml DMF, 75 .mu.l (0.68 mMol) NMM and 127
.mu.l (0.85 mMol) DEPC are added, followed by 0.30 g (1.5 mMol) of
2-chloro-5-amino-benzotrifluoride and a catalytic amount of DMAP.
After 20 h stirring at rt, the solution is poured into water and
EtOAc, the aqueous phase separated off and extracted twice with
EtOAc. The organic layers are washed with water and brine, dried
(Na.sub.2SO.sub.4) and concentrated. Column chromatography
(SiO.sub.2; EtOAc/hexane 2:8.fwdarw.3:7) and partial concentration
of the product containing fractions leads to crystallization.
Filtration and washing with hexane gives the title compound: MS:
[M+1].sup.+=493/495; HPLC: .sup.At.sub.Ret=16.7.
Example 32A
6-(2-Amino-6-chloro-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic
acid (4-fluoro-3-trifluoromethyl-phenyl)-amide
[0229] 231 mg (0.675 mMol) 6-hydroxy-benzooxazole-3-carboxylic acid
(4-fluoro-3-trifluoromethyl-phenyl)-amide (Step 31A.3) and 122 mg
(0.742 mMol) 2-amino-4,6-dichloropyrimidine are dissolved in 7 ml
DMF. Then 440 mg (1.35 mMol) Cs.sub.2CO.sub.3 are added and the
mixture is stirred for 24 h at rt. After concentration in vacuo,
the residue is re-dissolved in EtOAc and water/brine 1:1. The
aqueous layer is separated off and extracted twice with EtOAc. The
organic phases are washed with water/brine 1:1 and brine, dried
(Na.sub.2SO.sub.4) and concentrated. Chromatography (Combi Flash;
CH.sub.2Cl.sub.2/THF 97:3.fwdarw.9:1) gives the title compound: MS:
[M+1].sup.+=470/472; TLC(CH.sub.2Cl.sub.2/THF 9:1: R.sub.f=0.30;
HPLC: .sup.At.sub.Ret=15.7.
Example 32B
6-(2-Amino-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic acid
(4-fluoro-3-trifluoromethyl-phenyl)-amide
[0230] A solution of 59 mg (0.126 mMol)
6-(2-amino-6-chloro-pyrimidin-4-yloxy)-benzooxazole-3-carboxylic
acid (4-fluoro-3-trifluoromethyl-phenyl)-amide and 0.17 ml (1.2
mMol) Et.sub.3N in 6 ml THF is hydrogenated in presence of 25 mg
Pd/C (Engelhard 4505). The mixture is filtered, the filtrate
concentrated and the residue re-dissolved in EtOAc and water. The
aqueous layer is separated off and extracted twice with EtOAc. The
organic phases are washed with water and brine, dried
(Na.sub.2SO.sub.4) and partially concentrated. Addition of DIPE
gives the crystalline title compound: MS: [M+1].sup.+=436; HPLC:
.sup.At.sub.Ret=12.6.
Example 33
6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-4-chloro-phenyl)-amide
[0231] A solution of 100 mg (0.20 mMol)
6-(2-amino-6-chloro-pyrimidin-4-yloxy)-naphthalene-1-carboxylic
acid (3-trifluoromethyl-4-chloro-phenyl)-amide in 10 ml THF and 31
.mu.l (0.22 mMol) Et.sub.3N is hydrogenated in the presence of 40
mg Pd/C (10%; Engelhard 4505). The catalyst is filtered off, the
filtrate concentrated and the residue diluted with EtOAc and
H.sub.2O. The aqueous layer is extracted twice with EtOAc. The
organic layers are washed with water and brine, dried
(Na.sub.2SO.sub.4) and concentrated. Reversed phase MPLC gives the
title compound: MS: [M+1].sup.+=459; HPLC:
.sup.At.sub.Ret=13.3.
Examples 34 (a)-(b)
[0232] Via analogous routes (see Ex. 46-50) the following
derivatives can be obtained:
##STR00023##
Example 35
6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
[4-(4-methyl-piperazin-1-yl-methyl)-3-trifluoromethyl-phenyl]-amide
[0233] To a solution of 50 mg (0.178 mMol)
6-(2-amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (Step
15.1) and 53 mg (0.19 mMol)
4-(4-methyl-piperazin-1-yl-methyl)-3-trifluoromethyl-aniline in 2
ml DMF, 198 .mu.l (1.42 mMol) Et.sub.3N, 156 .mu.l (0.267 mMol)
propylphosphonic anhydride and 10 mg DMAP are added. After 3 days,
the mixture is poured into water and EtOAc, the aqueous phase
separated off and extracted twice with EtOAc. The organic layers
are washed with water and brine, dried (Na.sub.2SO.sub.4) and
concentrated. Reversed phase chromatography and crystallization
from DIPE/hexane gives the title compound: MS: [M+1].sup.+=537; TLC
(EtOAc/EtOH/NH.sub.3.sup.aq 80:20:1): R.sub.f=0.38; HPLC:
.sup.At.sub.Ret=9.2; Anal.: C, H, N, F.
Example 36
6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
[3,4-bis(trifluoromethyl)-phenyl]-amide
[0234] To a solution of 100 mg (0.356 mMol)
6-(2-amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (Step
15.1) and 89.6 mg (0.39 mMol) 3,4-bis(trifluoromethyl)-aniline in 4
ml DMF, 396 .mu.l (2.75 mMol) Et.sub.3N, 312 .mu.l (0.53 mMol)
propylphosphonic anhydride and 10 mg DMAP are added. After 16 h,
the mixture is poured into water and EtOAc, the aqueous phase
separated off and extracted twice with EtOAc. The organic layers
are washed with water and brine, dried (Na.sub.2SO.sub.4) and
concentrated. Chromatography (Combi Flash; EtOAc/hexane
1:1.fwdarw.EtOAc) gives the title compound: MS: [M+1].sup.+=493;
TLC (EtOAc): R.sub.f=0.54; HPLC: .sup.At.sub.Ret=12.6.
Example 37
[0235] The following compounds can be obtained analogously to Ex.
35 and 36.
TABLE-US-00003 ##STR00024## ##STR00025## ##STR00026## TLC R.sub.f
HPLC .sup.At.sub.Ret [min] m.p. [.degree. C.] MS [M + 1].sup.+
Anal. a) ##STR00027## 0.37.sup.1) 13.4 483 b) ##STR00028## 10.2 411
c) ##STR00029## 10.1 411 d) ##STR00030## 0.35.sup.1) 13.6 471 e)
##STR00031## 0.20.sup.2) 13.8 182-184 413 C, H, N f) ##STR00032##
0.43.sup.3) 14.2 210 459/461 g) ##STR00033## 0.44.sup.4) 12.9 217
397 C, H, N h) ##STR00034## 0.23.sup.5) 11.2 228 385 C, H, N i)
##STR00035## 0.13.sup.5) 12.9 236-237 415 j) ##STR00036##
0.28.sup.5) 12.3 212 421 C, H, N, F k) ##STR00037## 0.19.sup.5)
12.9 212-213 441 l) ##STR00038## 0.17.sup.5) 11.5 179 417 m)
##STR00039## 0.16.sup.5) 12.9 417 C, H, N n) ##STR00040##
0.30.sup.5) 10.2 275-276 403 o) ##STR00041## 0.43.sup.6) 9.2
171-172 309 C, H, N .sup.1)TLC(EtOAc); .sup.2)TLC(hexane/EtOAc
1:3); .sup.3)TLC(EtOAc/CH.sub.2Cl.sub.2 9:1);
.sup.4)TLC(EtOAc/CH.sub.2Cl.sub.2 4:1);
.sup.5)TLC(CH.sub.2Cl.sub.2/EtOH 19:1)
.sup.6)TLC(CH.sub.2Cl.sub.2/EtOH 9:1) *)3-cyclopropyl-aniline see:
Tet. Lett. 43 (2002), 6987; **)3-cyclopropyl-4-fluor-aniline
prepared from 3-brom-4-fluor-aniline analogously to the procedure
described in Tet. Lett. 43 (2002), 6987: TLC(hexane/Et0Ac 4:1):
R.sub.f = 0.15; ***)3-(.alpha.,.alpha.-difluorethyl)-aniline see:
DE2130452 Ex. 12b
Example 38
6-(6-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(3-cyclopropyl-4-fluoro-phenyl)-amide
[0236] To a solution of 267 mg (0.95 mMol)
6-(6-amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (Step
25.3) and 172 mg (1.14 mMol) 3-cyclopropyl-4-fluor-aniline in 5 ml
DMF, 1.32 ml (9.5 mMol) Et.sub.3N, 1.11 ml (1.9 mMol)
propylphosphonic anhydride and 51 mg DMAP are added. After 1 h, the
mixture is poured into water and EtOAc, the aqueous phase separated
off and extracted twice with EtOAc. The organic layers are washed
with water and brine, dried (Na.sub.2SO.sub.4) and concentrated.
Chromatography (Combi Flash; CH.sub.2Cl.sub.2/EtOH
99:1.fwdarw.19:1) gives the title compound: mp.: 256-257.degree.
C.; Anal.: C, H, N, F.
Example 39
[0237] The following compounds can be obtained analogously to Ex.
38 (eventually longer reaction times necessary).
TABLE-US-00004 ##STR00042## ##STR00043## ##STR00044## TLC R.sub.f
HPLC .sup.At.sub.Ret [min] m.p. [.degree. C] MS [M + 1].sup.+ Anal.
a) ##STR00045## 0.23.sup.1) 14.1 493 b) ##STR00046## 0.37.sup.2)
14.0 222-223 459/461 c) ##STR00047## 0.28.sup.2) 13.8 272 439 d)
##STR00048## 0.40.sup.3) 9.7 551 e) ##STR00049## 0.35.sup.2) 12.5
267 371 C, H, N f) ##STR00050## 0.29.sup.2) 13.7 218-219 399 C, H,
N g) ##STR00051## 0.45.sup.2) 14.3 186-187 413 C, H, N h)
##STR00052## 0.22.sup.3) 13.6 510 i) ##STR00053## 0.28.sup.4) 12.9
246 397 C, H, N j) ##STR00054## 0.09.sup.5) 11.3 251-252 385 C, H,
N k) ##STR00055## 0.27.sup.4) 12.4 250-251 421 C, H, N, F l)
##STR00056## 0.15.sup.5) 13.0 239-240 441 C, H, N, F m)
##STR00057## 0.18.sup.5) 11.8 182-183 417 C, H, N n) ##STR00058##
0.36.sup.2) 13.6 417 o) ##STR00059## 10.6 217-219 403 p)
##STR00060## 10.6 394 C, H, N .sup.1)TLC(EtOAc/CH.sub.2Cl.sub.2
1:1); .sup.2)TLC(EtOAc/CH.sub.2Cl.sub.2 9:1);
.sup.3)TLC(EtOAc/EtOH/NH.sub.3.sup.aq 80:20:1);
.sup.4)TLC(EtOAc/CH.sub.2Cl.sub.2 4:1);
.sup.5)TLC(CH.sub.2Cl.sub.2/EtOH 19:1) *)3-cyclopropyl-aniline see:
Tet. Lett. 43 (2002), 6987;
**)3-(.alpha.,.alpha.-difluorethyl)-aniline see: DE2130452 Ex.
12b
Example 40
6-(6-Methylamino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(4-morpholin-4-yl-3-trifluoromethyl-phenyl)-amide
[0238] To a solution of 295.3 mg (1.00 mMol)
6-(6-methylamino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
and 295 mg (1.2 mMol) 4-morpholin-4-yl-3-trifluoromethyl-aniline in
5 ml DMF, 1.39 ml (10 mMol) Et.sub.3N, 1.17 ml (2.0 mMol)
propylphosphonic anhydride and 50 mg (0.4 mMol) DMAP are added.
After 30 min, the mixture is poured into water and EtOAc, the
aqueous phase separated off and extracted 3 times with EtOAc. The
organic layers are washed 3 times with water and brine, dried
(Na.sub.2SO.sub.4) and concentrated. Column chromatography
(SiO.sub.2; CH.sub.2Cl.sub.2/EtOH 95:5) gives the title compound:
mp.: 156-157.degree. C.; MS: [M+1].sup.+=524.
[0239] The starting material is prepared as follows:
Step 40.1:
6-(6-Methylamino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic
acid
[0240] To a solution of 8.1 g (27 mMol)
6-(6-chloro-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (Step
25.1) in 100 ml THF, 200 ml of a 2 M solution of methylamin in THF
are added. After 3 days at rt, the suspension is concentrated
partially in vacuo, the solid filtered off and washed with ether.
The crude product dissolved in 300 ml water is treated with char
coal and filtered. The filtrate is acidified to pH 1 with 1 N HCl
and the formed precipitate filtered off, washed with water and
dried. Repeated stirring in ether followed by filtration gives the
title compound: m.p.: 267-268.degree. C.; MS: [M+1].sup.+=296.
Example 41
[0241] The following compounds can be obtained analogously to Ex.
40.
TABLE-US-00005 ##STR00061## ##STR00062## ##STR00063## TLC R.sub.f
HPLC .sup.At.sub.Ret [min] m.p. [.degree. C.] MS [M + 1].sup.+
Anal. a) ##STR00064## 0.29.sup.1) 11.7 152-153 439 b) ##STR00065##
0.26.sup.1) 11.9 154-155 457 c) ##STR00066## 0.22.sup.1) 12.5
102-104 427 d) ##STR00067## 0.30.sup.1) 12.6 141-142 427 e)
##STR00068## 0.22.sup.1) 12.5 148-149 473/475 f) ##STR00069##
0.22.sup.1) 12.2 238-239 453 g) ##STR00070## 0.23.sup.2) 8.5 551 h)
##STR00071## 0.22.sup.1) 12.3 211-212 497 i) ##STR00072##
0.51.sup.3) 12.7 144-145 411 C, H, N j) ##STR00073## 0.35.sup.4)
12.6 164 385 k) ##STR00074## 0.29.sup.4) 12.0 128-129 413 C, H, N
l) ##STR00075## 0.25.sup.4) 11.6 160-161 399 C, H, N
.sup.1)TLC(CH.sub.2Cl.sub.2/MeOH 19:1);
.sup.2)TLC(CH.sub.2C1.sub.2/MeOH/NH.sub.3.sup.aq 90:10:1);
.sup.3)TLC(CH.sub.2Cl.sub.2/acetone 2:1);
.sup.4)TLC(CH.sub.2Cl.sub.2/EtOH 19:1) *)3-cyclopropyl-aniline see:
Tet. Lett. 43 (2002), 6987
Example 42
6-(6-Chloro-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0242] To 8.38 g (27.9 mMol)
6-(6-chloro-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (Step
25.1), 31 ml (223 mMol) Et.sub.3N and 1 g (8 mMol) DMAP in 100 ml
ice-cooled DMF, 24.4 ml (41.8 mMol) propylphosphonic anhydride in
25 ml DMF are added dropwise during 20 min, followed by a solution
of 3.83 ml (30.6 mMol) 3-trifluormethyl-aniline in 25 ml DMF. After
90 min at rt, the mixture is concentrated partially in vacuo at
40.degree. C. The resulting residue is diluted with water and
EtOAc, the aqueous phase separated off and extracted twice with
EtOAc. The organic layers are washed with water and brine, dried
(Na.sub.2SO.sub.4) and concentrated. Column chromatography
(SiO.sub.2; CH.sub.2Cl.sub.2/THF
99:1.fwdarw.CH.sub.2Cl.sub.2/THF/Et.sub.3N 98:1:1) gives the title
compound: MS: [M+1].sup.+=444; TLC(CH.sub.2Cl.sub.2/THF 99:1):
R.sub.f=0.17; HPLC: .sup.At.sub.Ret=16.8.
Example 43
6-(6-Cyano-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0243] To a solution of 3.3 g (7.4 mMol)
6-(6-chloro-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide in 80 ml DMSO and 20 ml water,
0.42 g (3.7 mMol) 1,4-diazobicyclo[2,2,2]octan and 1.0 g (15 mMol)
KCN are added. The mixture is stirred for 30 min at 55.degree. C.
and then diluted with water, brine and EtOAc. The aqueous phase is
separated off and extracted twice with EtOAc. The organic layers
are washed with water and brine, dried (MgSO.sub.4) and
concentrated. The residue is re-dissolved in CH.sub.2Cl.sub.2 and
after addition of SiO.sub.2 concentrated again. The resulting
powder is put on top of a SiO.sub.2-column. Eluation with
CH.sub.2Cl.sub.2/EtOAc 98:2.fwdarw.93:7, partial concentration and
crystallization by adding hexane gives the title compound: m.p.:
167.degree. C.; MS: [M+1].sup.+=435; Anal.: C, H, N, F.
Example 44
6-(6-Aminomethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0244] 830 mg (1.91 mMol)
6-(6-cyano-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide in 40 ml THF and 7.3 ml
NH.sub.3.sup.aq 25% are hydrogenated in presence of 0.7 g
Raney-Nickel (Degussa B 113W). The aqueous layer is separated off
from the reaction mixture and extracted with EtOAc. The organic
phases are dried (Na.sub.2SO.sub.4) and concentrated. This residue
is re-dissolved in EtOAc/acetone and after addition of SiO.sub.2
concentrated again. The resulting powder is put on top of a
SiO.sub.2-column. Eluation with EtOAc/acetone/Et.sub.3N
80:20:0.fwdarw.80:20:1.fwdarw.60:40:1, partial concentration and
crystallization by adding hexane gives the title compound: MS:
[M+1].sup.+=439; TLC (EtOAc/acetone 2:1+NH.sub.3.sup.aq):
R.sub.f=0.35; HPLC: .sup.At.sub.Ret=12.5.
Example 45
{6-[5-(3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyrimidin-4--
ylmethyl}-carbamic acid methylester
[0245] A mixture of 100 mg (0.23 mMol)
6-(6-aminomethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide, 175 .mu.l (1.2 mMol) Et.sub.3N,
60 .mu.l (0.77 mMol) methyl chloroformate and a trace of DMAP in 3
ml THF is stirred over night at rt. The mixture is poured into
water and EtOAc, the aqueous phase separated off and extracted
twice with EtOAc. The organic layers are washed with water and
brine, dried (Na.sub.2SO.sub.4) and concentrated. Chromatography
(Combi Flash; hexane/EtOAc 7:3.fwdarw.1:1) gives the title
compound: MS: [M+1].sup.+=497; TLC (EtOAc/hexane 2:1):
R.sub.f=0.35; HPLC: .sup.At.sub.Ret=14.9.
Example 46
6-[5-(3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyrimidine-4--
carboxylic acid ethyl ester
[0246] A mixture of 5.36 g (12.07 mMol)
6-(6-chloro-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide (Ex. 42), 3.4 ml (24 mMol)
Et.sub.3N and 1.35 g PdCl.sub.2[P(C.sub.6H.sub.5).sub.3].sub.2 in
80 ml ethanol is prepared under a CO-atmosphere of 120 bar in an
autoclave. Then it is heated for 30 h at 110.degree. C. After
cooling to rt, the mixture is diluted with EtOH and filtered. The
residue is washed vigorously with EtOH and the filtrate
concentrated. Column chromatography (SiO.sub.2;
CH.sub.2Cl.sub.2/EtOAc 19:1.fwdarw.9:1) and partial concentration
leads to the crystalline title compound: m.p.: 194.degree. C.;
Anal.: C, H, N, F.
Example 47
6-[5-(3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyrimidine-4--
carboxylic acid
[0247] To 0.36 g (0.75 mMol)
6-[5-(3-trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyrimidine-4-
-carboxylic acid ethyl ester dissolved in 9 ml THF, 1.15 ml 1 M
LiOH in water are added. After 2 h at rt, the mixture is
concentrated in vacuo. The residue is dissolved in a mixture of
EtOAc, water and 1 N NaOH-solution. The aqueous layer is separated
off and extracted with EtOAc. The organic phases are washed with a
diluted NaOH-solution and discarded. The combined aqueous layers
are acidified with 2 N HCl and extracted twice with EtOAc. These
organic phases are washed with brine, dried (Na.sub.2SO.sub.4) and
concentrated. Crystallization from DIPE gives the title compound:
MS: [M+1].sup.+=454.
Example 48
6-[5-(3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyrimidine-4--
carboxylic acid dimethylamide
[0248] To 200 mg (0.435 mMol) of the lithium-salt of
6-[5-(3-trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyrimidine-4-
-carboxylic acid, 612 .mu.l (4.4 mMol) Et.sub.3N, 24 mg (0.2 mMol)
DMAP and 24 mg (0.53 mMol) Me.sub.2NH in 7 ml DMF, 516 .mu.l (0.88
mMol) propylphosphonic anhydride are added. After 2.5 h at rt, the
mixture is diluted with water and EtOAc, the aqueous phase
separated off and extracted twice with EtOAc. The organic layers
are washed with water and brine, dried (Na.sub.2SO.sub.4) and
concentrated. Chromatography (Combi Flash; hexane/EtOAc
3:2.fwdarw.2:3) gives the title compound: MS: [M+1].sup.+=481;
TLC(CH.sub.2Cl.sub.2/EtOAc 1:1): R.sub.f 0.18; HPLC:
.sup.At.sub.Ret=15.8.
Example 49
6-[5-(3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyrimidine-4--
carboxylic acid amide
[0249] To a solution of 207 mg (0.43 mMol)
6-[5-(3-trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyrimidine-4-
-carboxylic acid ethyl ester (Ex. 46) in 12 ml CH.sub.3CN and 5 ml
THF, 5 ml of NH.sub.3 (25% in water) are added. This mixture is
stirred in a sealed vessel for 7 h at rt, while a precipitation is
formed. Filtration and washing with CH.sub.3CN yields the title
compound: MS: [M-1]=451; HPLC: .sup.At.sub.Ret=15.2; Anal.: C, H,
N, F.
Example 50
6-[5-(3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyrimidine-4--
carboxylic acid methylamide
[0250] To 200 mg (0.435 mMol) of the lithium-salt of
6-[5-(3-trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyrimidine-4-
-carboxylic acid, 609 .mu.l (4.35 mMol) Et.sub.3N, 24 mg (0.2 mMol)
DMAP and 260 .mu.l (2 M in THF; 0.52 mMol) MeNH.sub.2 in 7 ml DMF,
510 .mu.l (0.87 mMol) propylphosphonic anhydride are added. After 1
h at rt, the mixture is diluted with water and EtOAc, the aqueous
phase separated off and extracted twice with EtOAc. The organic
layers are washed twice with water and brine, dried
(Na.sub.2SO.sub.4) and concentrated. Chromatography (Combi Flash;
CH.sub.2Cl.sub.2/EtOAc 4:1) gives the title compound: MS:
[M+1].sup.+=467; TLC (EtOAc): R.sub.f=0.55; HPLC:
.sup.At.sub.Ret=15.7.
Example 51
6-[5-(3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyrimidine-4--
carboxylic acid isopropylamide
[0251] To a solution of 197 mg (0.41 mMol)
6-[5-(3-trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyrimidine-4-
-carboxylic acid ethyl ester (Ex. 46) in 10 ml THF, 7 .mu.l (0.4
mMol) H.sub.2O and 0.7 ml (8 mMol) isopropylamine are added. This
mixture is stirred in a sealed vessel for 5 days at 45.degree. C.
Reversed phase chromatography gives the title compound: m.p.:
205-208.degree. C.; MS: [M+1].sup.+=495; Anal.: C, H, N, F.
Example 52
6-(6-Hydroxymethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0252] To 1.16 g (2.41 mMol)
6-[5-(3-trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyrimidine-4-
-carboxylic acid ethyl ester (Ex. 46) in 40 ml tert-butanol, 218 mg
(5.76 mMol) NaBH.sub.4 are added and the mixture is stirred for 1 h
at 70.degree. C. Then additional 109 mg NaBH.sub.4 are added and
stirring is continued for another 1 h at 80.degree. C. The reaction
mixture is concentrated in vacuo and the residue re-dissolved in
EtOAc and sat. NaHCO.sub.3. The separated aqueous phase is
extracted twice with EtOAc. The organic layers are washed with sat.
NaHCO.sub.3 and brine, dried (Na.sub.2SO.sub.4) and concentrated
after addition of SiO.sub.2. This powder is put on top of a
SiO.sub.2-column (CH.sub.2Cl.sub.2/EtOAc
2:1.fwdarw.1:1.fwdarw.EtOAc): At first the side product
6-(6-methyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide is eluted {MS: [M+1].sup.+=424;
TLC(CH.sub.2Cl.sub.2/EtOAc 1:1): R.sub.f=0.33; HPLC:
.sup.At.sub.Ret=15.1}, followed by the title compound: m.p.:
183-184.degree. C.; MS: [M+1].sup.+=440; TLC(CH.sub.2Cl.sub.2/EtOAc
1:1): R.sub.f=0.13; HPLC: .sup.At.sub.Ret=14.3; Anal.: C, H, N,
F.
Example 53
6-(6-Chloromethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0253] 1.0 ml (13.9 mMol) SOCl.sub.2 is added via syringe to a
solution of 610 mg (1.39 mMol)
6-(6-hydroxymethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide in 50 ml CH.sub.3CN and 10 ml THF.
After 15 min at rt, the solution is poured into 75 ml sat.
NaHCO.sub.3 and 75 ml water and then concentrated partially in
vacuo. The formed precipitate is filtered off and washed with
water, yielding the title compound: m.p.: 178-181.degree. C.; MS:
[M+1].sup.+=458/460; Anal.: C, H, N, F.
Example 54
6-(6-Methylaminomethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic
acid (3-trifluoromethyl-phenyl)-amide
[0254] In a sealed tube a mixture of 150 mg (0.328 mMol)
6-(6-chloromethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide, 10 mg (0.067 mMol) NaI and 0.8 ml
methylamine (2 M in THF) in 8 ml THF is stirred for 2.5 h at
80.degree. C. The reaction mixture is concentrated in vacuo and the
residue re-dissolved in EtOAc and sat. NaHCO.sub.3/H.sub.2O 1:1.
The separated aqueous phase is extracted twice with EtOAc. The
organic layers are washed with sat. NaHCO.sub.3/H.sub.2O 1:1 and
brine, dried (Na.sub.2SO.sub.4) and concentrated. Chromatography
(Combi Flash; EtOAc/(THF+2% Et.sub.3N) 19:1.fwdarw.1:1) gives the
title compound: m.p.: 141-143.degree. C.; MS: [M+1].sup.+=453;
Anal.: C, H, N.
Example 55
6-(6-Dimethylaminomethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic
acid (3-trifluoromethyl-phenyl)-amide
[0255] In a sealed tube a mixture of 150 mg (0.328 mMol)
6-(6-chloromethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide, 134 mg (1.64 mMol) dimethylamine
hydrochloride, 10 mg (0.067 mMol) NaI, 687 .mu.l (4.9 mMol)
Et.sub.3N and 8 ml THF is stirred for 4.25 h at 80.degree. C. Work
up analogously as described for Ex. 54 gives the title compound:
m.p.: 180-181.degree. C.; MS: [M+1].sup.+=467; Anal.: C, H, N,
F.
Example 56
{6-[5-(4-Fluoro-3-trifluoromethyl-phenylcarbamoyl)-naphthalen-2-ylsulfanyl-
]-pyrimidin-4-yl}-carbamic acid tert-butyl ester
[0256] To an ice-cooled solution of 127 mg (0.32 mMol)
6-(6-tert-butoxycarbonylamino-pyrimidin-4-ylsulfanyl)-naphthalene-1-carbo-
xylic acid and 86 mg (0.48 mMol) 4-fluoro-3-trifluoromethyl-aniline
in 3 ml DMF, 446 .mu.l (3.2 mMol) Et.sub.3N, 0.37 ml (0.63 mMol)
propylphosphonic anhydride and 4 mg DMAP are added. After 2 h at
rt, the mixture is poured into water and EtOAc, the aqueous phase
separated off and extracted twice with EtOAc. The organic layers
are washed twice with water and brine, dried (Na.sub.2SO.sub.4) and
concentrated. Re-crystallization from boiling CH.sub.3CN gives the
title compound: MS: [M+1].sup.+=559; TLC (hexane/EtOAc 1:1):
R.sub.f=0.47; Anal.: C, H, N, F.
[0257] The starting material is prepared as follows:
Step 56.1:
6-(6-Chloro-pyrimidin-4-ylsulfanyl)-naphthalene-1-carboxylic
acid
[0258] 894 mg (6.0 mMol) 4,6-Dichloro-pyrimidine and 1021 mg (5.0
mMol) 6-mercapto-naphthalene-1-carboxylic acid [preparation
described in J. Med. Chem. 32 (1989), 2493; purification by
chromatography (Combi Flash; hexane/EtOAc 7:3.fwdarw.3:2): m.p.:
212-213.degree. C.] are suspended in 16 ml acetone. Then 16 ml of 1
N NaOH in H.sub.2O are added. After 5 min at rt, the resulting
solution is poured into 200 ml of 1 N HCl in H.sub.2O and extracted
3 times with EtOAc. The organic layers are washed with water and
brine, dried (Na.sub.2SO.sub.4) and concentrated. Column
chromatography (SiO.sub.2; CH.sub.2Cl.sub.2/EtOAc 1:2) and
crystallization from EtOAc/hexane yields the title compound: m.p.:
209.degree. C.; MS: [M+1]=317.
Step 56.2:
6-(6-tert-Butoxycarbonylamino-pyrimidin-4-ylsulfanyl)-naphthale-
ne-1-carboxylic acid
[0259] A suspension of 195 mg (0.61 mMol)
6-(6-chloro-pyrimidin-4-ylsulfanyl)-naphthalene-1-carboxylic acid
and 495 mg (1.52 mMol) Cs.sub.2CO.sub.3 in 5 ml dioxane is degassed
repeatedly by evaporation and flushing with N.sub.2. Then 10.9 mg
(0.019 mMol) 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene, 5.6
mg (0.006 mMol) tris(dibenzylidenaceton)dipalladium(0) CHCl.sub.3
adduct and 85.8 mg (0.73 mMol) carbamic acid tert-butyl ester are
added successively. After 4 h stirring at 110.degree. C., another
10.9 mg 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene and 5.6 mg
tris(dibenzylidenaceton)dipalladium(0) CHCl.sub.3 adduct are added
and stirring is continued for 5 h. Then the cooled mixture is
poured into EtOAc and 5% citric acid in water, the aqueous layer
separated off and extracted twice with EtOAc. The organic layers
are washed with water and brine, dried (Na.sub.2SO.sub.4) and
concentrated. Chromatography (Combi Flash; CH.sub.2Cl.sub.2/EtOAc
99:1.fwdarw.CH.sub.2Cl.sub.2/(EtOAc+1% HOAc) 4:1) gives the title
compound: m.p.: 208-209.degree. C.; MS: [M-1]=396.
Example 57
6-(6-Amino-pyrimidin-4-ylsulfanyl)-naphthalene-1-carboxylic acid
(4-fluoro-3-trifluoromethyl-phenyl)-amide
[0260] To a solution of 80 mg (0.14 mMol)
{6-[5-(4-fluoro-3-trifluoromethyl-phenylcarbamoyl)-naphthalen-2-ylsulfany-
l]-pyrimidin-4-yl}-carbamic acid tert-butyl ester in 2 ml dioxane
are added 2 ml 2 M HCl in dioxane. After 9 h at rt, the solution is
diluted with EtOAc and sat. NaHCO.sub.3/H.sub.2O 1:1. The aqueous
phase is separated off and extracted twice with EtOAc. The organic
layers are washed with H.sub.2O and brine, dried (Na.sub.2SO.sub.4)
and concentrated. Chromatography (Combi Flash;
CH.sub.2Cl.sub.2/EtOAc 4:1.fwdarw.1:4) and crystallization from
EtOAc/hexane gives the title compound: m.p.: 221.degree. C.; MS:
[M+1].sup.+=459; TLC(CH.sub.2Cl.sub.2/EtOAc 1:2): R.sub.f=0.25.
Example 58
6-(6-Amino-pyrimidin-4-ylsulfanyl)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0261] To 1.65 g (5.55 mMol)
6-(6-amino-pyrimidin-4-ylsulfanyl)-naphthalene-1-carboxylic acid,
832 .mu.l (6.66 mMol) 3-trifluoromethyl-aniline, 7.87 ml (56.5
mMol) Et.sub.3N and 291 mg (2.38 mMol) DMAP in 30 ml DMF, 6.8 ml
(11.6 mMol) propylphosphonic anhydride are added dropwise. After 1
h at rt, the mixture is poured into water and EtOAc, the aqueous
phase separated off and extracted twice with EtOAc. The organic
layers are washed with water and brine, dried (Na.sub.2SO.sub.4)
and concentrated after addition of SiO.sub.2. The resulting powder
is put on top of a SiO.sub.2 column (CH.sub.2Cl.sub.2/EtOAc 9:1)
and the title compound eluted with CH.sub.2Cl.sub.2/EtOAc
4:1.fwdarw.3:7: m.p.: 205.degree. C.; MS: [M+1].sup.+=441;
TLC(CH.sub.2Cl.sub.2/EtOAc 1:1): R.sub.f=0.16; HPLC:
.sup.At.sub.Ret=13.0.
[0262] The starting material is prepared as follows:
Step 58.1:
6-(6-Amino-pyrimidin-4-ylsulfanyl)-naphthalene-1-carboxylic
acid
[0263] A mixture of 1.00 g (7.72 mMol) 4-amino-6-chloro-pyrimidine,
1.74 g (8.5 mMol) 6-mercapto-naphthalene-1-carboxylic acid, 10.8 g
K.sub.3PO.sub.4 and 35 mg (0.23 mMol) NaI in 50 ml NMP is stirred
for 2.5 h at 110.degree. C. Then the mixture is poured into 230 ml
of a 5% solution of citric acid in water, the crude product
filtered off and washed with water. Stirring in boiling isopropanol
and filtration gives the title compound: m.p.: 264-266.degree. C.;
MS: [M+1].sup.+=298.
Example 59
6-(6-Amino-pyrimidine-4-sulfinyl)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0264] To a suspension of 100 mg (0.227 mMol)
6-(6-amino-pyrimidin-4-ylsulfanyl)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide in 3 ml CH.sub.3COOH/H.sub.2O 1:1,
0.1 ml of a 35% solution of H.sub.2O.sub.2 are added. After 16 h at
rt, another 80 .mu.l of H.sub.2O.sub.2 are added and stirring is
continued for 4 h at 60.degree. C. Cooling to rt, filtration,
washing and drying (HV, 100.degree. C.) gives the title compound:
MS: [M+1].sup.+=457; HPLC: .sup.At.sub.Ret=13.3; IR: 1042 cm.sup.-1
(S.dbd.O).
Example 60
6-(6-Amino-pyrimidine-4-sulfonyl)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0265] To a solution of 110 mg (0.25 mMol)
6-(6-amino-pyrimidin-4-ylsulfanyl)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide in 5 ml CH.sub.3COOH, a solution
of 0.20 g (1.26 mMol) KMnO.sub.4 in 7.5 ml H.sub.2O is added
dropwise during 30 min. The mixture is poured into 200 ml of a 2.5%
solution of Na.sub.2SO.sub.3 in water. The precipitated solid is
filtered off, washed with water and dried. Chromatography (Combi
Flash; EtOAc/CH.sub.2Cl.sub.2 3:7.fwdarw.7:3) and crystallization
from ether gives the title compound: m.p.: 229-231.degree. C.; MS:
[M+1].sup.+=473; IR: 1156/1125 cm.sup.-1 (O.dbd.S.dbd.O).
Example 61
6-(6-Amino-pyrimidin-4-ylsulfanyl)-naphthalene-1-carboxylic acid
(3-trifluoromethoxy-phenyl)-amide
[0266] To 95 mg (0.32 mMol)
6-(amino-pyrimidin-4-ylsulfanyl)-naphthalene-1-carboxylic acid, 85
mg (0.48 mMol) 3-trifluoromethoxy-aniline, 446 .mu.l (3.2 mMol)
Et.sub.3N and 4 mg (0.03 mMol) DMAP in 3 ml DMF, 0.37 ml (0.63
mMol) propylphosphonic anhydride are added. After 3 h at rt, the
reaction mixture is worked up as described for Ex. 58, yielding the
title compound: m.p.: 197-199.degree. C.; MS: [M+1].sup.+=457.
Example 62
6-(Pyridin-4-yl-methyl)-naphthalene-1-carboxylic acid
(4-fluoro-3-trifluoromethyl-phenyl)-amide
[0267] A mixture of 22.4 mg (0.10 mMol) Pd(O.sub.2CCH.sub.3).sub.2,
52.6 mg (0.20 mMol) triphenylphosphine, 151 mg (0.33 mMol)
6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-naphthalene-1-carboxylic
acid (4-fluoro-3-trifluoromethyl-phenyl)-amide and 229.3 mg (1.08
mMol) K.sub.3PO.sub.4 in 3 ml toluene is degassed repeatedly by
evaporation and flushing with N.sub.2. Then 59 mg (0.36 mMol)
4-chloromethyl-pyridine hydrochloride are added and the mixture is
stirred at 80.degree. C. for 20 h, when additional 18.5 mg (0.082
mMol) Pd(O.sub.2CCH.sub.3).sub.2 and 43.1 mg (0.164 mMol)
triphenylphosphine are added. After 3 h at 110.degree. C. the
reaction mixture is poured into water and EtOAc. The aqueous phase
is separated off and extracted twice with EtOAc. The organic layers
are washed with water and brine, dried (Na.sub.2SO.sub.4) and
concentrated. Chromatography [Combi Flash;
CH.sub.2Cl.sub.2.fwdarw.CH.sub.2Cl.sub.2/(MeOH+10% NH.sub.3.sup.aq)
9:1] gives the title compound: MS: [M+1].sup.+=425; HPLC:
.sup.At.sub.Ret=12.7.
[0268] The starting material is prepared as follows:
Step 62.1: Trifluoro-methanesulfonic acid
5-(4-fluoro-3-trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yl
ester
[0269] 0.94 g (5.0 mMol) 6-hydroxy-naphthalene-1-carboxylic acid in
a mixture of 50 ml CH.sub.2Cl.sub.2, 25 ml dioxane and 2.4 ml (30
mMol) pyridine is cooled to -78.degree. C. Then a solution of 1.98
ml (12 mMol) trifluoro-methanesulfonic acid anhydride in 5 ml
CH.sub.2Cl.sub.2 is added dropwise and the mixture is warmed up to
rt. After 5 h, 1.43 g (8.0 mMol) 4-fluoro-3-trifluoro-aniline
dissolved in 5 ml CH.sub.2Cl.sub.2 are added and stirring is
continued over night. A formed precipitate is filtered off and
discarded and the filtrate diluted with EtOAc and sat.
NaHCO.sub.3/H.sub.2O 1:1. The aqueous phase is separated and
extracted twice with EtOAc. The organic layers are washed with
water and brine, dried (Na.sub.2SO.sub.4) and concentrated. Column
chromatography (SiO.sub.2; toluene/EtOAc 199:1.fwdarw.9:1) and
partial concentration leads to the crystalline title compound:
m.p.: 171-172.degree. C.; MS: [M-1]=480.
Step 62.2:
6-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-naphthalene-1--
carboxylic acid (4-fluoro-3-trifluoromethyl-phenyl)-amide
[0270] A mixture of 1.203 g (2.5 mMol) trifluoro-methanesulfonic
acid 5-(4-fluoro-3-trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yl
ester, 762 mg (3.0 mMol)
4,4,5,5,4',4',5',5'-octamethyl-[2,2']bi[1,3,2]dioxaborolanyl] and
736 mg (7.5 mMol) potassium acetate in 12 ml DMF is degassed
repeatedly by evaporation and flushing with N.sub.2. Then 100 mg
(0.12 mMol) of the dichloromethane complex of
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) are
added and the mixture is stirred for 3 h at 80.degree. C. The
mixture is diluted with EtOAc and H.sub.2O, the aqueous phase
separated off and extracted twice with EtOAc. The organic layers
are washed twice with water and brine, dried (Na.sub.2SO.sub.4) and
concentrated. Chromatography (Combi Flash: CH.sub.2Cl.sub.2/hexane
1:1; crude product added as solution in CH.sub.2Cl.sub.2 onto
preconditioned column and rapidly eluted with
CH.sub.2Cl.sub.2/hexane 1:1.fwdarw.CH.sub.2Cl.sub.2) gives the
title compound: MS: [M-1].sup.+=460; TLC(CH.sub.2Cl.sub.2):
R.sub.f=0.30; HPLC: .sup.At.sub.Ret=18.3.
Example 63
6-(2-Methyl-pyridin-4-yloxy)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0271] To a solution of 331 mg (1.0 mMol)
6-hydroxy-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide in 0.375 ml DMF and 1.37 ml DMPU
(dimethyl-propylene urea) is added 180 mg (1.1 mMol)
4-chloro-2-methyl-pyridine followed by 336 mg (3 mMol) potassium
t-butoxide. The dark viscous mixture is stirred 3 days at
100.degree. C. After cooling to rt the mixture is diluted with
EtOAc, washed with brine, dried over sodium sulfate and evaporated.
The remaining DMPU and DMF is distilled off in a Kugelrohr
apparatus (100.degree. C., under vacuum). The residue is purified
by flash-chromatography on a silica gel column and eluting with
EtOAc. Concentration of the pure samples leads to crystalline title
compound: MS: [M+1].sup.+=423; TLC (EtOAc): R.sub.f=0.5; HPLC:
.sup.Et.sub.Ret=3.42.
[0272] The starting material is prepared as follows:
Step 63.1: 6-hydroxy-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0273] To an ice-cooled solution of 17.2 g (65 mMol)
6-hydroxy-naphthalene-1-carboxylic and 9.9 g (65 mMol) HOBT in 260
ml of THF is added dropwise a solution of 14.4 g (70.2 mMol) DCC in
45 ml of THF over 20 minutes. The reaction mixture is stirred 15
minutes at 0.degree. C. and then 1 hour at rt. The solid formed is
removed by filtration and washed with a small amount of cold THF.
The filtrate is evaporated and the residue triturated with
EtOAc/hexanes 4:6. The crystalline activated ester was filtered off
and dried. 9.15 g of this active ester (30 mMol) are dissolved in
80 ml of THF and treated with 3.5 ml (30 mMol)
3-trifluoromethyl-anilin. After refluxing for 24 h another 0.35 ml
(3 mMol) 3-trifluoromethyl-anilin are added and the mixture is
refluxed for another 24 h. The solvent is removed and the residue
subjected to a flash-chromatography on silica gel using
EtOAc/hexanes 4:6. Pure fractions are evaporated and the residue is
triturated with petrol ether. The crystalline title compound is
filtered and dried: MS: [M+1].sup.+=332; TLC (EtOAc/hexanes 4:6):
R.sub.f=0.53; HPLC: .sup.Et.sub.Ret=3.8.
Example 64
4-[5-(3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyridine-2-ca-
rboxylic acid butyl ester
[0274] A mixture of 993 mg (3.0 mMol)
6-hydroxy-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide, 10 ml n-butanol, 1.286 g (7.5
mMol) 4-chloro-pyridine-2-carboxylic acid methyl ester, 0.5 ml (3.6
mMol) triethylamin and 10 mg 4-dimethylamino-pyridine is heated
under reflux for 5 days. After cooling the mixture is evaporated,
diluted with EtOAc and washed with diluted hydrochloric acid. The
EtOAc phase is dried with sodium sulfate, concentrated and the
residue is purified by flash-chromatography on a silica gel column
eluting with EtOAc/hexanes 4:6. Evaporation of the pure samples
leads to crystalline title compound: m.p.: 128-130.degree. C.; MS:
[M+1].sup.+=509; TLC (EtOAc): R.sub.f=0.27; HPLC:
.sup.Et.sub.Ret=4.57.
Example 65
4-[5-(3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyridine-2-ca-
rboxylic acid methylamide
[0275] 101 mg (0.2 mMol)
4-[5-(3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyridine-2-c-
arboxylic acid butyl ester and 1.0 ml of a 33% methylamine solution
in ethanol are heated for 1 h under reflux. The mixture is cooled,
concentrated and the residue is purified by flash-chromatography on
a silica gel column eluting with EtOAc/hexanes 6:4. Evaporation of
the pure samples leads to crystalline title compound: m.p.:
175-177.degree. C.; MS: [M+1].sup.+=466; HPLC:
.sup.Et.sub.Ret=4.18.
[0276] Using the same procedure as for the previous example the
following compounds were synthesized:
Example 66
4-[5-(3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-Pyridine-2-ca-
rboxylic acid amide
[0277] The title compound is obtained as a solid: m.p.:
117-120.degree. C.; MS: [M+1].sup.+=452; TLC (EtOAc/hexanes 6:4):
R.sub.f=0.3; HPLC: .sup.Et.sub.Ret=3.91.
Example 67
4-[5-(3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyridine-2-ca-
rboxylic acid (2-dimethylamino-ethyl)-amide
[0278] The title compound is obtained as a solid: m.p.:
80-82.degree. C.; MS: [M+1].sup.+=523; TLC (dichloromethane/ethanol
9:1 and 1% conc. ammonia): R.sub.f=0.3; HPLC:
.sup.Et.sub.Ret=3.46.
Example 68
6-(2-Amino-pyridin-4-yloxy)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0279] To a solution of 60 mg (0.11 mMol)
{4-[5-(3-trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyridin-2-y-
l}-carbamic acid tert-butyl ester in 1 ml dioxane, 30 .mu.l (0.12
mMol) of a 4 N hydrochloric acid solution in dioxane are added and
the resulting solution is heated under reflux for 8 h. The dioxane
is evaporated and the residue partitioned between EtOAc and
saturated sodium bicarbonate solution. The aqueous phase was
extracted twice with EtOAc. The combined EtOAc phases are washed
with brine, dried with sodium sulfate and evaporated. The residue
is purified by flash-chromatography on a silica gel column eluting
with dichloromethane/ethanol 95:5 containing 1% conc. ammonia.
Evaporation of the pure samples leads to crystalline title
compound: m.p.: 222-224.degree. C.; MS: [M+1].sup.+=424; TLC
(dichloromethane/ethanol 95:5 and 1% conc. ammonia): R.sub.f=0.3;
HPLC: .sup.Et.sub.Ret=3.46.
[0280] The starting material is prepared as follows:
Step 68.1:
4-[5-(3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-Py-
ridine-2-carboxylic acid
[0281] 165 mg (0.32 mMol)
4-[5-(3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyridine-2-c-
arboxylic acid butyl ester are dissolved in 6 ml of ethanol and
treated with 0.34 ml 1 N sodium hydroxide solution. The suspension
is heated for 2 h under reflux, cooled and the solvent evaporated.
The residue is triturated with EtOAc and filtered. The solid is
taken up in a small amount of water and acidified with 2 N
hydrochloric acid (pH .about.5). Extraction with EtOAc followed by
drying of the EtOAc extracts with sodium sulfate and evaporation of
the solvent gives pure title compound: MS: [M+1].sup.+=453; TLC
(EtOAc/hexanes 4:6): R.sub.f=0.35; HPLC: .sup.Et.sub.Ret=3.29.
Step 68.2:
{4-[5-(3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-p-
yridin-2-yl}-carbamic acid tert-butyl ester
[0282] A mixture of 113 mg (0.25 mMol)
4-[5-(3-trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyridine-2-c-
arboxylic acid, 1.5 ml tert.-butanol, 0.07 ml (0.3 mMol)
phosphorazidic acid diphenyl ester and 0.04 ml (0.03 mMol)
triethylamine is heated under reflux for 4 h. The solvent is
evaporated, the residue taken up in EtOAc and washed with saturated
sodium bicarbonate solution and brine, dried with sodium sulfate
and concentrated again. The residue is purified by
flash-chromatography on a silica gel column eluting with
EtOAc/hexanes 4:6. Evaporation of the pure samples leads to the
title compound: MS: [M+1].sup.+=524; TLC (EtOAc/hexanes 4:6):
R.sub.f=0.35; HPLC: .sup.Et.sub.Ret=4.07.
Example 69
{4-[5-(3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yloxy]-pyridin-2-yl-
}-carbamic acid methyl ester
[0283] To a mixture of 42 mg (0.1 mMol)
6-(2-amino-pyridin-4-yloxy)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide and 16 .mu.l (0.12 mMol)
triethylamine in 1 ml of THF are added 10 .mu.l (0.12 mMol) of
methyl chloroformate at rt After stirring for 1 h at rt the mixture
is diluted with EtOAc. This is then washed with saturated sodium
bicarbonate solution and brine, dried with sodium sulfate and
evaporated. The residue is purified by flash-chromatography on a
silica gel column eluting with EtOAc/hexanes 1:1. After a second
chromatography of the enriched fractions, the pure title compound
is obtained as a solid: m.p.: 230-232.degree. C.; MS:
[M+1].sup.+=482; TLC (EtOAc/hexanes 1:1): R.sub.f=0.45; HPLC:
.sup.Et.sub.Ret=3.69.
Example 70
6-[2-(2-Amino-pyrimidin-4-yl)-ethyl]-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0284] 0.069 g (0.148 mMol)
6-(2-Amino-6-chloro-pyrimidin-4-ylethynyl)-naphthalene-1-carboxylic
acid (3-trifluoromethyl-phenyl)-amide is hydrogenated in the
presence of 12 mg of magnesium oxide and 20 mg 10% palladium on
carbon in 5 ml of THF at rt. After 48 h the catalyst was filtered
off and the filtrate evaporated. The residue is chromatographed on
a 4 g silica gel column on a Combi-Flash Companion.TM. (Isco Inc.)
apparatus using a gradient of 20%.fwdarw.100% EtOAc in hexanes as
solvent. The title compound is obtained as a colorless solid: m.p.:
225-227.degree. C.; MS: [M+1].sup.+=435; TLC (EtOAc): R.sub.f=0.25;
HPLC: .sup.Et.sub.Ret=3.43.
[0285] The starting material is prepared as follows:
Step 70.1: Trifluoro-methanesulfonic acid
5-(3-trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yl ester
[0286] 1.324 g (4.0 mMol) 6-hydroxy-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide are dissolved in 7.2 ml of
pyridine and the solution is cooled to -10 to -15.degree. C. 0.824
ml (5 mMol) Trifluorosulfonic acid anhydride are added dropwise at
that temperature over 10 minutes. The mixture is then stirred at
0.degree. C. for 10 minutes and then 2 h at rt. The reaction
mixture is poured onto 25 ml of ice-water, stirred efficiently for
a few minutes and then extracted with tert.-butyl-methylether. The
organic phases are combined and washed with 1 N HCl and brine,
dried with sodium sulfate and concentrated to about 15 to 20 ml.
The suspension formed is cooled to 5.degree. C. to complete the
crystallization. The title compound is collected by filtration and
dried: m.p.: 177-178.degree. C.; MS: [M+1].sup.+=464; TLC
(EtOAc/hexanes 3:7): R.sub.f=0.34; HPLC: .sup.Et.sub.Ret=4.90.
Step 70.2: 6-Trimethylsilanylethynyl-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0287] 0.695 g (1.5 mMol) Trifluoro-methanesulfonic acid
5-(3-trifluoromethyl-phenylcarbamoyl)-naphthalen-2-yl ester, 0.015
g (0.079 mMol) copper (I) iodide and 17.4 mg (0.0248 mMol)
bis-(triphenylphosphine)-palladium dichloride are mixed in a
Schlenk apparatus under nitrogen and treated at it with a carefully
degassed solution of 0.233 ml (1.65 mMol) ethinyl-trimethylsilane
and 0.225 ml (1.62 mMol) triethylamine in 5.6 ml dry DMF. The clear
dark solution is kept at it for 16 h and then the DMF is evaporated
under reduced pressure. The residue is chromatographed on a 40 g
silica gel column on a Combi-Flash Companion.TM. (Isco Inc.)
apparatus using a gradient of 0%.fwdarw.20% EtOAc in hexanes as
solvent. The title compound is obtained as a tan solid: m.p.:
134-136.degree. C.; MS: [M+1].sup.+=412; TLC (EtOAc/hexanes 1:4):
R.sub.f=0.28; HPLC: .sup.Et.sub.Ret=5.40.
Step 70.3: 6-Ethynyl-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0288] 0.194 g (0.47 mMol)
6-Trimethylsilanylethynyl-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide is dissolved in 3.8 ml of methanol
at rt. After the addition of 0.1 g (0.724 mMol) potassium carbonate
the mixture is stirred for 16 at rt. The solvent was removed and
the residue partitioned between 10 ml of EtOAc and 5 ml of water.
The organic phase is washed with brine, dried with sodium sulfate
and evaporated. The title compound is obtained as a brown resin:
MS: [M+1].sup.+=340; HPLC: .sup.Et.sub.Ret=4.58.
Step 70.4:
6-(2-Amino-6-chloro-pyrimidin-4-ylethynyl)-naphthalene-1-carbox-
ylic acid (3-trifluoromethyl-phenyl)-amide
[0289] Nitrogen is passed through a solution of 130 mg (0.383 mMol)
6-ethynyl-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide and 57 mg (0.348 mMol)
2-amino-4,6-dichloro-pyrimidine in 1.3 ml DMF. After 10 to 15
minutes, 3.5 mg (0.0184 mMol) copper (I) iodide, 17.4 mg (0.0248
mMol) bis-(triphenylphosphine)-palladium dichloride and 52.2 .mu.l
(0.375 mMol) triethylamine are added and the mixture is stirred at
rt and under a nitrogen atmosphere for 16 h. The DMF is removed
under reduced pressure and the residue is chromatographed on a 12 g
silica gel column on a Combi-Flash Companion.TM. (Isco Inc.)
apparatus using a gradient of 0%.fwdarw.50% EtOAc in hexanes as
solvent. The title compound is obtained as a colorless solid: m.p.:
171-175.degree. C.; MS: [M+1].sup.+=465, 467; TLC (EtOAc/hexanes
1:1): R.sub.f=0.31; HPLC: .sup.Et.sub.Ret=4.74.
Example 71
6-(6-Amino-pyrimidin-4-ylethynyl)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0290] In a three-necked flask equipped with a reflux condenser,
nitrogen inlet and magnetic stirrer are placed 12.8 ml of
dimethoxy-ethane and 2.2 ml of water. Nitrogen is bubbled through
the solution for 5 minutes and then 33.3 mg (0.184 mMol) palladium
chloride, 51.1 mg (0.263 mMol) copper (I) iodide and 191 mg (0.693
mMol) triphenylphosphine are added and the mixture is heated to
40.degree. C. Next, 0.412 g (1 mMol)
6-trimethylsilanylethynyl-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide, 165 mg (1.25 mMol)
4-amino-6-chloropyrimidine and 629 mg (4.5 mMol) potassium
carbonate are added and the mixture stirred at 75.degree. C. for 15
h. After cooling the organic layer is separated and treated with
2.5 g of silica gel. The solvent is removed and the crude product
coated on silica gel chromatographed on a 40 g silica gel column on
a Combi-Flash Companion.TM. (Isco Inc.) apparatus using a gradient
of 30%.fwdarw.100% EtOAc in hexanes as solvent. The title compound
is obtained as a tan solid: m.p.: 217-220.degree. C.; MS:
[M+1].sup.+=433; TLC (EtOAc/hexanes 1:4): R.sub.f=0.19; HPLC:
.sup.Et.sub.Ret=3.36.
Example 71A
6-[(Z)-2-(6-Amino-pyrimidin-4-yl)-vinyl]-naphthalene-1-carboxylic
acid (3-trifluoromethyl-phenyl)-amide
[0291] 50 mg (0.116 mMol)
6-(6-Amino-pyrimidin-4-ylethynyl)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide are hydrogenated in 1 ml DMF
containing 9.45 .mu.l (0.14 mMol) ethylenediamine using 10 mg
Lindlar catalyst and under normal pressure. After 72 h at r.t. the
catalyst is removed and the solvent evaporated. The residue is
chromatographed on a 4 g silica gel column on a Combi-Flash
Companion.TM. (Isco Inc.) apparatus using a gradient of
60%.fwdarw.100% EtOAc in hexanes as solvent. The title compound is
obtained as a colorless resin: MS: [M+1].sup.+=435; HPLC:
.sup.Ft.sub.Ret=3.23.
Example 71B
6-[(E)-2-(6-Amino-pyrimidin-4-yl)-vinyl]-naphthalene-1-carboxylic
acid (3-trifluoromethyl-phenyl)-amide
[0292] Preparation of the CrSO.sub.4 solution: Under a nitrogen
atmosphere 5 g (12.7 mMol) chromium(III)sulfate hydrate are
dissolved in 32 ml of water and treated with 1.3 g of Zink powder.
The mixture is stirred over night at r.t. and yields a blue-green
solution. 21.6 mg (0.05 mMol)
6-(6-Amino-pyrimidin-4-ylethynyl)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide are dissolved in 2 ml of DMF and
treated under nitrogen with 180 .mu.l of the previously described
solution of CrSO.sub.4. The mixture is stirred at r.t. for 40 h and
then treated with 0.5 ml of a 2 N sodium carbonate solution. The
resulting suspension is filtered and the filtrate evaporated. The
crude product is coated on silica gel and chromatographed on a 4 g
silica gel column on a Combi-Flash Companion.TM. (Isco Inc.)
apparatus using a gradient of 30%.fwdarw.100% EtOAc in hexanes as
solvent. The title compound is obtained as a colorless material
containing about 20% of the Z-isomer: MS: [M+1].sup.+=435; TLC
(EtOAc): R.sub.f=0.17; HPLC: .sup.Et.sub.Ret=3.34.
Example 72
6-(6-Amino-pyrimidin-4-yloxy)-1H-indole-3-carboxylic acid
(3-trifluoromethyl-phenyl)-amide (Method A)
[0293] In a sealed tube, a solution of 50 mg (0.19 mMol)
6-(6-amino-pyrimidin-4-yloxy)-1H-indole-3-carboxylic acid, 69.1
.mu.l (0.56 mMol) 3-aminobenzotrifluoride and 128.9 .mu.l (0.93
mMol) Et.sub.3N in 1 ml DMF was treated with 131 .mu.l (0.22 mMol)
of propylphosphonic anhydride (ca. 50% in DMF) and stirred at rt
overnight. The reaction mixture was directly purified by reversed
phase prep-HPLC (Waters system) to give the title compound as its
TFA salt: MS: [M+1].sup.+=414; HPLC: .sup.Ft.sub.Ret=1.78.
[0294] The starting material is prepared as follows:
Step 72.1: 6-Hydroxy-1H-indole-3-carboxylic acid methyl ester
[0295] In a sealed flask, a mixture of 10.0 g (35.6 mMol)
6-benzyloxy-1H-indole-3-carboxylic acid methyl ester (synthesized
according to a literature procedure: M. Fedouloff and al. Bioorg.
Med. Chem. 9, 2001, 2119-2128), 2.26 g (35.6 mMol) ammonium formate
and 3.78 g Pd/C 10% in 200 ml EtOH was stirred at it for 1 h. The
catalyst was filtered and washed with hot MeOH. The filtrate was
evaporated to give the title compound: MS: [M+1].sup.+=192; HPLC:
.sup.Ft.sub.Ret=1.13.
Step 72.2: 6-(6-Chloro-pyrimidin-4-yloxy)-1H-indole-3-carboxylic
acid methyl ester
[0296] To a solution of 6.2 g (32.4 mMol)
6-hydroxy-1H-indole-3-carboxylic acid methyl ester in 50 ml
acetone, 35.7 ml (35.7 mMol) 1 N NaOH and 4.8 g (32.4 mMol)
4,6-dichloropyrimidine were added. The reaction mixture was stirred
at rt for 1 h during which time the product precipitate. The
reaction mixture was filtered and the solid washed with cold
acetone/water 1:1 then Et.sub.2O to give the title compound which
was used without further purification: MS: [M+1].sup.+=304; HPLC:
.sup.Ft.sub.Ret=1.94.
Step 72.3: 6-(6-Azido-pyrimidin-4-yloxy)-1H-indole-3-carboxylic
acid methyl ester
[0297] A mixture of 7.0 g (23.0 mMol)
6-(6-chloro-pyrimidin-4-yloxy)-1H-indole-3-carboxylic acid methyl
ester and 3.0 g (46.1 mMol) NaN.sub.3 in 75 ml DMF was stirred at
60.degree. C. for 2.5 h. The reaction mixture was diluted in EtOAc
then washed with water and brine. The organic layer was dried over
Na.sub.2SO.sub.4, filtered, and evaporated. Combi-Flash
Companion.TM. (Isco Inc.) column chromatography (SiO.sub.2;
gradient elution, hexane/EtOAc 8:2.fwdarw.4:6) yielded the title
compound: MS: [M+1].sup.+=311; HPLC: .sup.Ft.sub.Ret=2.07.
Step 72.4: 6-(6-Amino-pyrimidin-4-yloxy)-1H-indole-3-carboxylic
acid methyl ester
[0298] In a sealed flask, a suspension of 3.4 g (11.0 mMol)
6-(6-azido-pyrimidin-4-yloxy)-1H-indole-3-carboxylic acid methyl
ester, 1.4 g (22.1 mMol) ammonium formate and 1.2 g Pd/C 10% in 65
ml EtOH was stirred at rt for 1 h. The catalyst was filtered
through a Celite pad and washed with MeOH. The filtrate was
evaporated to give the title compound which was used without
further purification: MS: [M+1].sup.+=285; HPLC:
.sup.Ft.sub.Ret=1.08.
Step 72.5: 6-(6-Amino-pyrimidin-4-yloxy)-1H-indole-3-carboxylic
acid
[0299] A suspension of 3.38 g (11.9 mMol)
6-(6-amino-pyrimidin-4-yloxy)-1H-indole-3-carboxylic acid methyl
ester and 5.04 g (118.9 mMol) LiOH.H.sub.2O in 136 ml MeOH/H.sub.2O
5:3 was stirred at 80.degree. C. for 4 h. The clear solution was
cooled to rt, acidified by the addition of 6.7 ml (178.0 mMol)
formic acid, and concentrated under reduced pressure. The residue
was diluted in water and the formed solid was filtered and washed
with water to yield the title compound: MS: [M+1].sup.+271; HPLC:
.sup.Ft.sub.Ret=0.69.
Example 73
6-(6-Amino-pyrimidin-4-yloxy)-1H-indole-3-carboxylic acid
(3-methoxy-phenyl)-amide (Method B)
[0300] A solution of 50 mg (0.19 mMol)
6-(6-amino-pyrimidin-4-yloxy)-1H-indole-3-carboxylic acid, 68.0 mg
(0.56 mMol) 3-methoxyphenylamine, 102.0 .mu.l (0.93 mMol) NMM and
106 mg (0.22 mMol) HATU in 1 ml DMF was stirred at it overnight.
The reaction mixture was directly purified by reversed phase
prep-HPLC (Waters system) to give the title compound as its TFA
salt: MS: [M+1].sup.+=376; HPLC: .sup.Ft.sub.Ret=1.40.
Example 74
6-(6-Amino-pyrimidin-4-yloxy)-1H-indole-3-carboxylic acid
(4-fluoro-3-trifluoromethyl-phenyl)-amide (Method C)
[0301] A suspension of 50 mg (0.19 mMol)
6-(6-amino-pyrimidin-4-yloxy)-1H-indole-3-carboxylic acid in 2 ml
dioxane was treated with 134.6 .mu.l (1.85 mMol) SOCl.sub.2 and
stirred under reflux for 2 h. The reaction mixture was evaporated
under reduced pressure leading to the crude acid chloride. To a
solution of the crude acid chloride in 2 ml NMP, 35.6 .mu.l (0.278
mMol) 4-fluoro-3-(trifluoromethyl)aniline and 306 .mu.l (2.78 mMol)
NMM were added. The reaction mixture was stirred at it for 2 h then
directly purified reversed phase prep-HPLC (Waters system). After
lyophilization, the title compound was obtained as its TFA salt:
MS: [M+1].sup.+=432; HPLC: .sup.Gt.sub.Ret=2.83.
Example 75
[0302] The following compounds can be obtained analogously to Ex.
72, Ex. 73 or Ex. 74.
TABLE-US-00006 ##STR00076## ##STR00077## HPLC .sup.Ft.sub.Ret MS R
Methode [min] [M + 1].sup.+ a) ##STR00078## A 1.61 380 b)
##STR00079## A 1.76 414 c) ##STR00080## A 1.58 380 d ) ##STR00081##
A 1.71 468 e) ##STR00082## B 1.40 364 f) ##STR00083## B 1.48 360 g)
##STR00084## B 1.33 376 h) ##STR00085## C 2.21 490
Example 76
6-(6-Amino-pyrimidin-4-yloxy)-1-methyl-1H-indole-3-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0303] In a sealed flask, a solution of 16 mg (0.038 mMol)
6-(6-chloro-pyrimidin-4-yloxy)-1-methyl-1H-indole-3-carboxylic acid
(3-trifluoromethyl-phenyl)-amide in 1 ml NMP and 1 ml NH.sub.4OH
25% was stirred at 120.degree. C. for 2 h. The reaction mixture was
concentrated under reduced pressure and the residue purified by
prep-HPLC to give the title compound as its TFA salt: MS:
[M+1].sup.+=428; HPLC: .sup.Ft.sub.Ret=1.87.
[0304] The starting material is prepared as follows:
Step 76.1: 6-Benzyloxy-1-methyl-1H-indole-3-carboxylic acid methyl
ester
[0305] To a solution of 2.33 g (8.28 mMol)
6-benzyloxy-1H-indole-3-carboxylic acid methyl ester in 20 ml DMF,
4.05 g (12.42 mMol) Cs.sub.2CO.sub.3 and 1.03 ml (16.57 mMol) MeI
were added and the mixture was stirred at 60.degree. C. for 3 h.
The reaction middle was diluted in EtOAc and water, and the aqueous
phase was extracted with EtOAc (3 times). The combined organic
fractions were washed with brine, then dried over Na.sub.2SO.sub.4,
filtered, and evaporated. Purification via silica gel Combiflash
chromatography (gradient elution, hexane/tert-butyl-methylether 8:2
to 4:6) led to the title compound as a brownish solid: MS:
[M+1].sup.+=296; HPLC: .sup.Ft.sub.Ret=2.58; TLC
(tert-butyl-methylether/hexane 1:1): R.sub.f=0.34.
Step 76.2: 6-Benzyloxy-1-methyl-1H-indole-3-carboxylic acid
[0306] A suspension of 2.06 g (6.98 mMol)
6-benzyloxy-1-methyl-1H-indole-3-carboxylic acid methyl ester and
2.63 g (62.78 mMol) LiOH.H.sub.2O in 75 ml MeOH/H.sub.2O 2:1 was
stirred at 60.degree. C. overnight. The clear solution was cooled
to rt and concentrated. The residue was diluted in water and
acidified by the addition of 2 M HCl. The formed white precipitate
was collected by filtration, washed with water and dried at
40.degree. C. under high vacuum to give the title compound as an
off-white solid: MS: [M+1].sup.+=282; HPLC:
.sup.Ft.sub.Ret=2.12.
Step 76.3: 6-Hydroxy-1-methyl-1H-indole-3-carboxylic acid
[0307] In a sealed flask, a suspension of 1.57 g (5.58 mMol)
6-benzyloxy-1-methyl-1H-indole-3-carboxylic acid, 528 mg (8.37
mMol) ammonium formate and 594 mg Pd/C 10% in 25 ml EtOH was
stirred at rt for 2 h. The catalyst was filtered and washed with
hot MeOH. The filtrate was evaporated to give the title compound as
an off-white solid: MS: [M+1].sup.+=192; HPLC:
.sup.Ft.sub.Ret=0.85.
Step 76.4:
6-(6-Chloro-pyrimidin-4-yloxy)-1-methyl-1H-indole-3-carboxylic
acid
[0308] To a solution of 800 mg (4.18 mMol)
6-hydroxy-1-methyl-1H-indole-3-carboxylic acid in 20 ml acetone, 10
ml (10 mMol) 1 N NaOH and 935 mg (6.28 mMol) 4,6-dichloropyrimidine
were added. The reaction mixture was stirred at it for 2 h, then
concentrated under reduced pressure. The residue was diluted in
water and extracted with CH.sub.2Cl.sub.2 (2 times). The aqueous
phase was acidified by the addition of 2 N HCl (.fwdarw.pH 3-4) and
the resulting slurry was extracted with EtOAc (3 times). The
combined organic fractions were dried over Na.sub.2SO.sub.4,
filtered and evaporated to yield the title compound as a brown
solid which was used in the next step without further purification:
MS: [M+1].sup.+=304; HPLC: .sup.Ft.sub.Ret=1.68.
Step 76.5:
6-(6-Chloro-pyrimidin-4-yloxy)-1-methyl-1H-indole-3-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0309] A suspension of 60 mg (0.20 mMol)
6-(6-chloro-pyrimidin-4-yloxy)-1-methyl-1H-indole-3-carboxylic acid
in 2 ml dioxane was treated with 143.8 .mu.l (1.98 mMol) SOCl.sub.2
and stirred under reflux for 2 h. The reaction mixture was
evaporated under reduced pressure leading to the crude acid
chloride. To the crude acid chloride in 2 ml NMP, 36.9 .mu.l (0.30
mMol) 3-(trifluoromethyl)aniline and 326.5 .mu.l (2.96 mMol) NMM
were added. The reaction mixture was stirred at it for 2 h then
directly purified by injection in prep-HPLC (Waters system). After
lyophilization, the title compound was obtained: MS:
[M+1].sup.+=447; HPLC: .sup.Ft.sub.Ret=2.76.
Example 77
[0310] The following compounds can be obtained analogously to Ex.
76.
TABLE-US-00007 ##STR00086## ##STR00087## HPLC .sup.Ft.sub.Ret MS R
[min] [M + 1].sup.+ a) ##STR00088## 1.90 446 b) ##STR00089## 3.42
(.sup.Gt.sub.Ret) 504
Example 78
6-(6-Amino-pyrimidin-4-yloxy)-1-ethyl-1H-indole-3-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0311] Prepared as described in Ex. 74 from 50 mg (0.17 mMol)
6-(6-amino-pyrimidin-4-yloxy)-1-ethyl-1H-indole-3-carboxylic acid
and 31.3 .mu.l (0.25 mMol) 3-aminobenzotrifluoride:
[M+1].sup.+=442; HPLC: .sup.Ft.sub.Ret=1.93.
[0312] The starting material is prepared as follows:
Step 78.1: 6-Benzyloxy-1-ethyl-1H-indole-3-carboxylic acid methyl
ester
[0313] Prepared as described in Ex. 76, Step 76.1 from 2.0 g (7.11
mMol) 6-benzyloxy-1H-indole-3-carboxylic acid methyl ester and 1.06
ml (14.22 mMol) ethyl bromide: [M+1].sup.+=310; HPLC:
.sup.Gt.sub.Ret=3.61.
Step 78.2: 6-Benzyloxy-1-ethyl-1H-indole-3-carboxylic acid
[0314] Prepared as described in Ex. 76, Step 76.2 from 1.8 g (7.76
mMol) 6-benzyloxy-1-ethyl-1H-indole-3-carboxylic acid methyl ester:
[M+1].sup.+=296; HPLC: .sup.Ft.sub.Ret=2.27.
Step 78.3: 6-Hydroxy-1-ethyl-1H-indole-3-carboxylic acid
[0315] Prepared as described in Ex. 76, Step 76.3 from 1.64 g (5.55
mMol) 6-benzyloxy-1-ethyl-1H-indole-3-carboxylic acid:
[M+1].sup.+=206; HPLC: .sup.Ft.sub.Ret=1.05.
Step 78.4:
6-(6-Chloro-pyrimidin-4-yloxy)-1-ethyl-1H-indole-3-carboxylic
acid
[0316] Prepared as described in Ex. 76, Step 76.4 from 1.21 g (6.33
mMol) 6-hydroxy-1-ethyl-1H-indole-3-carboxylic acid and 1.89 g
(12.66 mMol) 4,6-dichloropyrimidine: [M+1].sup.+=318; HPLC:
.sup.Ft.sub.Ret=1.85.
Step 78.5:
6-(6-Azido-pyrimidin-4-yloxy)-1-ethyl-1H-indole-3-carboxylic
acid
[0317] A mixture of 1.5 g (4.72 mMol)
6-(6-chloro-pyrimidin-4-yloxy)-1-ethyl-1H-indole-3-carboxylic acid
and 1.23 g (18.88 mMol) NaN.sub.3 in 15 ml DMF was stirred at
60.degree. C. for 2.5 h. The reaction mixture was diluted in EtOAc
then washed with 2 M HCl and brine. The organic layer was dried
over Na.sub.2SO.sub.4, filtered, and evaporated. Combi-Flash
Companion.TM. (Isco Inc.) column chromatography (SiO.sub.2; hexane
with 2% AcOH/EtOAc 8:2.fwdarw.2:8) yielded the title compound: MS:
[M+1].sup.+=325; HPLC: .sup.Ft.sub.Ret=1.97.
Step 78.6:
6-(6-Amino-pyrimidin-4-yloxy)-1-ethyl-1H-indole-3-carboxylic
acid
[0318] Prepared as described in Ex. 72, Step 72.4 from 1.06 g (3.28
mMol) 6-(6-azido-pyrimidin-4-yloxy)-1-ethyl-1H-indole-3-carboxylic
acid, 418.0 mg (6.56 mMol) ammonium formate and 349.2 mg Pd/C 10%:
[M+1].sup.+=299; HPLC: .sup.Ft.sub.Ret=1.00.
Example 79
6-(6-Amino-pyrimidin-4-yloxy)-1-ethyl-1H-indole-3-carboxylic acid
(4-fluoro-3-trifluoromethyl-phenyl)-amide
[0319] Prepared as described in Ex. 78 from 50 mg (0.17 mMol)
6-(6-amino-pyrimidin-4-yloxy)-1-ethyl-1H-indole-3-carboxylic acid
and 32.3 .mu.l (0.25 mMol) 4-fluoro-3-(trifluoromethyl)aniline:
[M+1].sup.+=460; HPLC: .sup.Ft.sub.Ret=2.00.
Example 80
6-(6-Amino-pyrimidin-4-yloxy)-1-iso-propyl-1H-indole-3-carboxylic
acid (3-trifluoromethyl-phenyl)-amide
[0320] Prepared as described in Ex. 76 from 18 mg (0.038 mMol)
6-(6-chloro-pyrimidin-4-yloxy)-1-iso-propyl-1H-indole-3-carboxylic
acid (3-trifluoromethyl-phenyl)-amide: [M+1].sup.+=456; HPLC:
.sup.Gt.sub.Ret=3.14.
[0321] The starting material is prepared as follows:
Step 80.1: 6-Benzyloxy-1-iso-propyl-1H-indole-3-carboxylic acid
methyl ester
[0322] Prepared as described in Ex. 76, Step 76.1 from 1.0 g (3.56
mMol) 6-benzyloxy-1H-indole-3-carboxylic acid methyl ester and 667
.mu.l (7.10 mMol) 2-bromopropane: [M+1].sup.+=324; HPLC:
.sup.Gt.sub.Ret=3.72.
Step 80.2: 6-Benzyloxy-1-iso-propyl-1H-indole-3-carboxylic acid
[0323] Prepared as described in Ex. 76, Step 76.2 from 1.04 g (3.22
mMol) 6-benzyloxy-1-isopropyl-1H-indole-3-carboxylic acid methyl
ester: [M+1].sup.+=310; HPLC: .sup.Ft.sub.Ret=2.38.
Step 80.3: 6-Benzyloxy-1-iso-propyl-1H-indole-3-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0324] A suspension of 100 mg (0.32 mMol)
6-benzyloxy-1-iso-propyl-1H-indole-3-carboxylic acid in 2 ml
dioxane was treated with 235.2 .mu.l (3.23 mMol) SOCl.sub.2 and
stirred under reflux for 2 h. The reaction mixture was evaporated
under reduced pressure leading to the crude acid chloride. To the
crude acid chloride in 2 ml NMP, 60.3 .mu.l (0.48 mMol)
3-(trifluoromethyl)aniline and 534.2 .mu.l (4.85 mMol) NMM were
added. The reaction mixture was stirred at rt for 2 h then diluted
in water and extracted with tert-butyl-methylether. The organic
fraction was successively washed with 2 M HCl, 2 M
Na.sub.2CO.sub.3, and brine, then dried over Na.sub.2SO.sub.4,
filtered and evaporated. Combi-Flash Companion.TM. (Isco Inc.)
column chromatography (SiO.sub.2; hexane/EtOAc 95:5.fwdarw.6:4)
yielded the title compound: MS: [M+1].sup.+=453; HPLC:
.sup.Ft.sub.Ret=3.25.
Step 80.4: 6-Hydroxy-1-iso-propyl-1H-indole-3-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0325] Prepared as described in Ex. 76, Step 76.3 from 44 mg (0.097
mMol) 6-benzyloxy-1-isopropyl-1H-indole-3-carboxylic acid
(3-trifluoromethyl-phenyl)-amide: [M+1].sup.+=363; HPLC:
.sup.Ft.sub.Ret=2.43.
Step 80.5:
6-(6-Chloro-pyrimidin-4-yloxy)-1-iso-propyl-1H-indole-3-carboxy-
lic acid (3-trifluoromethyl-phenyl)-amide
[0326] Prepared as described in Ex. 76, Step 76.4 from 34 mg (0.094
mMol) 6-hydroxy-1-isopropyl-1H-indole-3-carboxylic acid
(3-trifluoromethyl-phenyl)-amide and 14.0 mg (0.094 mMol)
4,6-dichloropyrimidine: [M+1].sup.+=475; HPLC:
.sup.Ft.sub.Ret=3.00.
Example 81
6-(6-Acetylaminopyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(4-piperazin-1-ylmethyl-3-trifluoromethylphenyl)amide
[0327] 4.5 ml of 4 M solution of HCl in dioxane are added to a
stirred solution of 520 mg (0.727 mMol)
4-(4-{[6-(6-acetylamino-pyrimidin-4-yloxy)-naphthalene-1-carbonyl]-amino}-
-2-trifluoromethyl-benzyl)-piperazine-1-carboxylic acid tert-butyl
ester in 4.5 ml dioxane. After 2 hours, the mixture is neutralized
with aqueous 2 M NaOH. The precipitated product is filtered, washed
with water and dried. The solid is then dissolved in
CH.sub.2Cl.sub.2/MeOH 5:1 and the CH.sub.2Cl.sub.2 is evaporated
off under reduced pressure to afford a suspension which is filtered
to give the title compound as a beige solid: m.p.: 194-197.degree.
C.
[0328] The starting material is prepared as follows:
Step 81.1: 6-(6-Chloropyrimidin-4-yloxy)-naphthalene-1-carbonyl
chloride
[0329] A solution of 571 .mu.l (6.66 mMol) oxalyl chloride in 15 ml
CH.sub.2Cl.sub.2 is added to an ice-cooled solution of 1 g (step
25.1; 3.33 mMol)
6-(6-chloro-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid and 10
.mu.l DMF in 30 ml CH.sub.2Cl.sub.2. The reaction mixture is
stirred at room temperature for 1 h. The solvent is then evaporated
off under reduced pressure to afford the title compound as a brown
solid, which is used directly without further purification.
Step 81.2:
4-(4-{[6-(6-Chloro-pyrimidin-4-yloxy)-naphthalene-1-carbonyl]-a-
mino}-2-trifluoromethyl-benzyl)-piperazine-1-carboxylic acid
tert-butyl ester
[0330] A solution of 1.15 g (2.89 mMol)
6-(6-chloropyrimidin-4-yloxy)-naphthalene-1-carbonyl chloride in 20
ml CH.sub.2Cl.sub.2 is added to a stirred solution of 922 mg (2.51
mMol) 4-(4-amino-2-trifluoromethyl-benzyl)-piperazine-1-carboxylic
acid tert-butyl ester and 878 .mu.l (5.03 mMol)
diisopropylethylamine in 20 ml CH.sub.2Cl.sub.2. After 30 min, the
reaction mixture is poured into a mixture of water and
CH.sub.2Cl.sub.2. The aqueous phase is separated off and extracted
with CH.sub.2Cl.sub.2. The combined organic layers are washed with
water and brine, dried (Na.sub.2SO.sub.4) and concentrated. Column
chromatography (SiO.sub.2; CH.sub.2Cl.sub.2/EtOAc 1:1) gives the
title compound as a brown solid.
Step 81.3:
4-(4-{[6-(6-Acetylamino-pyrimidin-4-yloxy)-naphthalene-1-carbon-
yl]-amino}-2-trifluoromethyl-benzyl)-piperazine-1-carboxylic acid
tert-butyl ester
[0331] A mixture of 637 mg (0.97 mMol)
4-(4-{[6-(6-chloro-pyrimidin-4-yloxy)-naphthalene-1-carbonyl]-amino}-2-tr-
ifluoromethyl-benzylypiperazine-1-carboxylic acid tert-butyl ester,
86 mg (1.46 mMol) acetamide, 34 mg (0.058 mMol)
(9,9-dimethyl-9H-xanthene-4,5-diyl)bis[diphenylphosphine], 18 mg
(0.019 mMol) tris(dibenzylideneacetone)dipalladium, 448 mg (1.36
mMol) cesium carbonate in 5 ml dry dioxane is heated under an argon
atmosphere at 70.degree. C. for 3 h. The cooled suspension is
diluted with water, filtered (hyflo) and the residue is dissolved
in EtOAc. The solvent is evaporated off under reduced pressure to
afford the crude product which is used in the next step without
further purification.
Example 82
6-(6-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(4-piperazin-1-ylmethyl-3-trifluoromethylphenyl)amide
[0332] A solution of 260 mg (0.39 mMol)
6-(6-acetylamino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(4-piperazin-1-ylmethyl-3-trifluoromethylphenyl)amide in 2 ml HCl 4
M and 2 ml MeOH is heated at 50.degree. C. for 16 hours. After
cooling, the solution is neutralized with 4 ml NaOH 2 M and the
resulting suspension is filtered and washed with H.sub.2O. The
solid is then dried under high vacuum. Column chromatography
(SiO.sub.2; CH.sub.2Cl.sub.2/EtOH/NH.sub.3 90:9:1) gives the title
compound as colourless solid: mp.: 123-128.degree. C.
Example 83
{6-[5-(4-piperazin-1-ylmethyl-3-trifluoromethylphenylcarbamoyl)naphthalene-
-2-yloxy]pyrimidin-4-yl}carbamic acid methyl ester
[0333] This compound can be obtained analogously to example 81,
utilising methylcarbamate in lieu of acetamide in the step 81.3.
Beige solid: m.p.: 138-148.degree. C.
Example 84
6-(6-Acetylamino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
[4-(4-methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-amide
[0334] This compound can be obtained analogously to example 81,
utilising
4(4-methylpiperazin-1-ylmethyl)-3-trifluoromethylphenylamine in
lieu of
4-(4-amino-2-trifluoromethyl-benzyl)-piperazine-1-carboxylic acid
tert-butyl ester in the step 81.2. Beige powder: .sup.1H-NMR
(DMSO-d.sub.6): .delta. ppm 2.11 (3H, s) 2.15 (3H, s) 2.26-2.44
(8H, m) 3.57 (2H, s) 7.45 (1 H, dd, J=9.2, 2.4 Hz) 7.61 (1H, s)
7.64 (1H, dd, J=8.0, 7.2 Hz) 7.70 (1H, d, J=8.6 Hz) 7.78 (1H,
dJ=7.0 Hz) 7.85 (1H, d, J=2.4 Hz) 7.99 (1H, d, J=8.8 Hz) 8.07 (1H,
d, J=8.5 Hz) 8.25 (1H, s) 8.25 (1H, dd, J=5.1, 4.1 Hz) 8.48 (1H, s)
10.86 (1H, s) 10.96 (1H, s).
Example 85
6-(6-Aminopyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
[4-(4-methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-amide
[0335] This compound can be obtained analogously to example 82,
utilising
6-(6-acetylamino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
[4-(4-methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-amide
in lieu of
6-(6-acetylamino-pyrimidin-4-yloxy)naphthalene-1-carboxylic acid
(4-piperazin-1-ylmethyl-3-trifluoromethylphenyl)amide. Colourless
powder: .sup.1H-NMR (DMSO-d.sub.6): .delta. ppm 2.15 (3H, s)
2.29-2.35 (4H, m) 2.36-2.43 (4H, m) 3.57 (2H, s) 5.79 (1H, d, J=1.0
Hz) 6.86 (2H, s) 7.39 (1H, dd, J=9.2, 2.5 Hz) 7.62 (1H, dd, J=8.1,
7.1 Hz) 7.70 (1H, d, J=8.3 Hz) 7.76 (1H, dd, J=7.3, 1.3 Hz) 7.77
(1H, d, J=2.5 Hz) 7.99 (1H, dd, J=8.6, 1.2 Hz) 8.06 (1H, d, J=8.1
Hz) 8.06 (1H, d, J=1.0 Hz) 8.23 (1H, d, J=8.1 Hz) 8.24 (1H, s)
10.83 (1H, s)
Example 86
(6-{5-[4-(4-Methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenylcarbamoyl-
]-naphthalen-2-yloxy}-pyrimidin-4-yl)-carbamic acid methyl
ester
[0336] This compound can be obtained analogously to example 81,
utilising
4(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-phenylamine in
lieu of
4-(4-amino-2-trifluoromethyl-benzyl)-piperazine-1-carboxylic acid
tert-butyl ester in the step 81.2. and employing methylcarbamate in
lieu of acetamide in the step 81.3. Colourless powder: .sup.1H-NMR
(DMSO-d.sub.6): .delta. ppm 2.15 (3H, s) 2.24-2.47 (8H, m) 3.57
(2H, s) 3.68 (3H, s) 7.38 (1H,$) 7.47 (1 H, dd, J=9.2, 2.3 Hz) 7.66
(1H, dd, J=8.2, 7.3 Hz) 7.72 (1H, d, J=8.6 Hz) 7.80 (1H, d, J=7.0
Hz) 7.88 (1H, d, J=2.3 Hz) 8.01 (1H, d, J=8.21 Hz) 8.09 (1H, d,
J=8.2 Hz) 8.22-8.31 (m, 2 H) 8.46 (1H, s) 10.86 (1H, s) 10.90 (1H,
s)
Example 87
6-(6-Acetylamino-pyrimidin-4-yloxy)naphthalene-1-carboxylic acid
[4-(4-isopropylpiperazin-1-ylmethyl)-3-trifluoromethylphenyl]amide
[0337] This compound can be obtained analogously to example 81,
utilising
4-(4-isopropylpiperazin-1-ylmethyl)-3-trifluoromethylphenylamine in
lieu of
4-(4-amino-2-trifluoromethyl-benzyl)-piperazine-1-carboxylic acid
tert-butyl ester in step 81.2. pale yellow crystalline solid: m.p.:
210-213.degree. C.
Example 88
6-(6-Aminopyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
[4-(4-isopropylpiperazin-1-ylmethyl)-3-trifluoromethylphenyl]amide
[0338] This compound can be obtained analogously to example 82,
utilising
6-(6-acetylaminopyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
[4-(4-isopropylpiperazin-1-ylmethyl)-3-trifluoromethylphenyl]amide
in lieu of
6-(6-acetylamino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(4-piperazin-1-ylmethyl-3-trifluoromethylphenyl)amide. Colourless
powder: m.p.: 185-189.degree. C.
Example 89
(6-{5-[4-(4-Isopropyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenylcarbam-
oyl]-naphthalen-2-yloxy}-pyrimidin-4-yl)-carbamic acid methyl
ester
[0339] This compound can be obtained analogously to example 81,
utilising
4-(4-isopropylpiperazin-1-ylmethyl)-3-trifluoromethylphenylamine in
lieu of
4-(4-amino-2-trifluoromethyl-benzyl)-piperazine-1-carboxylic acid
tert-butyl ester in step 81.2. and employing methylcarbamate in
lieu of acetamide in the step 81.3. Colourless powder:
m.p.:=175-178.degree. C.
Example 90
7-(6-Acetylamino-pyrimidin-4-yloxy)-isoquinoline-4-carboxylic acid
[4-(4-methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-amide
[0340] A mixture of 300 mg (0.54 mMol)
7-(6-chloro-pyrimidin-4-yloxy)-isoquinoline-4-carboxylic acid
[4-(4-methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-amide,
47.7 mg (0.81 mMol) acetamide, 18.7 mg (0.032 mMol)
(9,9-dimethyl-9H-xanthene-4,5-diyl)bis[diphenylphosphine], 10 mg
(0.0108 mMol) tris(dibenzylideneacetone)dipalladium, 248 mg (0.75
mMol) cesium carbonate in 3 ml dry dioxane is heated under an argon
atmosphere at 70.degree. C. for 3 h. The cooled suspension is
diluted with water, filtered (hyflo) and the residue is dissolved
in EtOAc. The solvent is evaporated off under reduced pressure to
afford the crude product which is chromatographed by reversed phase
MPLC (Buchi system), yielding, after neutralisation with saturated
aqueous NaHCO.sub.3, the title compound as a beige solid:
.sup.1H-NMR (DMSO-d.sub.6): .delta. ppm 2.13 (3H, s) 2.15 (3H, s)
2.33 (4H, s) 2.36-2.42 (4H, m) 3.43 (1H, ddd, J=13.93, 6.98, 5.05
Hz) 3.57 (2H, s) 7.67 (1H, d, J=0.76 Hz) 7.72 (1H, d, J=9.16 Hz)
7.75 (1H, dd, J=9.09, 2.27 Hz) 7.99 (1H, dd, J=8.21, 1.52 Hz) 8.08
(1H, d, J=2.46 Hz) 8.24 (1H, d, J=1.71 Hz) 8.33 (1H, d, J=9.16 Hz)
8.49 (2H, d, J=0.82 Hz) 8.80 (1H, s) 9.43 (1H, s) 10.99 (1H, s)
11.00 (1H, s).
[0341] The starting material is prepared as follows:
Step 90.1: 7-(6-Chloro-pyrimidin-4-yloxy)-isoquinoline-4-carboxylic
acid
[4-(4-methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-amide
[0342] A mixture of 1.95 g (5.5 mMol)
7-(6-chloro-pyrimidin-4-yloxy)-isoquinoline-4-carboxylic acid (Step
93.2), 1.5 g (5.49 mMol)
4-(4-methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenylamine and
6.42 ml (46.2 mMol) triethylamine in 50 ml dry DMF is heated under
an argon atmosphere at 50.degree. C. A solution of 5.4 ml (8.2
mMol) propylphosphonic anhydride is then added. After 2 h, the
reaction mixture is poured onto an aqueous solution of NaHCO.sub.3
and stirred at 0.degree. C. for 1 h. The suspension is then
filtered (hyflo) and the solid residue is dissolved in
CH.sub.2Cl.sub.2/MeOH 5:1. The solvent is evaporated off under
reduced pressure to afford a crude product which is purified by
reversed phase MPLC (Buchi system), yielding, after neutralisation
with saturated aqueous NaHCO.sub.3, the title compound as a orange
solid.
Example 91
(6-{4-[4-(4-Methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenylcarbamoyl-
]-isoquinolin-7-yloxy}-pyrimidin-4-yl)-carbamic acid methyl
ester
[0343] This compound can be obtained analogously to example 90,
utilising methylcarbamate in lieu of acetamide. Beige solid:
.sup.1H-NMR (DMSO-d.sub.6): .delta. ppm 2.15 (3H, s) 2.29-2.35 (4H,
m) 2.36-2.43 (4H, m) 3.57 (2H, s) 3.69 (3H, s) 7.43 (1H, d, J=1.0
Hz) 7.72 (1H, d, J=8.5 Hz) 7.75 (1H, dd, J=9.1, 2.4 Hz) 7.99 (1H,
dd, J=8.6, 1.1 Hz) 8.09 (1H, d, J=2.5 Hz) 8.24 (1H, d, J=2.1 Hz)
8.34 (1H, d, J=9.2 Hz) 8.45 (1H, d, J=1 Hz) 8.80 (1H, s) 9.43 (1H,
d, J=0.5 Hz) 10.86 (1H, s) 10.99 (1H, s).
Example 92
7-(6-Amino-pyrimidin-4-yloxy)-isoquinoline-4-carboxylic acid
[4-(4-methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-amide
[0344] This compound can be obtained analogously to example 82,
utilising
7-(6-acetylamino-pyrimidin-4-yloxy)-isoquinoline-4-carboxylic acid
[4-(4-methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-amide
(example 90) in lieu of
6-(6-acetylamino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(4-piperazin-1-ylmethyl-3-trifluoromethylphenyl)amide (example 81).
Pale yellow powder: m.p.: 119-122.degree. C.; 1H-NMR (DMSO-d6):
.ident. ppm 2.15 (s, 3H) 2.23-2.46 (m, 8H) 3.57 (s, 2H) 5.90 (s,
1H) 6.95 (s, 2H) 7.67-7.77 (m, 2H) 7.97-8.11 (m, 3H) 8.26 (s, 1H)
8.33 (d, J=9.4 Hz, 1H) 8.80 (s, 1H) 9.44 (s, 1H) 11.01 (s, 1H).
Example 93
7-(6-Amino-pyrimidin-4-yloxy)-isoquinoline-4-carboxylic acid
[5-tert-butyl-2-(4-isopropyl-phenyl)-2H-pyrazol-3-yl]-amide
[0345] 49.0 mg (0.089 mMol)
7-(6-Azido-pyrimidine-4-yloxy)-isoquinoline-4-carboxylic acid
[5-tert-butyl-2-(4-isopropyl-phenyl)-2H-pyrazol-3-yl]-amide is
dissolved in 5 ml MeOH and submitted to hydrogenation over 12 mg
Raney-Nickel at atmospheric pressure at rt for 4 h. After
completion the reaction mixture is filtered over a pad of celite
and concentrated to give the title compound: m.p.: 131-133.degree.
C.; MS: [M+1]+=522.
[0346] The starting material is prepared as follows:
Step 93.1: 7-Hydroxy-isoquinoline-4-carboxylic acid
[0347] 2.5 g (12.3 mMol) 7-Methoxy-isoquinoline-4-carboxylic acid
are dissolved in 10 ml HBr/HOAc (33% wt) and 0.5 ml H.sub.2O is
added. The reaction mixture is warmed to 130.degree. C. in a sealed
tube. After 3 h it is allowed to cool to ambient temperature. All
volatiles are removed under reduced pressure and the remaining
crude product is used without further purification for the next
step.
Step 93.2:
7-(6-Chloro-pyrimidine-4-yloxy)-isoquinoline-4-carboxylic acid
[0348] 2.3 g (12.3 mMol) 7-Hydroxy-isoquinoline-4-carboxylic acid
are dissolved in 60 ml acetone and 27 ml of an 1 M aqueous solution
of NaOH are added, followed by 1.9 g (13.2 mMol)
4,6-dichloropyrimidine. The reaction is stirred at ambient
temperature for 12 h and acetone is removed under reduced pressure.
The remaining aqueous solution is acidified with 1M aqueous HCl.
The resulting yellow precipitate of the product is isolated by
filtration, washed repeatedly with cold water and dried under high
vacuum at 60.degree. C.
Step 93.3: 7-(6-Chloro-pyrimidine-4-yloxy)-isoquinoline-4-carboxyl
chloride
[0349] 1.6 g (5.5 mMol)
7-(6-Chloro-pyrimidine-4-yloxy)-isoquinoline-4-carboxylic acid are
suspended in CH.sub.2Cl.sub.2 and 0.57 ml (6.6 mMol) oxalylchloride
are added. The reaction is then stirred under reflux for 2 h,
cooled to ambient temperature and concentrated under reduced
pressure. The remaining crude product is used without further
purification for the next step.
Step 93.4:
7-(6-Chloro-pyrimidine-4-yloxy)-isoquinoline-4-carboxylic acid
[5-tert-butyl-2-(4-isopropyl-phenyl)-2H-pyrazol-3-yl]-amide
[0350] 0.5 g (1.5 mMol)
7-(6-Chloro-pyrimidine-4-yloxy)-isoquinoline-4-carboxyl chloride
are dissolved in 4 ml CH.sub.2Cl.sub.2 and a solution of 0.4 g
5-tert-butyl-2-(4-isopropyl-phenyl)-2-H-pyrazol-3-ylamine
(described for example in GB 0500435.3; 1.5 mMol) and 76 .mu.l (1.7
mMol) pyridine dissolved in 4 ml CH.sub.2Cl.sub.2 are added
dropwise at rt. The reaction is stirred for 1.5 h at it and then
concentrated under reduced pressure. The residual crude product is
purified by flash chromatography (SiO.sub.2, CH.sub.2Cl.sub.2/MeOH,
gradient 0-8% MeOH) to give the title compound as a yellow
solid.
Step 93.5: 7-(6-Azido-pyrimidine-4-yloxy)-isoquinoline-4-carboxylic
acid
[5-tert-butyl-2-(4-isopropyl-phenyl)-2H-pyrazol-3-yl]-amide
[0351] 128.0 mg (0.24 mMol)
7-(6-Chloro-pyrimidine-4-yloxy)-isoquinoline-4-carboxylic acid
[5-tert-butyl-2-(4-isopropyl-phenyl)-2H-pyrazol-3-yl]-amide are
dissolved in 5 ml DMF and 31.0 mg (0.47 Mmol) NaN.sub.3 are added
in one portion at rt. The reaction mixture is stirred for 1.5 h at
70.degree. C. and then concentrated under reduced pressure. The
residual crude product is submitted to flash chromatography
(SiO.sub.2; CH.sub.2Cl.sub.2/MeOH; gradient 0-5% MeOH) to give the
title compound as a yellow solid.
Example 94
7-(6-Amino-pyrimidin-4-yloxy)-isoquinoline-4-carboxylic acid
[5-tert-butyl-2-(4-fluoro-phenyl)-2H-pyrazol-3-yl]-amide
[0352] The title compound is prepared in analogy to Ex. 93 using
5-tert-butyl-2-(4-fluoro-phenyl)-2H-pyrazol-3-ylamine: m.p.:
124-126.degree. C.; MS: [M+1].sup.+=498.
Example 95
7-(6-Methylamino-pyrimidin-4-yloxy)-isoquinoline-4-carboxylic acid
(4-fluoro-3-trifluoromethyl-phenyl)-amide
[0353] 490 mg (1.0 mMol)
7-(6-Chloro-pyrimidin-4-yloxy)-isoquinoline-4-carboxylic acid
(4-fluoro-3-trifluoromethyl-phenyl)-amide are treated with a
solution of methylamine in EtOH (33% wt) at rt. The reaction
mixture is stirred for 1.5 h at ambient temperature. It is then
concentrated under reduced pressure and the remaining crude product
submitted to flash chromatography (SiO.sub.2,
CH.sub.2Cl.sub.2/MeOH; gradient 1-8% MeOH) to give the title
compound as a yellow solid: m.p.: 255-257.degree. C.; MS:
[M+1].sup.+=458.
[0354] The starting material is prepared as follows:
Step 95.1: 7-(6-Chloro-pyrimidin-4-yloxy)-isoquinoline-4-carboxylic
acid (4-fluoro-3-trifluoromethyl-phenyl)-amide
[0355] The title compound is prepared in analogy to Step 93.4. from
7-(6-chloro-pyrimidine-4-yloxy)-isoquinoline-4-carboxyl chloride
and 4-fluoro-3-trifluoromethyl-phenylamine.
Example 96
7-(6-Methylamino-pyrimidin-4-yloxy)-isoquinoline-4-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0356] The title compound is prepared in analogy to Ex. 95 from
3-trifluoromethyl-phenylamine: m.p.: 205-208.degree. C.; MS:
[M+1].sup.+=440.
Example 97
[0357] The following compounds can be obtained in analogy to
Example 93 (Q=H) or Example 95 (Q=CH.sub.3) starting from
6-(6-chloropyrimidin-4-yloxy)-naphthalene-1-carbonyl chloride (step
81.1) and appropriate 2-amino pyrazoles (described for example in
GB 0500435.3).
TABLE-US-00008 ##STR00090## Q ##STR00091## m.p. [.degree. C.] MS [M
+ 1].sup.+ Name a) ##STR00092## 130-135 550
6-(6-Methylamino-pyrimidin-4-yloxy)-naphthalene- 1-carboxylic acid
[5-tert-butyl-2-(4- dimethylaminomethyl-phenyl)-2H-pyrazole-3-yl]-
amide b) ##STR00093## -- 605
6-(6-Methylamino-pyrinnidin-4-yloxy)-naphthalene- 1-carboxylic
acid{5-tert-butyl-2-[4-(4-methyl-
piperazin-1-ylmethyl)-phenyl]-2H-pyrazol-3-yl}- amide c)
##STR00094## -- 578 6-(6-Amino-pyrimidin-4-yloxy)-naphthalene-1-
carboxylic acid {5-tert-butyl-2-[4-(morpholin-4-
ylmethyl)-phenyl]-2H-pyrazol-3-yl}-amide d) ##STR00095## 125-128
592 6-(6-Methylamino-pyrimidin-4-yloxy)-naphthalene- 1-carboxylic
acid {5-tert-butyl-2-[4-(morpholin-4-
ylmethyl)-phenyl]-2H-pyrazol-3-yl}-amide e) CH.sub.3 3-CH.sub.3
105-110 507 6-(6-Methylamino-pyrimidin-4-yloxy)-naphthalene-
1-carboxylic acid[5-tert-butyl-2-(3-methyl-phenyl)-
2H-pyrazol-3-yl]amide f) ##STR00096## 105-110 592
6-(6-Methylamino-pyrimidin-4-yloxy)-naphthalene- 1-carboxylic acid
{5-tert-butyl-2-[3-(morpholin-4-
ylmethyl)-phenyl]-2H-pyrazol-3-yl)-amide g) ##STR00097## 140-145
536 6-(6-Amino-pyrimidin-4-yloxy)-naphthalene-1- carboxylic
acid[5-tert-butyl-2-(3-
dimethylaminometyl-phenyl)-2H-pyrazol-3-yl]- amide h) ##STR00098##
114-116 550 6-(6-Methylamino-pyrimidin-4-yloxy)-naphthalene-
1-carboxylic acid[5-tert-butyl-2-(3-
dimethylaminometyl-phenyl)-2H-pyrazol-3-yl]- amide i) ##STR00099##
290-291 550 6-(6-Amino-pyrimidin-4-yloxy)-naphthalene-1- carboxylic
acid[5-tert-butyl-2-(3-
dimethylcarbamoyl-phenyl)-2H-pyrazol-3-yl]-amide j) ##STR00100##
247-249 564 6-(6-Methylamino-pyrimidin-4-yloxy)-naphthalene-
1-carboxylic acid[5-tert-butyl-2-(3-
dimethylcarbamoyl-phenyl)-2H-pyrazol-3-yl]-amide
Example 98
6-(2-Chloro-pyrimidin-4-ylsulfanyl)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0358] To 0.92 g (2.90 mMol)
6-(2-chloro-pyrimidin-4-ylsulfanyl)-naphthalene-1-carboxylic acid,
436 .mu.l (3.49 mMol) 3-trifluoromethyl-aniline, 4.12 ml (29.6
mMol) Et.sub.3N and 153 mg (1.25 mMol) DMAP in 15 ml DMF, 3.56 ml
(6.1 mMol) propylphosphonic anhydride are added dropwise. After 1 h
at rt, the mixture is poured into water and EtOAc, the aqueous
phase separated off and extracted twice with EtOAc. The organic
layers are washed with water and brine, dried (Na.sub.2SO.sub.4)
and concentrated after addition of SiO.sub.2. The resulting powder
is put on top of a SiO.sub.2 column (hexane/EtOAc 9:1). The title
compound is eluted with hexane/EtOAc 9:1.fwdarw.2:1 and
crystallized from hexane: MS: [M+1].sup.+=460/462; TLC
(hexane/EtOAc 2:1): R.sub.f=0.21; HPLC: .sup.At.sub.Ret=17.3.
[0359] The starting material is prepared as follows:
Step 98.1:
6-(2-Chloro-pyrimidin-4-ylsulfanyl)-naphthalene-1-carboxylic
acid
[0360] A mixture of 1.5 g (10 mMol) 2,4-dichloro-pyrimidine, 1.72 g
(8.4 mMol) 6-mercapto-naphthalene-1-carboxylic acid [preparation
described in J. Med. Chem. 32 (1989), 2493] are suspended in 27 ml
acetone. Then 20 ml of 1 N NaOH in H.sub.2O are added. After 1 h at
rt, the resulting solution is poured into 300 ml of 1 N HCl in
H.sub.2O and extracted 3 times with EtOAc. The organic layers are
washed with water and brine, dried (Na.sub.2SO.sub.4) and
concentrated partially to yield the crystalline title compound: MS:
[M+1]=317; HPLC: .sup.At.sub.Ret=14.0.
Example 99
{4-[5-(3-Trifluoromethyl-phenylcarbamoyl)-naphthalen-2-ylsulfanyl]-pyrimid-
in-2-yl}-carbamic acid tert-butyl ester
[0361] A solution of 770 mg (1.67 mMol)
6-(2-chloro-pyrimidin-4-ylsulfanyl)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide in 10 ml dioxane is degassed
repeatedly by evaporation and flushing with N.sub.2. Then 818 mg
(2.5 mMol) Cs.sub.2CO.sub.3, 60 mg (0.10 mMol)
4,5-bis(diphenylphosphino)-9,9-dimethylxanthene, 31 mg (0.034 mMol)
tris(dibenzylidenaceton)dipalladium(0) and 235 mg (2.0 mMol)
carbamic acid tert-butyl ester are added successively. After 2.5 h
stirring at 110.degree. C., the mixture is cooled to it and another
30 mg 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene, 16 mg
tris(dibenzylidenaceton)dipalladium(0) and 235 mg carbamic acid
tert-butyl ester are added and stirring is continued for 90 min.
Then the cooled mixture is poured into EtOAc and water, the aqueous
layer separated off and extracted twice with EtOAc. The organic
layers are washed with water and brine, dried (Na.sub.2SO.sub.4)
and concentrated together with 10 g SiO.sub.2. The resulting powder
is put on top of a chromatography column (SiO.sub.2; hexane/EtOAc
9:1) and the title compound eluted with hexane/EtOAc
9:1.fwdarw.3:2: MS: [M+1]=541; HPLC: .sup.At.sub.Ret=15.5.
Example 100
6-(2-Amino-pyrimidin-4-ylsulfanyl)-naphthalene-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0362] A mixture of 117 (0.217 mMol)
{4-[5-(3-trifluoromethyl-phenylcarbamoyl)-naphthalen-2-ylsulfanyl]-pyrimi-
din-2-yl}-carbamic acid tert-butyl ester in 6 ml dioxane and 3.5 ml
HCl 4 N in dioxane is stirred for 18 h at rt. The resulting
solution is poured into EtOAc and sat. NaHCO.sub.3, the aqueous
layer separated off and extracted twice with EtOAc. The organic
layers are washed with water and brine, dried (Na.sub.2SO.sub.4)
and concentrated. Chromatography (Combi Flash;
CH.sub.2Cl.sub.2/EtOAc 4:1.fwdarw.1:4) and crystallization from
hexane gives the title compound: MS: [M+1].sup.+=441;
TLC(CH.sub.2Cl.sub.2/EtOAc 1:2): R.sub.f=0.34; HPLC:
.sup.At.sub.Ret=12.8.
Example 101
6-(6-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(2,4-dichloro-3,5-dimethoxy-phenyl)-amide (A) and
6-(6-amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(2,6-dichloro-3,5-dimethoxy-phenyl)-amide (B)
[0363] A suspension of 113 mg (0.27 mMol)
6-(6-amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(3,5-dimethoxy-phenyl)-amide (Ex. 39m) in 3 ml acetonitrile is
cooled to 0.degree. C. Then 3.1 ml of a 0.2 M solution of
SO.sub.2Cl.sub.2 in CH.sub.2Cl.sub.2 is added dropwise during 10
min. Then the mixture is poured into sat. Na.sub.2CO.sub.3/H.sub.2O
1:3 and EtOAc, the aqueous layer separated off and extracted twice
with EtOAc. The organic layers are washed with water and brine,
dried (Na.sub.2SO.sub.4) and concentrated. Chromatography (Combi
Flash; ether.fwdarw.EtOAc) gives first A [MS: [M+1].sup.+=485/487;
TLC (EtOAc): R.sub.f=0.42; .sup.1H-NMR (DMSO-d.sub.6): 7.43 ppm (s,
HC.sup.6)], followed by B [MS: [M+1].sup.+=485/487; TLC (EtOAc):
R.sub.f=0.35; .sup.1H-NMR (DMSO-d.sub.6): 7.00 ppm (s,
HC.sup.4)]
Example 102
6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(2,4-dichloro-3,5-dimethoxy-phenyl)-amide (A) and
6-(2-amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(2,6-dichloro-3,5-dimethoxy-phenyl)-amide (B)
[0364] As described in Ex. 101, 500 mg (1.2 mMol)
6-(2-amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(3,5-dimethoxy-phenyl)-amide (Ex. 371) in 13 ml acetonitrile are
chlorinated with 12 ml of a 0.2 M solution of SO.sub.2Cl.sub.2
giving A [MS: [M+1].sup.+=485/487; TLC(CH.sub.2Cl.sub.2/EtOAc 1:9):
R.sub.f=0.37; .sup.1H-NMR (DMSO-d.sub.6): 7.40 ppm (s, HC.sup.6)]
and B [MS: [M+1].sup.+=485/487; TLC(CH.sub.2Cl.sub.2/EtOAc 1:9):
R.sub.f=0.25; .sup.1H-NMR (DMSO-d.sub.6): 6.98 ppm (s,
HC.sup.4)].
Example 103
6-(6-Acetylamino-pyrimidin-4-yloxy)-isoquinoline-1-carboxylic acid
(4-fluoro-3-trifluoromethyl-phenyl)-amide
[0365] 200 mg (0.43 mMol)
6-(6-Chloro-pyrimidin-4-yloxy)-isoquinoline-1-carboxylic acid
(4-fluoro-3-trifluoromethyl-phenyl)-amide, 38 mg (0.64 mMol)
acetamide, 15 mg (0.026 mMol)
(9,9-dimethyl-9H-xanthene-4,5-diyl)bis[diphenylphosphine], 8 mg
(0.008 mMol) tris(dibenzylideneacetone)dipalladium and 199 mg (0.6
mMol) cesium carbonate in 5 ml dry dioxane are heated under an
argon atmosphere at 70.degree. C. for 5 h. The cooled suspension is
diluted with water, filtered (hyflo) and the residue is dissolved
in EtOAc. The solvent is evaporated off under reduced pressure to
afford the crude product which is purified by column chromatography
(SiO.sub.2; CH.sub.2Cl.sub.2 pure) to give the title compound as a
yellow solid: .sup.1H-NMR (DMSO-d.sub.6): .delta. ppm 2.13 (s, 3H)
7.57 (t, J=9.8 Hz, 1H) 7.65 (dd, J=9.38, 2.35 Hz, 1H) 7.70 (s, 1H)
7.96 (d, J=2.3 Hz, 1H) 8.10 (d, J=5.5 Hz, 1H) 8.16-8.23 (m, 1H)
8.45 (dd, J=6.4, 2.5 Hz, 1H) 8.53 (s, 1H) 8.66 (d, J=5.9 Hz, 1H)
9.01 (d, J=9.4 Hz, 1H) 11.06 (s, 1H) 11.26 (s, 1H).
[0366] The starting material is prepared as follows:
Step 103.1:
6-(6-Chloro-pyrimidin-4-yloxy)-isoquinoline-1-carboxylic acid
[0367] 40 ml (20 mMol) of a 0.5 M solution of sodium methylate in
MeOH are added to a suspension of 1.9 g (10 mMol)
6-hydroxy-isoquinoline-1-carboxylic acid (CAS 174299-07-1) in 50 ml
MeOH and sonicated until a solution is obtained. The solvent is
then evaporated off. The residue is dried in high vacuum for 4 h
and 100 ml DMF are added. The suspension is cooled to 10.degree. C.
and a solution of 1.55 g (10 mMol) 4,6-dichloropyrimidine in 25 ml
DMF is added. The reaction mixture is stirred at room temperature
for 14 h. The solvent is evaporated off and the mixture is
partitioned between H.sub.2O/EtOAc. After extraction, the aqueous
phase is neutralized with a 1 N solution of HCl. The suspension is
extracted with EtOAc, washed with H.sub.2O and brine, dried
(MgSO.sub.4) and concentrated to give a beige powder: .sup.1H-NMR
(DMSO-d.sub.6): .delta. ppm 7.60 (s, 1H) 7.68 (dd, J=9.4, 2.3 Hz,
1H) 7.98 (d, J=2.3 Hz, 1H) 8.04 (d, J=5.5 Hz, 1H) 8.59 (d, J=5.9
Hz, 1H) 8.66 (s, 1H) 8.68 (s, 1H).
Step 103.2: 6-(6-Chloro-pyrimidin-4-yloxy)-isoquinoline-1-carbonyl
chloride
[0368] A solution of 870 .mu.l (10.2 mMol) oxalyl chloride in 10 ml
CH.sub.2Cl.sub.2 is added to an ice-cooled solution of 1.54 g (5.1
mMol) 6-(6-chloro-pyrimidin-4-yloxy)-isoquinoline-1-carboxylic acid
and 10 .mu.l DMF in 75 ml CH.sub.2Cl.sub.2. The reaction mixture is
stirred at room temperature for 1 h. The solvent is then evaporated
off under reduced pressure to afford the title compound as a brown
solid, which is used directly without further purification.
Step 103.3:
6-(6-Chloro-pyrimidin-4-yloxy)-isoquinoline-1-carboxylic acid
(4-fluoro-3-trifluoromethyl-phenyl)-amide
[0369] A solution of 319 mg (1 mMol)
6-(6-chloro-pyrimidin-4-yloxy)-isoquinoline-1-carbonyl chloride in
20 ml CH.sub.2Cl.sub.2 is added to a stirred solution of 127 .mu.l
(1 mMol) 4-fluoro-3-trifluoromethylaniline and 316 .mu.l (1.81
mMol) diisopropylethylamine in 5 ml CH.sub.2Cl.sub.2. After 30 min,
the reaction mixture is poured into a mixture of water and
CH.sub.2Cl.sub.2. The aqueous phase is separated off and extracted
with CH.sub.2Cl.sub.2. The combined organic layers are washed with
water and brine, dried (Na.sub.2SO.sub.4) and concentrated. Column
chromatography (SiO.sub.2; CH.sub.2Cl.sub.2/EtOAc 9:1) gives the
title compound as a pale yellow solid: .sup.1H-NMR (DMSO-d.sub.6):
.delta. ppm 7.53-7.60 (m, 1H) 7.61 (d, J=0.8 Hz, 1H) 7.69 (dd,
J=9.4, 2.3 Hz, 1H) 8.01 (d, J=2.3 Hz, 1H) 8.11 (d, J=5.9 Hz, 1H)
8.17-8.24 (m, 1H) 8.45 (dd, J=6.6, 2.3 Hz, 1H) 8.66-8.71 (m, 2H)
9.03 (d, J=9.38 Hz, 1H) 11.27 (s, 1H).
Example 104
6-(6-Amino-pyrimidin-4-yloxy)-isoquinoline-1-carboxylic acid
(4-fluoro-3-trifluoromethyl-phenyl)-amide
[0370] This compound can be obtained analogously to example 82,
utilising
6-(6-acetylamino-pyrimidin-4-yloxy)-isoquinoline-1-carboxylic acid
(4-fluoro-3-trifluoromethyl-phenyl)-amide in lieu of
6-(6-acetylamino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid
(4-piperazin-1-ylmethyl-3-trifluoromethylphenyl)amide (example 81).
Colourless powder: m.p.: 219-222.degree. C.; .sup.1H-NMR
(DMSO-d.sub.6): .delta. ppm 5.92 (d, J=1.0 Hz, 1H) 6.96 (s, 2H)
7.50-7.60 (m, 2H) 7.83 (d, J=2.4 Hz, 1H) 8.07 (d, J=5.4 Hz, 1H) 8.1
(d, J=0.82 Hz, 1H) 8.12-8.22 (m, 1H) 8.42 (dd, J=6.5, 2.5 Hz, 1H)
8.61 (d, J=5.56 Hz, 1H) 8.96 (d, J=9.3 Hz, 1H) 11.21 (s, 1H).
Example 105
6-(6-Amino-pyrimidin-4-yloxy)-isoquinoline-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide
[0371] This compound can be obtained analogously to example 104,
utilising
6-(6-acetylamino-pyrimidin-4-yloxy)-isoquinoline-1-carboxylic acid
(3-trifluoromethyl-phenyl)-amide in lieu of
6-(6-acetylamino-pyrimidin-4-yloxy)-isoquinoline-1-carboxylic acid
(4-fluoro-3-trifluoromethyl-phenyl)-amide and employing
3-aminobenzotrifluoride in lieu of
4-fluoro-3-trifluoromethylaniline in the step 103.3. Colourless
powder: m.p.: 197-200.degree. C.; 1H-NMR (DMSO-d.sub.6): .delta.
ppm 5.92 (d, J=0.8 Hz, 1H) 6.96 (s, 2H) 7.48 (d, J=7.7 Hz, 1H) 7.56
(dd, J=9.3, 2.5 Hz, 1H) 7.62 (t, J=8.0 Hz, 1H) 7.83 (d, J=2.4 Hz,
1H) 8.03-8.14 (m, 3H) 8.40 (s, 1H) 8.61 (d, J=5.6 Hz, 1H) 8.93 (d,
J=9.3 Hz, 1H) 11.16 (s, 1H).
Example 106
6-(6-Acetylamino-pyrimidin-4-yloxy)-isoquinoline-1-carboxylic acid
[4-(4-methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-amide
[0372] This compound can be obtained analogously to example 103,
utilising 6-(6-chloro-pyrimidin-4-yloxy)-isoquinoline-1-carboxylic
acid
[4-(4-methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-amide
in lieu of 6-(6-chloro-pyrimidin-4-yloxy)-isoquinoline-1-carboxylic
acid (4-fluoro-3-trifluoromethyl-phenyl)-amide and employing
4(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-phenylamine in
lieu of 4-fluoro-3-trifluoromethylaniline in the step 103.3. Yellow
powder: .sup.1H-NMR (DMSO-d.sub.6): .delta. ppm 2.13 (s, 3H) 2.16
(s, 3H) 2.25-2.45 (m, 8H) 3.58 (s, 2H) 7.62 (dd, J=9.3, 2.4 Hz, 1H)
7.68 (d, J=0.7 Hz, 1H) 7.72 (d, J=8.5 Hz, 1H) 7.93 (d, J=2.3 Hz,
1H) 8.03-8.14 (m, 2H) 8.35 (d, J=1.9 Hz, 1H) 8.51 (s, 1H) 8.63 (d,
J=5.6 Hz, 1H) 8.95 (d, J=9.3 Hz, 1H) 11.02 (s, 1H) 11.12 (s,
1H).
Example 107
(6-{1-[4-(4-Methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenylcarbamoyl-
]isoquinolin-6-yloxy}-pyrimidin-4-yl)-carbamic acid methyl
ester
[0373] This compound can be obtained analogously to example 106,
utilising methylcarbamate in lieu of acetamide. Beige powder: m.p.:
203-205.degree. C.; 1H-NMR (DMSO-d6): .delta. ppm 2.17 (s, 3H)
2.27-2.47 (m, 8H) 3.58 (s, 2H) 3.70 (s, 3H) 7.44 (d, J=0.8 Hz, 1H)
7.63 (dd, J=9.3, 2.5 Hz, 1H) 7.72 (d, J=8.5 Hz, 1H) 7.93 (d, J=2.4
Hz, 1H) 8.03-8.13 (m, 2H) 8.35 (d, J=1.9 Hz, 1H) 8.46 (d, J=0.9 Hz,
1H) 8.63 (d, J=5.6 Hz, 1H) 8.95 (d, J=9.3 Hz, 1H) 10.88 (s, 1H)
11.12 (s, 1H).
Example 108
6-(6-Acetylamino-pyrimidin-4-yloxy)-isoquinoline-1-carboxylic acid
[4-(4-isopropyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-amide
[0374] This compound can be obtained analogously to example 103,
utilising 6-(6-chloro-pyrimidin-4-yloxy)-isoquinoline-1-carboxylic
acid
[4-(4-isopropyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-amide
in lieu of 6-(6-chloro-pyrimidin-4-yloxy)-isoquinoline-1-carboxylic
acid (4-fluoro-3-trifluoromethyl-phenyl)-amide and employing
4-(4-isopropylpiperazin-1-ylmethyl)-3-trifluoromethyl-phenylamine
in lieu of 4-fluoro-3-trifluoromethylaniline in the step 103.3.
Beige powder: 1H-NMR (DMSO-d6): .delta. ppm 0.96 (d, J=6.5 Hz, 6H)
2.13 (s, 3H) 2.34-2.48 (m, 8H) 2.60 (sept., J=6.5 Hz, 1H) 3.56 (s,
2H) 7.62 (dd, J=9.3, 2.5 Hz, 1H) 7.68 (d, J=0.9 Hz, 1H) 7.73 (d,
J=8.5 Hz, 1H) 7.93 (d, J=2.5 Hz, 1H) 8.03-8.13 (m, 2H) 8.35 (d,
J=2.1 Hz, 1H) 8.51 (d, J=1.0 Hz, 1H) 8.63 (d, J=5.6 Hz, 1H) 8.95
(d, J=9.3 Hz, 1H) 11.02 (s, 1H) 11.12 (s, 1H).
Example 109
(6-{1-[4-(4-Isopropyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenylcarbam-
oyl]isoquinolin-6-yloxy}-pyrimidin-4-yl)-carbamic acid methyl
ester
[0375] This compound can be obtained analogously to example 108,
utilising methylcarbamate in lieu of acetamide. Beige powder:
1H-NMR (DMSO-d6): .delta. ppm 0.96 (d, J=6.5 Hz, 6H) 2.35-2.48 (m,
8H) 2.60 (sept., J=6.5 Hz, 1H) 3.56 (s, 2H) 3.70 (s, 3H) 7.44 (d,
J=0.9 Hz, 1H) 7.63 (dd, J=9.3, 2.5 Hz, 1H) 7.73 (d, J=8.3 Hz, 1H)
7.93 (d, J=2.4 Hz, 1H) 8.03-8.13 (m, 2H) 8.35 (d, J=2.1 Hz, 1H)
8.46 (d, J=0.9 Hz, 1H) 8.63 (d, J=5.6 Hz, 1H) 8.95 (d, J=9.2 Hz,
1H) 10.88 (s, 1H) 11.12 (s, 1H).
Example 110
6-(2-Amino-pyrimidin-4-yloxy)-isoquinoline-1-carboxylic acid
(4-fluoro-3-trifluoromethyl-phenyl)-amide
[0376] A solution of 27 mg (0.042 mMol)
6-(2-amino-6-chloro-pyrimidin-4-yloxy)-isoquinoline-1-carboxylic
acid(4-fluoro-3-trifluoromethyl-phenyl)-amide in 3 ml THF and 60
.mu.l (0.42 mMol) Et.sub.3N is hydrogenated in presence of 15 mg
Pd/C (10%; Engelhard 4505). The catalyst is filtered off, the
filtrate concentrated and re-dissolved in EtOAc and water. The
separated aqueous layer is extracted twice with EtOAc. The organic
phases are washed with water and brine, dried (Na.sub.2SO.sub.4)
and concentrated. Reversed phase chromatography gives the title
compound: MS: [M+1].sup.+=444; HPLC: .sup.At.sub.Ret=13.6.
[0377] The starting material is prepared as follows:
Step 110.1:
6-(2-Amino-6-chloro-pyrimidin-4-yloxy)-isoquinoline-1-carboxylic
acid(4-fluoro-3-trifluoromethyl-phenyl)-amide
[0378] To a suspension of 80 mg (0.423 mMol)
6-hydroxy-isoquinoline-1-carboxylic acid in 1 ml methanol, 157
.mu.l (0.85 mMol) of a 5.4 M solution of NaOCH.sub.3 in methanol
are added. Treatment under ultrasound produces a clear solution
which is concentrated in vacuo and finally dried for 3 h at
50.degree. C. Then 4 ml of DMEU followed by a solution of 154 mg
(0.94 mMol) of 2-amino-4,6-dichloro-pyrimidine are added to the
residue. Stirring for 3 d at rt leads to
6-(2-amino-6-chloro-pyrimidin-4-yloxy)-isoquinoline-1-carboxylic
acid {MS: [M-1]=315}. Then 590 .mu.l (4.24 mMol) Et.sub.3N, 23 mg
(0.19 mMol) DMAP, 70 .mu.l (0.544 mMol)
4-fluoro-3-trifluoromethyl-aniline and finally 490 .mu.l (0.85
mMol) propylphosphonic anhydride are added successively. After 16 h
at rt, the mixture is diluted with EtOAc and water. The separated
aqueous layer is extracted twice with EtOAc. The organic phases are
washed with water and brine, dried (Na.sub.2SO.sub.4) and
concentrated. Chromatography [Combi Flash; hexane/EtOAc
4:1.fwdarw.1:1] gives the title compound: MS: [M+1].sup.+=478; TLC
(hexane/EtOAc 1:1): R.sub.f=0.37; HPLC: .sup.At.sub.Pet=17.8.
Example 111
[0379] The following isoquinoline carboxamides can be prepared
analogously:
##STR00101##
Example 112
6-[(6-Aminopyrimidin-4-yl)oxy]-N-[4-(4-morpholin-4-ylcyclohexyl)phenyl]-1--
naphthamide
Step 112.1: 4,6-Dimethoxy-1,3,5-triazin-2-yl
6-hydroxy-1-naphthoate
[0380] Add 21.4 g (0.11 mol) of 6-hydroxy-1-naphthoic acid in to
450 mL of acetonitrile, then added 33.2 g (0.12 mol) of
4-(4,6-Dimethoxy-[1,3,5]triazin-2-yl)-4-methyl-morpholin-4-ium
chloride, and stir at room temperature overnight. Add 165 mL of
water, stir for 5 min, filter, and rinse the cake with 150 mL of
water. Dry at room temperature in a vacuum oven to obtain
4,6-dimethoxy-1,3,5-triazin-2-yl 6-hydroxy-1-naphthoate 27.22 g
(72.9%).
Step 112.2: 4-(4-Morpholin-4-yl-cyclohexyl)-phenylamine
a) Dimethyl
1-(4-nitrophenyl)-4-oxo-1,3-cyclohexanedicarboxylate
[0381] Charge a 2000-mL reactor with 156.9 g of ethyl
4-nitrophenylacetate. Add 443 g of tetrahydrofuran. Stir the
solution and cool it to -10.degree. C. Add in one portion 15.58 g
of Triton B [40% (w/w) solution of trimethylbenzylammonium
hydroxide in methanol] and then add a solution of 161.4 g of methyl
acrylate in 221.5 g of tetrahydrofuran in 45 min keeping the
reaction temperature below -10.degree. C. Warm the mixture to
5.degree. C. over 15 min. Stir the mixture at 5.degree. C. until
ethyl 4-nitrophenylacetate is completely consumed. Continue
stirring and add slowly from a dropping funnel 540.6 g of 30% (w/w)
of sodium methoxide in methanol in 90 min. Stir the reaction at
5.degree. C. for 1 h then warm the mixture to 22.degree. C. over 1
h and stir the mixture for 16 h. Cool the reaction to 0-5.degree.
C. Charge a separate flask with 1500 g of deionized water. Cool the
contents to 0-5.degree. C. Add the cold reaction mixture to the
cold water with vigorous stirring. Complete the addition in 30-60
min keeping the batch at 5-10.degree. C. Rinse the reactor with 136
g of methanol. Keep the mixture cold (<10.degree. C.) and
acidify to pH 1-2 by controlled addition of 577.2 g of 6 N HCl.
Stir the mixture at 5-10.degree. C. for 2 h. Filter the solids.
Wash the cake with water (3.times.600 mL). Dry the product at
45-50.degree. C./.apprxeq.30 mbar (18 h). Yield 235.6 g.
b) 4-(4-Nitrophenyl)-cyclohexanone
[0382] Charge a 2000-mL reactor with 80.48 g of dimethyl
1-(4-nitrophenyl)-4-oxo-1,3-cyclohexanedicarboxylate, 98.0 g of
sodium acetate, trihydrate and 440.4 g of dimethyl sulfoxide. Stir
the mixture and add 27.0 g of deionized water. Warm the mixture to
130.degree. C. Hold the reaction at 130.degree. C. for 2 h. Warm
the reaction to 150.degree. C. Hold the batch at 150-155.degree. C.
for 2.5 h. Cool the reaction to 22.degree. C. Stir the reaction
mixture and add from a dropping funnel a solution of 80.6 g of
sodium bicarbonate dissolved in 1320 mL of deionized water at a
rate to keep the reaction temperature at 25-30.degree. C. Stir the
resulting dark slurry for 2 h. Filter the solids and wash the cake
with 160 g of deionized water then with 2.times.120 g of deionized
water. Dry the product at 45-50.degree. C./.apprxeq.30 mbar (18 h).
Yield 41.9 g. Purity: 76.4%. This material is carried into the next
step as such.
c) trans-4-[4-(4-Nitrophenyl)cyclohexyl]morpholine
hydrochloride
[0383] Charge a nitrogen flushed 1-L, 4-necked round-bottomed flask
equipped with a mechanical stirrer, a thermometer a reflux
condenser and an addition funnel, with 50.0 g (0.228 mol) of
4-(4-Nitrophenyl)-cyclohexanone and 541 g (600 mL) of ethyl
acetate. Stir and heat the suspension to reflux. Hold the reaction
at reflux for 30 min. Cool the mixture to 50.degree. C. and filter
the solids. Wash the flask and filter cake with 45 g (50 mL) of
ethyl acetate. Combine the wash with the filtrate and transfer to a
clean 2-L reactor equipped with a mechanical stirrer, a thermometer
a reflux condenser and an addition funnel. Stir the mixture at
25.degree. C. Add 19.9 g (0.228 mol) of morpholine and 6.8 g (6.5
mL) of glacial acetic acid. Add 67.7 g (0.319 mol) of sodium
triacetoxyborohydride in 5 portions over 15 minutes maintaining the
reaction temperature at 22.degree. C. throughout the addition. Stir
the mixture at 25.degree. C. until 4-(4-Nitrophenyl)-cyclohexanone
is consumed (3 h). Carefully add 500 mL of water over 30 min.
Transfer to a nitrogen-flushed 3-L, 4-necked round-bottomed flask
equipped with overhead stirrer, nitrogen inlet and outlet,
thermocouple and pH probe. Adjust the pH to 1.5-2.0 with 12 N
hydrochloric acid (.apprxeq.50 mL) while maintaining a reaction
temperature at 20-25.degree. C. Stir for 15 min and separate the
phases. Extract the organic phase with 2.times.125 mL of 2 N
hydrochloric acid solution. Separate the phases and combine the
aqueous extracts (pH=0.8). Add to the combined aqueous extracts 350
mL of ethyl acetate. Stir and adjust the pH to 8.5 with the
addition of 50% sodium hydroxide (.apprxeq.82 mL). Stir for 15 min
and separate the phases. Clarify the organic phase by filtering
through glass-fiber filter paper.
[0384] Distil the solvent under vacuum (30.degree. C./40 mbar). Add
to the residue 500 mL of 200 proof ethanol. Distil the solvent
under vacuum (30.degree. C./40 mbar). Add to the residue 650 mL of
200 proof ethanol. Stir and add 115.0 mL of sodium methoxide, (25%
w/w solution in methanol) over 2-3 min. Heat the mixture to reflux
and hold it at reflux for 6 h. Cool the mixture to 22.degree. C.
Stir and add 6 N hydrochloric acid solution (.about.145 mL) over 15
min until pH is <2.5. Add 180 g of water and stir for 15 min.
Filter through a 9 cm.times.1 cm pad of Filter Cel. Wash the filter
cake with a solution of 60 mL of ethanol in 30 mL of water and
combine the wash with the filtrate. The product thus obtained as a
solution in ethanol/water was used directly in the next step.
d) 4-(4-Morpholin-4-yl-cyclohexyl)-phenylamine
[0385] Purge the Mettler-Toledo RC1 reaction calorimeter by
pressurizing with nitrogen to 50 psig (4.5 bar abs), and
depressurizing to 0 psig. Repeat the
pressurization/depressurization cycle four times. Add 6.71 g of 10%
palladium on carbon (50% water wet). Purge with nitrogen five times
as described above. Add the aqueous ethanol solution of
trans-4-[4-(4-nitrophenyl)cyclohexyl]morpholine hydrochloride from
the previous step. With the reaction mixture under 1 atm of
nitrogen, stir the vessel at an agitation rate of 500 rpm and heat
the batch temperature to 50.degree. C. over a 30 min period. Let
the batch temperature equilibrate at 50.degree. C. at an agitation
rate of 550 rpm and turn off the agitator. Purge the headspace of
N2, and replace with H2 by pressurizing with H2 to 50 psig (4.5 bar
abs), depressurizing to 0 psig, and repeating the
pressurization/depressurization cycle 4 times. After the final
depressurization, set the reactor pressure to 50 psig (4.5 bar
abs), agitate at 550 rpm to start the reaction. The reaction is
exothermic. Continue hydrogenation until the uptake of hydrogen gas
levels off. Cool the reaction to 25.degree. C. Purge five times
with nitrogen. Remove the reaction mixture from the RC1. Wash the
reactor with 250 mL of water and combine the wash with the batch.
Filter the batch and distil (35.+-.5.degree. C., 35 mbar) to remove
ethanol. Add to the residue 500 mL of ethyl acetate. Stir and
adjust the pH to 9.5.+-.0.5 with the addition of sodium hydroxide,
50% in water (.apprxeq.35 g, 22 mL). Separate the phases. Extract
the aqueous phase once with 250 mL of ethyl acetate and combine the
organic extracts. Wash the organic phase with 150 mL of water, once
with 150 mL of brine and concentrate to a solid residue.
Chromatograph the crude product on silica gel using ethyl
acetate/triethylamine (100:1) as the mobile phase to afford product
(31 g, 68% overall corrected yield from ketone) as a yellow solid.
Mp. 161-163.degree. C.
Step 112.3:
6-Hydroxy-N-[4-(4-morpholin-4-ylcyclohexyl)phenyl]-1-naphthamide
[0386] Mix 4,6-Dimethoxy-1,3,5-triazin-2-yl 6-hydroxy-1-naphthoate
(3.44 g 10.5 mmol), 4-(4-Morpholin-4-yl-cyclohexyl)-phenylamine
(2.74 g, 10.5 mmol), and 50 mL of N-methylpyrrolidone, stir, and
hold at 55.degree. C. for 5.5 h. Cool to room temperature, quench
with 150 mL of water and 50 mL of ethyl acetate. Filter and dry at
65.degree. C. in a vacuum oven to obtain
6-hydroxy-N-[4-(4-morpholin-4-ylcyclohexyl)phenyl]-1-naphthamide
2.34 g (52%).
Step 112.4:
6-[(6-Aminopyrimidin-4-yl)oxy]-N-[4-(4-morpholin-4-ylcyclohexyl)phenyl]-1-
-naphthamide
[0387] To a 100-mL flask, charge
6-hydroxy-N-[4-(4-morpholin-4-ylcyclohexyl)phenyl]-1-naphthamide
(2.34 g, 5.9 mmol), 4-amino-6-chloropyrimidine (0.80 g, 6.2 mmol),
potassium hydroxide (0.418 g, 7.45 mmol), potassium iodide (0.979
g, 5.9 mmol), and N-methylpyrrolidone (45 mL). Hold at 135.degree.
C. for 13 h. Cool to 50.degree. and slowly add water (90 mL), and
hold at 50.degree. C. for 30 min. Cool to room temperature filter
and rinse with water. Dry at 65.degree. C. in a vacuum oven to
obtain crude
6-[(6-aminopyrimidin-4-yl)oxy]-N-[4-(4-morpholin-4-ylcyclohexyl)phenyl]-1-
-naphthamide 2.19 g (Y. 71%, purity. 88.5%). The crude product was
purified by chromatography on silica gel using
CH.sub.2Cl.sub.2/MeOH/Et.sub.3N=95/5/1. MS. [M+1].sup.+=524
Example 113
6-[(2-Aminopyrimidin-4-yl)oxy]-N-[4-(4-morpholin-4-ylcyclohexyl-1)phenyl]--
1-naphthamide
[0388] In a nitrogen flushed 50 mL 4-neck round-bottom flask
equipped with a magnetic stirrer, thermocouple and cooling bath,
suspend 1.0 g (3.55 mmol) of
6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid and
0.97 g (3.73 mmol) of 4-(4-Morpholin-4-yl-cyclohexyl)-phenylamine
in 10 mL of N,N-dimethylformamide (DMF). Stir the suspension and
add 1.5 mL (10.65 mmol) of triethylamine to obtain a brown solution
(21.degree. C.). Add 0.52 g (4.26 mmol) of
N,N-dimethylaminopyridine and cool to 4.degree. C. Add by drops,
2.72 g (4.26 mmol) of 1-propanephosphonic acid cyclic anhydride (50
wt. % solution in ethyl acetate) while maintaining a batch
temperature of .ltoreq.10.degree. C. throughout the addition.
Remove the cooling bath and allow the reaction mixture to warm to
20.degree. C. over 15 min. Stir the reaction mixture at 20.degree.
C. for 30 min. and monitor the reaction for the disappearance of
6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid by
HPLC. Pour the reaction mixture into a rapidly stirring solution of
20 mL water and 20 mL brine (a thick precipitate forms). Stir the
resulting suspension of 15 min. Filter the solids through
polypropylene filter paper, wash the filter cake with 50 mL of ice
water and dry the solids at 50.degree. C., 50 mbar for 16 h. Grind
the solids transfer them to a nitrogen flushed 50 mL. 4-neck
round-bottom flask equipped with a magnetic stirrer, thermocouple
and heating mantle. Add 35 mL of methanol. Stir the suspension and
heat to 65.degree. C. Hold the suspension at this temperature for 1
h, cool to 25.degree. C. over 30 min and hold for 30 min. Filter
the solids through polypropylene filter paper, wash the filter cake
with 5 mL of cold (4.degree. C.) methanol and dry the solids at
50.degree. C., 50 mbar to afford 1.6 g of
6-[(2-Aminopyrimidin-4-yl)oxy]-N-[4-(4-morpholin-4-ylcyclohexyl)phenyl]-1-
-naphthamide (86% yield).
Example 114
Dry-Filled Capsules
[0389] 5000 capsules, each comprising as active ingredient 0.25 g
of one of the compounds of formula I mentioned in the preceding
Examples, are prepared as follows:
[0390] Composition
TABLE-US-00009 active ingredient 1250 g talcum 180 g wheat starch
120 g magnesium stearate 80 g lactose 20 g
[0391] Preparation process: The mentioned substances are pulverised
and forced through a sieve of 0.6 mm mesh size. 0.33 g portions of
the mixture are introduced into gelatin capsules using a
capsule-filling machine.
Example 115
Soft Capsules
[0392] 5000 soft gelatin capsules, each comprising as active
ingredient 0.05 g of one of the compounds of formula I mentioned in
the preceding Examples, are prepared as follows:
[0393] Composition
TABLE-US-00010 active ingredient 250 g PEG 400 1 litre Tween 80 1
litre
[0394] Preparation process: The active ingredient is pulverised and
suspended in PEG 400 (polyethylene glycol having an M.sub.r of from
approx. 380 to approx. 420, Fluka, Switzerland) and Tween.RTM.80
(polyoxyethylene sorbitan monolaurate, Atlas Chem. Ind. Inc., USA,
supplied by Fluka, Switzerland) and ground in a wet pulveriser to a
particle size of approx. from 1 to 3 .mu.m. 0.43 g portions of the
mixture are then introduced into soft gelatin capsules using a
capsule-filling machine.
* * * * *